Loading…
Reported covered position: Health Policy Advisor for Senate HELP and Finance Committee.
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act
For the People Act of 2021
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act Discussions regarding H.R.1, One Big Beautiful Bill Act regarding bio-pharmaceutical provisions
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2025 · second_quarter · Q2
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act Discussions regarding H.R.1, One Big Beautiful Bill Act regarding bio-pharmaceutical provisions
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2025 · first_quarter · Q1
Source: Senate LDA
Methane Waste Prevention Act of 2021
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act Discussions regarding H.R.1, One Big Beautiful Bill Act regarding bio-pharmaceutical provisions
To provide for a limitation on availability of funds for Executive Office of the President, Office of National Drug Control Policy, Salaries and Expenses for fiscal year 2024.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes H.R.2071, to amend Part D of title XVII of the Social Security Act to require the secretary of Health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical provisions
To provide for a limitation on availability of funds for Executive Office of the President, Office of National Drug Control Policy, Salaries and Expenses for fiscal year 2024.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions Inflation Reduction Act implementation H.R.7625, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes H.R.2071, to amend Part D of title XVII of the Social Security Act to require the secretary of Health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical provisions
To provide for a limitation on availability of funds for U.S. Department of Interior, US Fish and Wildlife Service, Multinational Species Conservation Fund for fiscal year 2024.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes H.R.2071, to amend Part D of title XVII of the Social Security Act to require the secretary of Health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical provisions
To provide for a limitation on availability of funds for U.S. Department of Interior, US Fish and Wildlife Service, Multinational Species Conservation Fund for fiscal year 2024.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes
To provide for a limitation on availability of funds for U.S. Department of Interior, US Fish and Wildlife Service, Multinational Species Conservation Fund for fiscal year 2024.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions Inflation Reduction Act implementation H.R.7625, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes H.R.2071, to amend Part D of title XVII of the Social Security Act to require the secretary of Health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical provisions
To provide for a limitation on availability of funds for U.S. Department of Interior, US Fish and Wildlife Service, Multinational Species Conservation Fund for fiscal year 2024.
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes
PATIENT Act of 2023
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Discussions regarding health equity H.R.830, HELP Copays Act of 2023 H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Biosimilars reimbursement issues International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathways to Innovation Cures (EPIC) Act ORPHAN Act Implementation of Inflation Reduction Act of 2022 MINI Act
Lowering Drug Costs for American Families Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Discussions regarding health equity H.R.830, HELP Copays Act of 2023 H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Biosimilars reimbursement issues International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathways to Innovation Cures (EPIC) Act ORPHAN Act Implementation of Inflation Reduction Act of 2022 MINI Act
RESPOND Act of 2024
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions Inflation Reduction Act implementation H.R.7625, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes H.R.2071, to amend Part D of title XVII of the Social Security Act to require the secretary of Health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical provisions
The 340B PATIENTS Act of 2024
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes H.R.2071, to amend Part D of title XVII of the Social Security Act to require the secretary of Health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical provisions
The 340B PATIENTS Act of 2024
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes
The 340B PATIENTS Act of 2024
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes
Discussions regarding health equity H.R.830, HELP Copays Act of 2023 H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Biosimilars reimbursement issues International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathways to Innovation Cures (EPIC) Act ORPHAN Act Implementation of Inflation Reduction Act of 2022 MINI Act
Extending Temporary Emergency Scheduling of Fentanyl Analogues Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathway Implementation of Inflation Reduction Act of 2022 MINI Act H.R. 8412, Clinical Trial Modernization Act S.652/H.R.2630, Safe Step Act Mental health issues Biosimilars reimbursement issues
Extending Temporary Emergency Scheduling of Fentanyl Analogues Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathways to Innovation Cures (EPIC) Act ORPHAN Act Implementation of Inflation Reduction Act of 2022 MINI Act H.R. 8412, Clinical Trial Modernization Act S.652/H.R.2630, Safe Step Act
Freedom to Haul Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathways to Innovation Cures (EPIC) Act ORPHAN Act Implementation of Inflation Reduction Act of 2022 MINI Act H.R. 8412, Clinical Trial Modernization Act S.652/H.R.2630, Safe Step Act
Freedom to Haul Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathway Implementation of Inflation Reduction Act of 2022 MINI Act H.R. 8412, Clinical Trial Modernization Act S.652/H.R.2630, Safe Step Act Mental health issues Biosimilars reimbursement issues
Moving and Fostering Innovation to Revolutionize Smarter Transportation Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathway Implementation of Inflation Reduction Act of 2022 MINI Act H.R. 8412, Clinical Trial Modernization Act S.652/H.R.2630, Safe Step Act Mental health issues Biosimilars reimbursement issues
Moving and Fostering Innovation to Revolutionize Smarter Transportation Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathways to Innovation Cures (EPIC) Act ORPHAN Act Implementation of Inflation Reduction Act of 2022 MINI Act H.R. 8412, Clinical Trial Modernization Act S.652/H.R.2630, Safe Step Act
Access to Innovative Treatments Act of 2023
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions H.R. 2630/S.464, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity End of year health package/PBM reform H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
Access to Innovative Treatments Act of 2023
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/H.R. 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions H.R. 2630/S.464, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity End of year health package/PBM reform H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
Protecting Patients Against PBM Abuses Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/H.R. 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
Protecting Patients Against PBM Abuses Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions H.R. 2630/S.464, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity End of year health package/PBM reform H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
PATIENT Act of 2023
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions H.R. 2630/S.464, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity End of year health package/PBM reform H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
PATIENT Act of 2023
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/H.R. 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
Protecting Health Care for All Patients Act of 2023
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions H.R. 2630/S.464, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity End of year health package/PBM reform H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
Protecting Health Care for All Patients Act of 2023
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/HR 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023
Protecting Health Care for All Patients Act of 2023
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/HR 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity HR 5376, the Build Back Better Act regarding all bio-pharmaceutical provisions PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023
Protecting Health Care for All Patients Act of 2023
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/H.R. 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
Lowering Drug Costs for American Families Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions H.R. 2630/S.464, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity End of year health package/PBM reform H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
Lowering Drug Costs for American Families Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/H.R. 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
Share the Savings with Seniors Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/HR 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity HR 5376, the Build Back Better Act regarding all bio-pharmaceutical provisions PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023
Share the Savings with Seniors Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions H.R. 2630/S.464, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity End of year health package/PBM reform H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
Share the Savings with Seniors Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/H.R. 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/H.R. 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions H.R. 2630/S.464, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity End of year health package/PBM reform H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions H.R. 2630/S.464, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity End of year health package/PBM reform H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/HR 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/H.R. 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/HR 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity HR 5376, the Build Back Better Act regarding all bio-pharmaceutical provisions PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023
American Rescue Plan Act of 2021
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/HR 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity HR 5376, the Build Back Better Act regarding all bio-pharmaceutical provisions PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023
American Rescue Plan Act of 2021
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions H.R. 2630/S.464, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity End of year health package/PBM reform H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
American Rescue Plan Act of 2021
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/H.R. 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
American Rescue Plan Act of 2021
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/HR 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/HR 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity HR 5376, the Build Back Better Act regarding all bio-pharmaceutical provisions PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/HR 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/H.R. 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
Pharmacy Benefit Manager Transparency Act of 2022
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/HR 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023
Pharmacy Benefit Manager Transparency Act of 2022
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/HR 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity HR 5376, the Build Back Better Act regarding all bio-pharmaceutical provisions PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023
Pharmacy Benefit Manager Transparency Act of 2022
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/H.R. 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/H.R. 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/HR 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity HR 5376, the Build Back Better Act regarding all bio-pharmaceutical provisions PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions H.R. 2630/S.464, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity End of year health package/PBM reform H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/HR 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023
American Rescue Plan Act of 2021
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/HR 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity Issues regarding HR 6833, Continuing Resolution HR 5376, the Build Back Better Act regarding all bio-pharmaceutical provisions Discussions regarding HR 3173, Improving Seniors' Timely Access to Care Act PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022
American Rescue Plan Act of 2021
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464, Safe Step Act - regarding all bio-pharmaceutical related provisions Issues related to the Reauthorization of the Prescription Drug User Fee Act (PDUFA) - regarding all bio-pharmaceutical related provisions. No bill number HR 4385, Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions HR 7667, Food and Drug Amendments 2022 Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity S 4293, Pharmacy Benefit Manager Transparency Act of 2022
American Rescue Plan Act of 2021
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464, Safe Step Act - regarding all bio-pharmaceutical related provisions Issues related to the Reauthorization of the Prescription Drug User Fee Act (PDUFA) - regarding all bio-pharmaceutical related provisions. No bill number HR 4385, Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions HR 7667, Food and Drug Amendments 2022 Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity Issues regarding HR 6833, Continuing Resolution HR 5376, the Build Back Better Act regarding all bio-pharmaceutical provisions
American Rescue Plan Act of 2021
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
HR 1319 - American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464 - Safe Step Act - regarding all bio-pharmaceutical related provisions Issues related to the Reauthorization of the Prescription Drug User Fee Act (PDUFA) - regarding all bio-pharmaceutical related provisions. No bill number Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions. No bill number. Issues Related to the Food and Drug Administration's accelerated approval process - regarding all bio-pharmaceutical related provisions. No bill number. H.R 4385 - Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions. E- Prescribing Information- regarding modernizing the distribution of prescribing information. No bill number Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number. Essential Medicines/Buy American - regarding all bio-pharmaceutical related provisions. No bill number.
Lower Costs, More Cures Act of 2021
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Issues related to access and reimbursement of Chimeric Antigen Receptor Theraph (CAR T) Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related HR 5237, to amend titles XI, XVIII, and XIX of the Social Security Act to lower prescrition drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients/ out-of-poclet costs HR 3, Elijah E. Cummings Lower Drig Costs NOW Act regarding all bio-pharmaceutical provisions HR 19, Lower Cost, More Cures Act of 2021, regarding all bio-pharmaceutical related issues
Medicare Prescription Drug Price Negotiation Act of 2021
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes - regarding all bio-pharmaceutical related provisions. H.R 5376, the Build Back Better Act - regarding all bio-pharmaceutical related provisions and corporate tax provisions.
Medicare Drug Price Negotiation Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes - regarding all bio-pharmaceutical related provisions. H.R 5376, the Build Back Better Act - regarding all bio-pharmaceutical related provisions and corporate tax provisions.
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/HR 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity Issues regarding HR 6833, Continuing Resolution HR 5376, the Build Back Better Act regarding all bio-pharmaceutical provisions Discussions regarding HR 3173, Improving Seniors' Timely Access to Care Act PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022
Consolidated Appropriations Act, 2023
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Discussions regarding HR 2617, Consolidated Appropriations Act of 2023
Elijah E. Cummings Lower Drug Costs Now Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Issues related to access and reimbursement of Chimeric Antigen Receptor Theraph (CAR T) Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related HR 5237, to amend titles XI, XVIII, and XIX of the Social Security Act to lower prescrition drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients/ out-of-poclet costs HR 3, Elijah E. Cummings Lower Drig Costs NOW Act regarding all bio-pharmaceutical provisions HR 19, Lower Cost, More Cures Act of 2021, regarding all bio-pharmaceutical related issues
Elijah E. Cummings Lower Drug Costs Now Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Issues related to access and reimbursement of Chimeric Antigen Receptor Theraph (CAR T) Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions HR 5237, to amend titles XI, XVIII, and XIX of the Social Security Act to lower prescrition drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients/ out-of-poclet costs HR 3, Elijah E. Cummings Lower Drig Costs NOW Act regarding all bio-pharmaceutical provisions Issues related to the Inflation Reduction Act of 2022
Improving Seniors’ Timely Access to Care Act of 2021
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/HR 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity Issues regarding HR 6833, Continuing Resolution HR 5376, the Build Back Better Act regarding all bio-pharmaceutical provisions Discussions regarding HR 3173, Improving Seniors' Timely Access to Care Act PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022
Cancer Drug Parity Act of 2021
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
HR 1319 - American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464 - Safe Step Act - regarding all bio-pharmaceutical related provisions Issues related to the Reauthorization of the Prescription Drug User Fee Act (PDUFA) - regarding all bio-pharmaceutical related provisions. No bill number Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions. No bill number. Issues Related to the Food and Drug Administration's accelerated approval process - regarding all bio-pharmaceutical related provisions. No bill number. H.R 4385 - Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions. E- Prescribing Information- regarding modernizing the distribution of prescribing information. No bill number Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number. Essential Medicines/Buy American - regarding all bio-pharmaceutical related provisions. No bill number.
Cancer Drug Parity Act of 2021
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464, Safe Step Act - regarding all bio-pharmaceutical related provisions Issues related to the Reauthorization of the Prescription Drug User Fee Act (PDUFA) - regarding all bio-pharmaceutical related provisions. No bill number HR 4385, Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions HR 7667, Food and Drug Amendments 2022 Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity Issues regarding HR 6833, Continuing Resolution HR 5376, the Build Back Better Act regarding all bio-pharmaceutical provisions
Cancer Drug Parity Act of 2021
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464, Safe Step Act - regarding all bio-pharmaceutical related provisions Issues related to the Reauthorization of the Prescription Drug User Fee Act (PDUFA) - regarding all bio-pharmaceutical related provisions. No bill number HR 4385, Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions HR 7667, Food and Drug Amendments 2022 Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity S 4293, Pharmacy Benefit Manager Transparency Act of 2022
United States Innovation and Competition Act of 2021
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number S 1854, the National Critical Capabilities Act of 2021 - regarding all bio-pharmaceutical related provisions HR 4521, United States Innovation and Competition Act of 2021 S 1260, USICA conference bill
United States Innovation and Competition Act of 2021
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number S 1854, the National Critical Capabilities Act of 2021 - regarding all bio-pharmaceutical related provisions HR 4521, United States Innovation and Competition Act of 2021 S 1260, USICA conference bill
Reduced Costs and Continued Cures Act of 2021
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Issues related to access and reimbursement of Chimeric Antigen Receptor Theraph (CAR T) Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related HR 5237, to amend titles XI, XVIII, and XIX of the Social Security Act to lower prescrition drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients/ out-of-poclet costs HR 3, Elijah E. Cummings Lower Drig Costs NOW Act regarding all bio-pharmaceutical provisions HR 19, Lower Cost, More Cures Act of 2021, regarding all bio-pharmaceutical related issues
Reduced Costs and Continued Cures Act of 2021
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Issues related to access and reimbursement of Chimeric Antigen Receptor Theraph (CAR T) Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions HR 5237, to amend titles XI, XVIII, and XIX of the Social Security Act to lower prescrition drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients/ out-of-poclet costs HR 3, Elijah E. Cummings Lower Drig Costs NOW Act regarding all bio-pharmaceutical provisions Issues related to the Inflation Reduction Act of 2022
Reduced Costs and Continued Cures Act of 2021
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions HR 5237, to amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients/ out-of-pocket costs Issues related to the Inflation Reduction Act of 2022
Inflation Reduction Act of 2022
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464, Safe Step Act - regarding all bio-pharmaceutical related provisions Issues related to the Reauthorization of the Prescription Drug User Fee Act (PDUFA) - regarding all bio-pharmaceutical related provisions. No bill number HR 4385, Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions HR 7667, Food and Drug Amendments 2022 Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity Issues regarding HR 6833, Continuing Resolution HR 5376, the Build Back Better Act regarding all bio-pharmaceutical provisions
Inflation Reduction Act of 2022
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/HR 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity Issues regarding HR 6833, Continuing Resolution HR 5376, the Build Back Better Act regarding all bio-pharmaceutical provisions Discussions regarding HR 3173, Improving Seniors' Timely Access to Care Act PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022
Inflation Reduction Act of 2022
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes - regarding all bio-pharmaceutical related provisions. H.R 5376, the Build Back Better Act - regarding all bio-pharmaceutical related provisions and corporate tax provisions.
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464, Safe Step Act - regarding all bio-pharmaceutical related provisions Issues related to the Reauthorization of the Prescription Drug User Fee Act (PDUFA) - regarding all bio-pharmaceutical related provisions. No bill number HR 4385, Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions HR 7667, Food and Drug Amendments 2022 Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity Issues regarding HR 6833, Continuing Resolution HR 5376, the Build Back Better Act regarding all bio-pharmaceutical provisions
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/HR 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity Issues regarding HR 6833, Continuing Resolution HR 5376, the Build Back Better Act regarding all bio-pharmaceutical provisions Discussions regarding HR 3173, Improving Seniors' Timely Access to Care Act PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022
Food and Drug Amendments of 2022
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464, Safe Step Act - regarding all bio-pharmaceutical related provisions Issues related to the Reauthorization of the Prescription Drug User Fee Act (PDUFA) - regarding all bio-pharmaceutical related provisions. No bill number HR 4385, Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions HR 7667, Food and Drug Amendments 2022 Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity Issues regarding HR 6833, Continuing Resolution HR 5376, the Build Back Better Act regarding all bio-pharmaceutical provisions
Food and Drug Amendments of 2022
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464, Safe Step Act - regarding all bio-pharmaceutical related provisions Issues related to the Reauthorization of the Prescription Drug User Fee Act (PDUFA) - regarding all bio-pharmaceutical related provisions. No bill number HR 4385, Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions HR 7667, Food and Drug Amendments 2022 Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity S 4293, Pharmacy Benefit Manager Transparency Act of 2022
United States Innovation and Competition Act of 2021
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number S 1854, the National Critical Capabilities Act of 2021 - regarding all bio-pharmaceutical related provisions HR 4521, United States Innovation and Competition Act of 2021 S 1260, USICA conference bill
United States Innovation and Competition Act of 2021
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number S 1854, the National Critical Capabilities Act of 2021 - regarding all bio-pharmaceutical related provisions HR 4521, United States Innovation and Competition Act of 2021 S 1260, USICA conference bill
National Critical Capabilities Defense Act of 2021
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number S 1854, the National Critical Capabilities Act of 2021 - regarding all bio-pharmaceutical related provisions HR 4521, United States Innovation and Competition Act of 2021 S 1260, USICA conference bill
National Critical Capabilities Defense Act of 2021
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
International Reference Pricing/Most Favored Nation regarding all bio-pharmaceutical related issues. No bill number. Essential Medicines/Buy American - regarding all bio-pharmaceutical related provisions. No bill number. Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number. S.1854, the National Critical Capabilities Act of 2021 - regarding all bio-pharmaceutical related provisions
National Critical Capabilities Defense Act of 2021
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number S 1854, the National Critical Capabilities Act of 2021 - regarding all bio-pharmaceutical related provisions HR 4521, United States Innovation and Competition Act of 2021 S 1260, USICA conference bill
Pharmacy Benefit Manager Transparency Act of 2022
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464, Safe Step Act - regarding all bio-pharmaceutical related provisions Issues related to the Reauthorization of the Prescription Drug User Fee Act (PDUFA) - regarding all bio-pharmaceutical related provisions. No bill number HR 4385, Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions HR 7667, Food and Drug Amendments 2022 Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity S 4293, Pharmacy Benefit Manager Transparency Act of 2022
Pharmacy Benefit Manager Transparency Act of 2022
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/HR 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity Issues regarding HR 6833, Continuing Resolution HR 5376, the Build Back Better Act regarding all bio-pharmaceutical provisions Discussions regarding HR 3173, Improving Seniors' Timely Access to Care Act PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464, Safe Step Act - regarding all bio-pharmaceutical related provisions Issues related to the Reauthorization of the Prescription Drug User Fee Act (PDUFA) - regarding all bio-pharmaceutical related provisions. No bill number HR 4385, Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions HR 7667, Food and Drug Amendments 2022 Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity S 4293, Pharmacy Benefit Manager Transparency Act of 2022
HR 1319 - American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464 - Safe Step Act - regarding all bio-pharmaceutical related provisions Issues related to the Reauthorization of the Prescription Drug User Fee Act (PDUFA) - regarding all bio-pharmaceutical related provisions. No bill number Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions. No bill number. Issues Related to the Food and Drug Administration's accelerated approval process - regarding all bio-pharmaceutical related provisions. No bill number. H.R 4385 - Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions. E- Prescribing Information- regarding modernizing the distribution of prescribing information. No bill number Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number. Essential Medicines/Buy American - regarding all bio-pharmaceutical related provisions. No bill number.
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464, Safe Step Act - regarding all bio-pharmaceutical related provisions Issues related to the Reauthorization of the Prescription Drug User Fee Act (PDUFA) - regarding all bio-pharmaceutical related provisions. No bill number HR 4385, Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions HR 7667, Food and Drug Amendments 2022 Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity Issues regarding HR 6833, Continuing Resolution HR 5376, the Build Back Better Act regarding all bio-pharmaceutical provisions
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/HR 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity Issues regarding HR 6833, Continuing Resolution HR 5376, the Build Back Better Act regarding all bio-pharmaceutical provisions Discussions regarding HR 3173, Improving Seniors' Timely Access to Care Act PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022
Medicare Drug Price Negotiation Act
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes - regarding all bio-pharmaceutical related provisions. H.R 5376, the Build Back Better Act - regarding all bio-pharmaceutical related provisions and corporate tax provisions.
American Rescue Plan Act of 2021
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
HR 1319 - American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S.464 - Safe Step Act - regarding all bio-pharmaceutical related provisions H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes - regarding all bio-pharmaceutical related provisions. International Reference Pricing/Most Favored Nation - regarding all bio-pharmaceutical related issues. No bill number. Issues related to the six protected classes of medicines under Medicare Part D - regarding all bio-pharmaceutical related issues. No bill number. H.R 1319 - The American Rescue Plan - regarding all bio-pharmaceutical related provisions. Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions. No bill number. Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions. No bill number. Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number. Essential Medicines/Buy American - regarding all bio-pharmaceutical related provisions. No bill number. H.R 5237 - To amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes - regarding all bio-pharmaceutical related provisions. H.R 5376, the Build Back Better Act - regarding all bio-pharmaceutical related provisions.
American Rescue Plan Act of 2021
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 2163 To amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for an medication step therapy protocol, and for other purposes regarding all bio-pharmaceutical related provisions. H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes regarding all bio-pharmaceutical related provisions. International Reference Pricing/Most Favored Nation regarding all bio-pharmaceutical related issues. No bill number. Issues related to the six protected classes of medicines under Medicare Part D regarding all bio-pharmaceutical related issues. No bill number. H.R 1319 - The American Rescue Plan regarding all bio-pharmaceutical related provisions. Cancer Drug Parity Act/Oral Parity regarding all bio-pharmaceutical related provisions. No bill number. Issues related to the 340B Drug Pricing Program regarding all bio-pharmaceutical related provisions. No bill number. Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number.
American Rescue Plan Act of 2021
Client: BRISTOL-MYERS SQUIBB COMPANY · Firm: BRISTOL-MYERS SQUIBB COMPANY
H.R. 2163 - To amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for an medication step therapy protocol, and for other purpose - regarding all bio-pharmaceutical related provisions. H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purpose - regarding all bio-pharmaceutical related provisions. International Reference Pricing/Most Favored Nation - regarding all bio-pharmaceutical related issues. No bill number. Issues related to the six protected classes of medicines under Medicare Part D - regarding all bio-pharmaceutical related issues. No bill number. H.R 1319 - The American Rescue Plan - regarding all bio-pharmaceutical related provisions. H.R 4385 - Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions. Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions. No bill number. Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number. H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act - Establishes several programs and requirements relating to the prices of prescription drugs, health care coverage and costs, and public health - regarding all bio-pharmaceutical related provisions H.R. 19 - Lower Cost, More Cures Act of 2021 - To provide for certain reforms with respect to the Medicare program under title XVIII of the Social Security Act, the Medicaid program under title XIX of such Act, the Food and Drug Administration, and for other purpose - regarding all bio-pharmaceutical related provisions H.R 5237 - To amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes - regarding all bio-pharmaceutical related provisions. H.R 5376 the Build Back Better Act - regarding all bio-pharmaceutical related provision.
Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 MINI Act ORPHAN Act Mental Health Appropriations Language FY26
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act
Intellectual Property Reform concerning bio-pharmaceutical industry
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2024 · fourth_quarter · Q4
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes
International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues
Intellectual Property Reform concerning bio-pharmaceutical industry Discussions regarding the Patent Eligibility Restoration Act
Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 MINI Act Biosimilars reimbursement issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2024 · third_quarter · Q3
Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathway Implementation of Inflation Reduction Act of 2022 MINI Act H.R. 8412, Clinical Trial Modernization Act S.652/H.R.2630, Safe Step Act Mental health issues Biosimilars reimbursement issues
Intellectual Property Reform concerning bio-pharmaceutical industry
International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2024 · second_quarter · Q2
Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathways to Innovation Cures (EPIC) Act ORPHAN Act Implementation of Inflation Reduction Act of 2022 MINI Act H.R. 8412, Clinical Trial Modernization Act S.652/H.R.2630, Safe Step Act
Intellectual Property Reform concerning bio-pharmaceutical industry
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes H.R.2071, to amend Part D of title XVII of the Social Security Act to require the secretary of Health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical provisions
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2024 · first_quarter · Q1
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions Inflation Reduction Act implementation H.R.7625, the 340B PATIENTS Act H.R.2163, to amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for a medication step therapy protocol, and for other purposes H.R.2071, to amend Part D of title XVII of the Social Security Act to require the secretary of Health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical provisions
Intellectual Property Reform concerning bio-pharmaceutical industry Trade-Related aspects of Intellectual Property (TRIPS) Waiver
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2023 · fourth_quarter · Q4
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions Inflation Reduction Act implementation
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions H.R. 2630/S.464, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity End of year health package/PBM reform H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2023 · third_quarter · Q3
H.R. 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/H.R. 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023 Discussions in support of H.R.5376, Share the Savings with Seniors Act Discussions in support of H.R.5539, ORPHAN Cures Act H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Discussions in support of H.R.2880, Protecting Patients Against PBM Abuses Act H.R.2408, Access to Innovative Treatments Act of 2023
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions Inflation Reduction Act implementation
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2023 · second_quarter · Q2
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/HR 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Discussions regarding health equity PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023
Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions Issues related to the Inflation Reduction Act of 2022 IRA implementation
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2023 · first_quarter · Q1
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/HR 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity HR 5376, the Build Back Better Act regarding all bio-pharmaceutical provisions PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022 H.R.485, Protecting Health Care for All Patients of 2023 Act H.R.830, HELP Copays Act of 2023
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions Issues related to the Inflation Reduction Act of 2022 IRA implementation
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2022 · fourth_quarter · Q4
Discussions regarding HR 2617, Consolidated Appropriations Act of 2023
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions HR 5237, to amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients/ out-of-pocket costs Issues related to the Inflation Reduction Act of 2022
Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2022 · third_quarter · Q3
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464, Safe Step Act - regarding all bio-pharmaceutical related provisions Issues related to the Reauthorization of the Prescription Drug User Fee Act (PDUFA) - regarding all bio-pharmaceutical related provisions. No bill number HR 4385, Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions HR 7667, Food and Drug Amendments 2022 Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity Issues regarding HR 6833, Continuing Resolution HR 5376, the Build Back Better Act regarding all bio-pharmaceutical provisions
Issues related to access and reimbursement of Chimeric Antigen Receptor Theraph (CAR T) Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions HR 5237, to amend titles XI, XVIII, and XIX of the Social Security Act to lower prescrition drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients/ out-of-poclet costs HR 3, Elijah E. Cummings Lower Drig Costs NOW Act regarding all bio-pharmaceutical provisions Issues related to the Inflation Reduction Act of 2022
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2022 · second_quarter · Q2
Issues related to access and reimbursement of Chimeric Antigen Receptor Theraph (CAR T) Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related HR 5237, to amend titles XI, XVIII, and XIX of the Social Security Act to lower prescrition drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients/ out-of-poclet costs HR 3, Elijah E. Cummings Lower Drig Costs NOW Act regarding all bio-pharmaceutical provisions HR 19, Lower Cost, More Cures Act of 2021, regarding all bio-pharmaceutical related issues
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464, Safe Step Act - regarding all bio-pharmaceutical related provisions Issues related to the Reauthorization of the Prescription Drug User Fee Act (PDUFA) - regarding all bio-pharmaceutical related provisions. No bill number HR 4385, Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions HR 7667, Food and Drug Amendments 2022 Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity S 4293, Pharmacy Benefit Manager Transparency Act of 2022
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2022 · first_quarter · Q1
HR 1319 - American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464 - Safe Step Act - regarding all bio-pharmaceutical related provisions Issues related to the Reauthorization of the Prescription Drug User Fee Act (PDUFA) - regarding all bio-pharmaceutical related provisions. No bill number Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions. No bill number. Issues Related to the Food and Drug Administration's accelerated approval process - regarding all bio-pharmaceutical related provisions. No bill number. H.R 4385 - Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions. E- Prescribing Information- regarding modernizing the distribution of prescribing information. No bill number Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number. Essential Medicines/Buy American - regarding all bio-pharmaceutical related provisions. No bill number.
Intellectual Property Reform concerning bio-pharmaceutical industry. No related bill number
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2021 · first_quarter · 1A
Proposed policies regarding corporate tax reform regarding all bio-pharmaceutical related provisions. No bill number Import Taxes regarding all bio-pharmaceutical related provisions. No bill number.
HR 1319 - American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S.464 - Safe Step Act - regarding all bio-pharmaceutical related provisions H.R. 2163 To amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for an medication step therapy protocol, and for other purposes -regarding all bio-pharmaceutical related provisions. H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes - regarding all bio-pharmaceutical related provisions. International Reference Pricing/Most Favored Nation - regarding all bio-pharmaceutical related issues. No bill number. Issues related to the six protected classes of medicines under Medicare Part D - regarding all bio-pharmaceutical related issues. No bill number. H.R 1319 - The American Rescue Plan - regarding all bio-pharmaceutical related provisions. Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions. No bill number. Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions. No bill number. Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number. Essential Medicines/Buy American - regarding all bio-pharmaceutical related provisions. No bill number.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2021 · fourth_quarter · Q4
Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions. No bill number.
H.R. 2163 - To amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for an medication step therapy protocol, and for other purpose - regarding all bio-pharmaceutical related provisions. H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purpose - regarding all bio-pharmaceutical related provisions. International Reference Pricing/Most Favored Nation - regarding all bio-pharmaceutical related issues. No bill number. Issues related to the six protected classes of medicines under Medicare Part D - regarding all bio-pharmaceutical related issues. No bill number. H.R 1319 - The American Rescue Plan - regarding all bio-pharmaceutical related provisions. H.R 4385 - Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions. Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions. No bill number. Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number. H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act - Establishes several programs and requirements relating to the prices of prescription drugs, health care coverage and costs, and public health - regarding all bio-pharmaceutical related provisions H.R. 19 - Lower Cost, More Cures Act of 2021 - To provide for certain reforms with respect to the Medicare program under title XVIII of the Social Security Act, the Medicaid program under title XIX of such Act, the Food and Drug Administration, and for other purpose - regarding all bio-pharmaceutical related provisions H.R 5237 - To amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes - regarding all bio-pharmaceutical related provisions. H.R 5376 the Build Back Better Act - regarding all bio-pharmaceutical related provision.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2021 · third_quarter · Q3
International Reference Pricing/Most Favored Nation regarding all bio-pharmaceutical related issues. No bill number. Essential Medicines/Buy American regarding all bio-pharmaceutical related provisions. No bill number. Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number.
Proposed policies regarding corporate tax reform regarding all bio-pharmaceutical related provisions. No bill number Import Taxes regarding all bio-pharmaceutical related provisions. No bill number.
H.R. 2163 - To amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for an medication step therapy protocol, and for other purposes regarding all bio-pharmaceutical related provisions. H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes regarding all bio-pharmaceutical related provisions. International Reference Pricing/Most Favored Nation regarding all bio-pharmaceutical related issues. No bill number. Issues related to the six protected classes of medicines under Medicare Part D regarding all bio-pharmaceutical related issues. No bill number. H.R 1319 - The American Rescue Plan regarding all bio-pharmaceutical related provisions. H.R 4385 - Cancer Drug Parity Act/Oral Parity regarding all bio-pharmaceutical related provisions. Issues related to the 340B Drug Pricing Program regarding all bio-pharmaceutical related provisions. No bill number. Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number. H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act - Establishes several programs and requirements relating to the prices of prescription drugs, health care coverage and costs, and public health regarding all bio-pharmaceutical related provisions H.R. 19 - Lower Cost, More Cures Act of 2021 - To provide for certain reforms with respect to the Medicare program under title XVIII of the Social Security Act, the Medicaid program under title XIX of such Act, the Food and Drug Administration, and for other purposes regarding all bio-pharmaceutical related provisions H.R 5237 - To amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes - regarding all bio-pharmaceutical related provisions.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2021 · second_quarter · Q2
Intellectual Property Reform concerning bio-pharmaceutical industry. No related bill number Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number. S.1435/H.R. 2873 - Affordable Prescriptions for Patients Act of 2021 - prohibition on product hopping
International Reference Pricing/Most Favored Nation regarding all bio-pharmaceutical related issues. No bill number. Essential Medicines/Buy American regarding all bio-pharmaceutical related provisions. No bill number. Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2021 · first_quarter · Q1
Proposed policies regarding corporate tax reform regarding all bio-pharmaceutical related provisions. No bill number Import Taxes regarding all bio-pharmaceutical related provisions. No bill number.
H.R. 2163 To amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for an medication step therapy protocol, and for other purposes regarding all bio-pharmaceutical related provisions. H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes regarding all bio-pharmaceutical related provisions. International Reference Pricing/Most Favored Nation regarding all bio-pharmaceutical related issues. No bill number. Issues related to the six protected classes of medicines under Medicare Part D regarding all bio-pharmaceutical related issues. No bill number. H.R 1319 - The American Rescue Plan regarding all bio-pharmaceutical related provisions. Cancer Drug Parity Act/Oral Parity regarding all bio-pharmaceutical related provisions. No bill number. Issues related to the 340B Drug Pricing Program regarding all bio-pharmaceutical related provisions. No bill number. Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2020 · third_quarter · 3A
H.R. 1158, Further Consolidated Appropriations Act of 2020, regarding all bio-pharmaceutical related provisions H.R.1865, Further Consolidated Appropriations Act of 2020, regarding all bio-pharmaceutical related provisions
S. 73, End Taxpayer Subsidies for Drug Ads Act, regarding all bio-pharmaceutical related provisions. S. 378/H.R. 1093, Stop Price Gouging Act, regarding all bio-pharmaceutical related provisions. S. 425, LifeBOAT Act, regarding all bio-pharmaceutical related provisions.
H.R. 107, Burgess: Rebate cap, regarding all bio-pharmaceutical related provisions. H.R. 275, Medicare Prescription Drug Negotiation Act, regarding all bio-pharmaceutical related provisions. H.R. 366, Insulin Access for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1034, D. Collins/S. 640, Kennedy: Phair Pricing Act - Share the savings, regarding all bio-pharmaceutical related provisions. H.R. 1035, Prescription Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1332, Fair Care Act, regarding all bio-pharmaceutical related provisions. H.R. 1346, Medicare Buy-In and Health Care Stabilization Act, regarding all bio-pharmaceutical related provisions. H.R. 1384, Medicare for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1781, Payment Commission Data Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1788, Limits the penalty for Part B late enrollment to 15 percent and twice the period of no enrollment, regarding all bio-pharmaceutical related provisions. H.R. 2087, Reporting drug pricing information to Medicare, regarding all bio-pharmaceutical related provisions. H.R. 2113, Prescription STAR Act, regarding all bio-pharmaceutical related provisions. H.R.3, Lower Drug Costs Now Act of 2019, regarding all bio-pharmaceutical related provisions S. 62, Empowering Medicare Seniors to Negotiate Drug Prices, regarding all bio-pharmaceutical related provisions. S. 99, Medicare Drug Price Negotiation Act, regarding all bio-pharmaceutical related provisions. S. 205, Right Rebate Act, regarding all bio-pharmaceutical related provisions. S. 377/H.R. 1046, Medicare Negotiation and Competitive Licensing Act, regarding all bio-pharmaceutical related provisions. S. 470, Medicare at 50 Act, regarding all bio-pharmaceutical related provisions. S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 , regarding all bio-pharmaceutical related provisions. S. 475, RxCAP Act, regarding all bio-pharmaceutical related provisions. S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU Act) of 2019, regarding all bio-pharmaceutical related provisions. S. 551, REFUND Act of 2019, regarding all bio-pharmaceutical related provisions. S. 691, Expands Part D OOP assistance for low-income seniors and individuals with disabilities, regarding all bio-pharmaceutical related provisions. S. 801/H.R. 1781, Allows MedPAC and MACPAC to have access to information on drug rebates, regarding all bio-pharmaceutical related provisions. S. 981, Medicare-X Choice Act of 2019, regarding all bio-pharmaceutical related provisions. Pending rule to change the Rebate Safe Harbor, regarding all bio-pharmaceutical related provisions. H.R. 1839, Medicaid Services Investment and Accountability Act, regarding all bio-pharmaceutical related provisions H.R. 2452, Medicare for America Act, regarding all bio-pharmaceutical related provisions H.R. 3107, Improving Seniors Timely Access to Care Act, regarding all bio-pharmaceutical related provisions H.R. 3327, Drug Price Transparency for Medicare Patients Act, regarding all bio-pharmaceutical related provisions S. 1261/H.R. 2463, Choose Medicare Act, regarding all bio-pharmaceutical related provisions S. 1497, Health Care Price Check Act, regarding all bio-pharmaceutical related provisions S. 2081, a bill to require drug manufacturers to provide rebates for drugs furnished under Medicare Part B for which the growth in average sales price has exceeded inflation, regarding all bio-pharmaceutical related provisions. S. 2543, Prescription Drug Pricing Reduction Act of 2019, regarding all bio-pharmaceutical provisions. H.R. 19/S.3129 , Lower Costs, More Cures Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 6218/S. 3457, Preserving Patient Access to Home Infusion Act, regarding all bio-pharmaceutical related provisions No Bill, Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2020 · second_quarter · 2A
H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 985, Fair Access for Safe and Timely (FAST) Generics Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 986, Protecting American with Preexisting Conditions Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1010, Short-Term, Limited Duration Insurance (STLDI), regarding all bio-pharmaceutical related provisions. H.R. 1323, Rural Hospital Frontier Fairness Act, regarding all bio-pharmaceutical related provisions. H.R. 1385, State Allowance for a Variety of Exchanges (SAVE) Act, regarding all bio-pharmaceutical related provisions. H.R. 1386, Expanded Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act, regarding all bio-pharmaceutical related provisions. H.R. 1409, Transparency in All Health Care Pricing Act, regarding all bio-pharmaceutical related provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions. H.R. 1478, Insulin importation, regarding all bio-pharmaceutical related provisions. H.R. 1503, Orange Book Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1506, Fair and Immediate Release (FAIR) of Generics Act, regarding all bio-pharmaceutical related provisions. H.R. 1520, Purple Book Continuity Act, regarding all bio-pharmaceutical related provisions. H.R. 2011, Protecting Access to Biosimilars Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2038, State-based , Market-Oriented, Prescription Drug Negotiations Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2064, Product Sample reporting, regarding all bio-pharmaceutical related provisions. S. 61, Safe and Affordable Drugs from Canada Act, regarding all bio-pharmaceutical related provisions. S. 97, Affordable and Safe Drug Importation Act, regarding all bio-pharmaceutical related provisions. S. 102, Prescription Drug Price Relief Act, regarding all bio-pharmaceutical related provisions. S. 344/H.R. 990, Hatch-Waxman Integrity Act, regarding all bio-pharmaceutical related provisions. S. 366/H.R. 1188, FLAT Prices Act- Reduced exclusivity period for certain price hikes, regarding all bio-pharmaceutical related provisions. S. 418, FDA Accountability for Public Safety Act, regarding all bio-pharmaceutical related provisions. S. 419, Protecting Americans from Dangerous Opioids Act, regarding all bio-pharmaceutical related provisions. S. 637, CURE High Drug Prices Act, regarding all bio-pharmaceutical related provisions. S. 657, Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. S. 658, Accelerated Drug Approval for Prescription Therapies Act, regarding all bio-pharmaceutical related provisions. S. 659, Biologic Patent Transparency Act, regarding all bio-pharmaceutical related provisions. S. 660, Transparency in Petitions Act, regarding all bio-pharmaceutical related provisions. S. 709, Establishes public dashboard for price and utilization of drugs purchased by federal programs, regarding all bio-pharmaceutical related provisions. S. 741 /H.R. 1730, Cancer Drug Parity Act, regarding all bio-pharmaceutical related provisions. S. 844, Short Competition Act, regarding all bio-pharmaceutical related provisions. S. 977, Transparent Drug Pricing Act of 2019, regarding all bio-pharmaceutical related provisions. S. 989, STEER Act, regarding all bio-pharmaceutical related provisions. S. 1140, A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009, regarding all bio-pharmaceutical related provisions. S.1169, FDA citizen petition, regarding all bio-pharmaceutical related provisions. S. 1209, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications, regarding all bio-pharmaceutical related provisions. H.R. 2115, Public Disclosure of Drug Discounts Act, regarding all bio-pharmaceutical related provisions H.R.2296/S.1391, FAIR Drug Pricing Act, regarding all bio-pharmaceutical related provisions H.R.2700, Lowering Prescription Drug Costs and Extending Community Health Centers and other Health Priorities Act, regarding all bio-pharmaceutical related provisions H.R. 3223, Pharmacy Benefit Manager Accountability Study Act, regarding all bio-pharmaceutical related provisions S. 1361/H.R.2584, Preventive Health Savings Act, regarding all bio-pharmaceutical related provisions S. 1437, DTC Act, regarding all bio-pharmaceutical related provisions S.1532, Pharmacy Benefit Managers Accountability Study Act, regarding all bio-pharmaceutical related provisions S.1636, Ensuring Innovation Act, regarding all bio-pharmaceutical related provisions S. 1664, Prescription Drug Price Reporting Act, regarding all bio-pharmaceutical related provisions S. 1801, Affordable Medications Act, regarding all bio-pharmaceutical related provisions S. 1895, Lowering Health Costs Act, regarding all bio-pharmaceutical related provisions S. 1897, a bill to establish a process for updating the labeling of certain drugs with outdated labeling, regarding all bio-pharmaceutical related provisions S. 1897/H.R. 3523, End Price Gouging for Medications Act, regarding all bio-pharmaceutical related provisions S. 2004, Emergency Access to Insulin Act, regarding all bio-pharmaceutical related provisions H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions H.R 748/S. 3548, Coronavirus Aid, Relief and Economic Security Act (CARES Act), regarding all bio-pharmaceutical provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, regarding all bio-pharmaceutical related provisions
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2020 · fourth_quarter · 4A
H.R. 107, Burgess: Rebate cap, regarding all bio-pharmaceutical related provisions. H.R. 275, Medicare Prescription Drug Negotiation Act, regarding all bio-pharmaceutical related provisions. H.R. 366, Insulin Access for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1034, D. Collins/S. 640, Kennedy: Phair Pricing Act - Share the savings, regarding all bio-pharmaceutical related provisions. H.R. 1035, Prescription Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1332, Fair Care Act, regarding all bio-pharmaceutical related provisions. H.R. 1346, Medicare Buy-In and Health Care Stabilization Act, regarding all bio-pharmaceutical related provisions. H.R. 1384, Medicare for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1781, Payment Commission Data Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1788, Limits the penalty for Part B late enrollment to 15 percent and twice the period of no enrollment, regarding all bio-pharmaceutical related provisions. H.R. 2087, Reporting drug pricing information to Medicare, regarding all bio-pharmaceutical related provisions. H.R. 2113, Prescription STAR Act, regarding all bio-pharmaceutical related provisions. H.R.3, Lower Drug Costs Now Act of 2019, regarding all bio-pharmaceutical related provisions S. 62, Empowering Medicare Seniors to Negotiate Drug Prices, regarding all bio-pharmaceutical related provisions. S. 99, Medicare Drug Price Negotiation Act, regarding all bio-pharmaceutical related provisions. S. 205, Right Rebate Act, regarding all bio-pharmaceutical related provisions. S. 377/H.R. 1046, Medicare Negotiation and Competitive Licensing Act, regarding all bio-pharmaceutical related provisions. S. 470, Medicare at 50 Act, regarding all bio-pharmaceutical related provisions. S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 , regarding all bio-pharmaceutical related provisions. S. 475, RxCAP Act, regarding all bio-pharmaceutical related provisions. S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU Act) of 2019, regarding all bio-pharmaceutical related provisions. S. 551, REFUND Act of 2019, regarding all bio-pharmaceutical related provisions. S. 691, Expands Part D OOP assistance for low-income seniors and individuals with disabilities, regarding all bio-pharmaceutical related provisions. S. 801/H.R. 1781, Allows MedPAC and MACPAC to have access to information on drug rebates, regarding all bio-pharmaceutical related provisions. S. 981, Medicare-X Choice Act of 2019, regarding all bio-pharmaceutical related provisions. Pending rule to change the Rebate Safe Harbor, regarding all bio-pharmaceutical related provisions. H.R. 1839, Medicaid Services Investment and Accountability Act, regarding all bio-pharmaceutical related provisions H.R. 2452, Medicare for America Act, regarding all bio-pharmaceutical related provisions H.R. 3107, Improving Seniors Timely Access to Care Act, regarding all bio-pharmaceutical related provisions H.R. 3327, Drug Price Transparency for Medicare Patients Act, regarding all bio-pharmaceutical related provisions S. 1261/H.R. 2463, Choose Medicare Act, regarding all bio-pharmaceutical related provisions S. 1497, Health Care Price Check Act, regarding all bio-pharmaceutical related provisions S. 2081, a bill to require drug manufacturers to provide rebates for drugs furnished under Medicare Part B for which the growth in average sales price has exceeded inflation, regarding all bio-pharmaceutical related provisions. S. 2543, Prescription Drug Pricing Reduction Act of 2019, regarding all bio-pharmaceutical provisions. H.R. 19/S.3129 , Lower Costs, More Cures Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 6218/S. 3457, Preserving Patient Access to Home Infusion Act, regarding all bio-pharmaceutical related provisions No Bill, Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Most Favored Nation (MFN) Model - (CMS-5528-IFC)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2020 · fourth_quarter · Q4
H.R. 2209, To establish the position of Chief Pharmaceutical Negotiator in the Office of the United States Trade Representative responsible for conducting trade negotiations and enforcing trade agreements related to acts, policies, and practices of foreign governments that fail to appropriately reward United States innovation with respect to pharmaceuticals, and for other purposes, regarding all bio-pharmaceutical related provisions. Unite States, Mexico, Canada Trade Agreement, regarding all bio-pharmaceutical related provisions. S. 3537, Protecting our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions S. 3538, Strengthening Americas Supply Chain and National Security Act, regarding all bio-pharmaceutical related provisions No Bill, potential Buy American executive order for health-related goods, regarding all bio-pharmaceutical related provisions H.R. 4710, Pharmaceutical Independence Long-Term Readiness Reform Act, regarding all bio-pharmaceutical related provisions H.R. 4866, National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 5381, International Pharmaceutical Transparency Act of 2019 , regarding all bio-pharmaceutical related provisions H.R. 5982, Safe Medicine Act, regarding all bio-pharmaceutical related provisions H.R. 6049/S3343, Medical Supply Chain Security Act, regarding all bio-pharmaceutical related provisions H.R. 6080, Preventing Drug Shortages Act, regarding all bio-pharmaceutical , regarding all bio-pharmaceutical related provisions related provisions H.R. 6393, Strengthening America's Supply Chain and National Security Act, regarding all bio-pharmaceutical related provisions H.R.6399/S.3715 , SAVE Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6431, Made in America Emergency Preparedness Act, regarding all bio-pharmaceutical related provisions H.R. 6482, Protecting Our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6670, Prescription for American Drug Independence Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6690, Bring Entrepreneurial Advancements To Consumers Here In North America Act ,regarding all bio-pharmaceutical related provisions H.R. 6708/S. 3432, Securing America's Medicine Cabinet Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6930, MADE in America Act of 2020, regarding all bio-pharmaceutical related provisions S. 3635, Protecting Our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions S. 2723, Mitigating Emergency Drug Shortages Act, regarding all bio-pharmaceutical related provisions S.3945, Bring Entrepreneurial Advancements To Consumers Here In North America Act, regarding all bio-pharmaceutical related provisions
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2020 · third_quarter · Q3
H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 985, Fair Access for Safe and Timely (FAST) Generics Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 986, Protecting American with Preexisting Conditions Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1010, Short-Term, Limited Duration Insurance (STLDI), regarding all bio-pharmaceutical related provisions. H.R. 1323, Rural Hospital Frontier Fairness Act, regarding all bio-pharmaceutical related provisions. H.R. 1385, State Allowance for a Variety of Exchanges (SAVE) Act, regarding all bio-pharmaceutical related provisions. H.R. 1386, Expanded Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act, regarding all bio-pharmaceutical related provisions. H.R. 1409, Transparency in All Health Care Pricing Act, regarding all bio-pharmaceutical related provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions. H.R. 1478, Insulin importation, regarding all bio-pharmaceutical related provisions. H.R. 1503, Orange Book Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1506, Fair and Immediate Release (FAIR) of Generics Act, regarding all bio-pharmaceutical related provisions. H.R. 1520, Purple Book Continuity Act, regarding all bio-pharmaceutical related provisions. H.R. 2011, Protecting Access to Biosimilars Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2038, State-based , Market-Oriented, Prescription Drug Negotiations Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2064, Product Sample reporting, regarding all bio-pharmaceutical related provisions. S. 61, Safe and Affordable Drugs from Canada Act, regarding all bio-pharmaceutical related provisions. S. 97, Affordable and Safe Drug Importation Act, regarding all bio-pharmaceutical related provisions. S. 102, Prescription Drug Price Relief Act, regarding all bio-pharmaceutical related provisions. S. 344/H.R. 990, Hatch-Waxman Integrity Act, regarding all bio-pharmaceutical related provisions. S. 366/H.R. 1188, FLAT Prices Act- Reduced exclusivity period for certain price hikes, regarding all bio-pharmaceutical related provisions. S. 418, FDA Accountability for Public Safety Act, regarding all bio-pharmaceutical related provisions. S. 419, Protecting Americans from Dangerous Opioids Act, regarding all bio-pharmaceutical related provisions. S. 637, CURE High Drug Prices Act, regarding all bio-pharmaceutical related provisions. S. 657, Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. S. 658, Accelerated Drug Approval for Prescription Therapies Act, regarding all bio-pharmaceutical related provisions. S. 659, Biologic Patent Transparency Act, regarding all bio-pharmaceutical related provisions. S. 660, Transparency in Petitions Act, regarding all bio-pharmaceutical related provisions. S. 709, Establishes public dashboard for price and utilization of drugs purchased by federal programs, regarding all bio-pharmaceutical related provisions. S. 741 /H.R. 1730, Cancer Drug Parity Act, regarding all bio-pharmaceutical related provisions. S. 844, Short Competition Act, regarding all bio-pharmaceutical related provisions. S. 977, Transparent Drug Pricing Act of 2019, regarding all bio-pharmaceutical related provisions. S. 989, STEER Act, regarding all bio-pharmaceutical related provisions. S. 1140, A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009, regarding all bio-pharmaceutical related provisions. S.1169, FDA citizen petition, regarding all bio-pharmaceutical related provisions. S. 1209, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications, regarding all bio-pharmaceutical related provisions. H.R. 2115, Public Disclosure of Drug Discounts Act, regarding all bio-pharmaceutical related provisions H.R.2296/S.1391, FAIR Drug Pricing Act, regarding all bio-pharmaceutical related provisions H.R.2700, Lowering Prescription Drug Costs and Extending Community Health Centers and other Health Priorities Act, regarding all bio-pharmaceutical related provisions H.R. 3223, Pharmacy Benefit Manager Accountability Study Act, regarding all bio-pharmaceutical related provisions S. 1361/H.R.2584, Preventive Health Savings Act, regarding all bio-pharmaceutical related provisions S. 1437, DTC Act, regarding all bio-pharmaceutical related provisions S.1532, Pharmacy Benefit Managers Accountability Study Act, regarding all bio-pharmaceutical related provisions S.1636, Ensuring Innovation Act, regarding all bio-pharmaceutical related provisions S. 1664, Prescription Drug Price Reporting Act, regarding all bio-pharmaceutical related provisions S. 1801, Affordable Medications Act, regarding all bio-pharmaceutical related provisions S. 1895, Lowering Health Costs Act, regarding all bio-pharmaceutical related provisions S. 1897, a bill to establish a process for updating the labeling of certain drugs with outdated labeling, regarding all bio-pharmaceutical related provisions S. 1897/H.R. 3523, End Price Gouging for Medications Act, regarding all bio-pharmaceutical related provisions S. 2004, Emergency Access to Insulin Act, regarding all bio-pharmaceutical related provisions H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions H.R 748/S. 3548, Coronavirus Aid, Relief and Economic Security Act (CARES Act), regarding all bio-pharmaceutical provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, regarding all bio-pharmaceutical related provisions
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2020 · second_quarter · Q2
H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 985, Fair Access for Safe and Timely (FAST) Generics Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 986, Protecting American with Preexisting Conditions Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1010, Short-Term, Limited Duration Insurance (STLDI), regarding all bio-pharmaceutical related provisions. H.R. 1323, Rural Hospital Frontier Fairness Act, regarding all bio-pharmaceutical related provisions. H.R. 1385, State Allowance for a Variety of Exchanges (SAVE) Act, regarding all bio-pharmaceutical related provisions. H.R. 1386, Expanded Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act, regarding all bio-pharmaceutical related provisions. H.R. 1409, Transparency in All Health Care Pricing Act, regarding all bio-pharmaceutical related provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions. H.R. 1478, Insulin importation, regarding all bio-pharmaceutical related provisions. H.R. 1503, Orange Book Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1506, Fair and Immediate Release (FAIR) of Generics Act, regarding all bio-pharmaceutical related provisions. H.R. 1520, Purple Book Continuity Act, regarding all bio-pharmaceutical related provisions. H.R. 2011, Protecting Access to Biosimilars Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2038, State-based , Market-Oriented, Prescription Drug Negotiations Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2064, Product Sample reporting, regarding all bio-pharmaceutical related provisions. S. 61, Safe and Affordable Drugs from Canada Act, regarding all bio-pharmaceutical related provisions. S. 97, Affordable and Safe Drug Importation Act, regarding all bio-pharmaceutical related provisions. S. 102, Prescription Drug Price Relief Act, regarding all bio-pharmaceutical related provisions. S. 344/H.R. 990, Hatch-Waxman Integrity Act, regarding all bio-pharmaceutical related provisions. S. 366/H.R. 1188, FLAT Prices Act- Reduced exclusivity period for certain price hikes, regarding all bio-pharmaceutical related provisions. S. 418, FDA Accountability for Public Safety Act, regarding all bio-pharmaceutical related provisions. S. 419, Protecting Americans from Dangerous Opioids Act, regarding all bio-pharmaceutical related provisions. S. 637, CURE High Drug Prices Act, regarding all bio-pharmaceutical related provisions. S. 657, Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. S. 658, Accelerated Drug Approval for Prescription Therapies Act, regarding all bio-pharmaceutical related provisions. S. 659, Biologic Patent Transparency Act, regarding all bio-pharmaceutical related provisions. S. 660, Transparency in Petitions Act, regarding all bio-pharmaceutical related provisions. S. 709, Establishes public dashboard for price and utilization of drugs purchased by federal programs, regarding all bio-pharmaceutical related provisions. S. 741 /H.R. 1730, Cancer Drug Parity Act, regarding all bio-pharmaceutical related provisions. S. 844, Short Competition Act, regarding all bio-pharmaceutical related provisions. S. 977, Transparent Drug Pricing Act of 2019, regarding all bio-pharmaceutical related provisions. S. 989, STEER Act, regarding all bio-pharmaceutical related provisions. S. 1140, A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009, regarding all bio-pharmaceutical related provisions. S.1169, FDA citizen petition, regarding all bio-pharmaceutical related provisions. S. 1209, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications, regarding all bio-pharmaceutical related provisions. H.R. 2115, Public Disclosure of Drug Discounts Act, regarding all bio-pharmaceutical related provisions H.R.2296/S.1391, FAIR Drug Pricing Act, regarding all bio-pharmaceutical related provisions H.R.2700, Lowering Prescription Drug Costs and Extending Community Health Centers and other Health Priorities Act, regarding all bio-pharmaceutical related provisions H.R. 3223, Pharmacy Benefit Manager Accountability Study Act, regarding all bio-pharmaceutical related provisions S. 1361/H.R.2584, Preventive Health Savings Act, regarding all bio-pharmaceutical related provisions S. 1437, DTC Act, regarding all bio-pharmaceutical related provisions S.1532, Pharmacy Benefit Managers Accountability Study Act, regarding all bio-pharmaceutical related provisions S.1636, Ensuring Innovation Act, regarding all bio-pharmaceutical related provisions S. 1664, Prescription Drug Price Reporting Act, regarding all bio-pharmaceutical related provisions S. 1801, Affordable Medications Act, regarding all bio-pharmaceutical related provisions S. 1895, Lowering Health Costs Act, regarding all bio-pharmaceutical related provisions S. 1897, a bill to establish a process for updating the labeling of certain drugs with outdated labeling, regarding all bio-pharmaceutical related provisions S. 1897/H.R. 3523, End Price Gouging for Medications Act, regarding all bio-pharmaceutical related provisions S. 2004, Emergency Access to Insulin Act, regarding all bio-pharmaceutical related provisions H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions H.R 748/S. 3548, Coronavirus Aid, Relief and Economic Security Act (CARES Act), regarding all bio-pharmaceutical provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, regarding all bio-pharmaceutical related provisions
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2020 · first_quarter · Q1
H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 985, Fair Access for Safe and Timely (FAST) Generics Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 986, Protecting American with Preexisting Conditions Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1010, Short-Term, Limited Duration Insurance (STLDI), regarding all bio-pharmaceutical related provisions. H.R. 1323, Rural Hospital Frontier Fairness Act, regarding all bio-pharmaceutical related provisions. H.R. 1385, State Allowance for a Variety of Exchanges (SAVE) Act, regarding all bio-pharmaceutical related provisions. H.R. 1386, Expanded Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act, regarding all bio-pharmaceutical related provisions. H.R. 1409, Transparency in All Health Care Pricing Act, regarding all bio-pharmaceutical related provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions. H.R. 1478, Insulin importation, regarding all bio-pharmaceutical related provisions. H.R. 1503, Orange Book Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1506, Fair and Immediate Release (FAIR) of Generics Act, regarding all bio-pharmaceutical related provisions. H.R. 1520, Purple Book Continuity Act, regarding all bio-pharmaceutical related provisions. H.R. 2011, Protecting Access to Biosimilars Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2038, State-based , Market-Oriented, Prescription Drug Negotiations Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2064, Product Sample reporting, regarding all bio-pharmaceutical related provisions. S. 61, Safe and Affordable Drugs from Canada Act, regarding all bio-pharmaceutical related provisions. S. 97, Affordable and Safe Drug Importation Act, regarding all bio-pharmaceutical related provisions. S. 102, Prescription Drug Price Relief Act, regarding all bio-pharmaceutical related provisions. S. 344/H.R. 990, Hatch-Waxman Integrity Act, regarding all bio-pharmaceutical related provisions. S. 366/H.R. 1188, FLAT Prices Act- Reduced exclusivity period for certain price hikes, regarding all bio-pharmaceutical related provisions. S. 418, FDA Accountability for Public Safety Act, regarding all bio-pharmaceutical related provisions. S. 419, Protecting Americans from Dangerous Opioids Act, regarding all bio-pharmaceutical related provisions. S. 637, CURE High Drug Prices Act, regarding all bio-pharmaceutical related provisions. S. 657, Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. S. 658, Accelerated Drug Approval for Prescription Therapies Act, regarding all bio-pharmaceutical related provisions. S. 659, Biologic Patent Transparency Act, regarding all bio-pharmaceutical related provisions. S. 660, Transparency in Petitions Act, regarding all bio-pharmaceutical related provisions. S. 709, Establishes public dashboard for price and utilization of drugs purchased by federal programs, regarding all bio-pharmaceutical related provisions. S. 741 /H.R. 1730, Cancer Drug Parity Act, regarding all bio-pharmaceutical related provisions. S. 844, Short Competition Act, regarding all bio-pharmaceutical related provisions. S. 977, Transparent Drug Pricing Act of 2019, regarding all bio-pharmaceutical related provisions. S. 989, STEER Act, regarding all bio-pharmaceutical related provisions. S. 1140, A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009, regarding all bio-pharmaceutical related provisions. S.1169, FDA citizen petition, regarding all bio-pharmaceutical related provisions. S. 1209, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications, regarding all bio-pharmaceutical related provisions. H.R. 2115, Public Disclosure of Drug Discounts Act, regarding all bio-pharmaceutical related provisions H.R.2296/S.1391, FAIR Drug Pricing Act, regarding all bio-pharmaceutical related provisions H.R.2700, Lowering Prescription Drug Costs and Extending Community Health Centers and other Health Priorities Act, regarding all bio-pharmaceutical related provisions H.R. 3223, Pharmacy Benefit Manager Accountability Study Act, regarding all bio-pharmaceutical related provisions S. 1361/H.R.2584, Preventive Health Savings Act, regarding all bio-pharmaceutical related provisions S. 1437, DTC Act, regarding all bio-pharmaceutical related provisions S.1532, Pharmacy Benefit Managers Accountability Study Act, regarding all bio-pharmaceutical related provisions S.1636, Ensuring Innovation Act, regarding all bio-pharmaceutical related provisions S. 1664, Prescription Drug Price Reporting Act, regarding all bio-pharmaceutical related provisions S. 1801, Affordable Medications Act, regarding all bio-pharmaceutical related provisions S. 1895, Lowering Health Costs Act, regarding all bio-pharmaceutical related provisions S. 1897, a bill to establish a process for updating the labeling of certain drugs with outdated labeling, regarding all bio-pharmaceutical related provisions S. 1897/H.R. 3523, End Price Gouging for Medications Act, regarding all bio-pharmaceutical related provisions S. 2004, Emergency Access to Insulin Act, regarding all bio-pharmaceutical related provisions H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions H.R 748/S. 3548, Coronavirus Aid, Relief and Economic Security Act (CARES Act), regarding all bio-pharmaceutical related provisions
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2019 · fourth_quarter · Q4
S. 73, End Taxpayer Subsidies for Drug Ads Act, regarding all bio-pharmaceutical related provisions. S. 378/H.R. 1093, Stop Price Gouging Act, regarding all bio-pharmaceutical related provisions. S. 425, LifeBOAT Act, regarding all bio-pharmaceutical related provisions.
H.R. 1499, Protecting Consumer Access to Generic Drugs Act, regarding all bio-pharmaceutical related provisions H.R. 965, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 1344, Competitive DRUGS Act, regarding all bio-pharmaceutical related provisions. H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions S. 64, Preserve Access to Affordable Generics and Biosimilars Act,regarding all bio-pharmaceutical related provisions. S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R.2375, Preserve Access to Affordable Generics and Biosimilars Act, regarding all bio-pharmaceutical related provisions H.R. 2387, STOP GAMES Act, regarding all bio-pharmaceutical related provisions H.R. 3199, TERM Act, regarding all bio-pharmaceutical related provisions S. 440, PACED Act, regarding all bio-pharmaceutical related provisions S. 1224/H.R.2374, Stop STALLING Act, regarding all bio-pharmaceutical related provisions S.1416, Affordable Prescriptions for Patients Act, regarding all bio-pharmaceutical related provisions S. 1617, Second Look at Drug Patents Act, regarding all bio-pharmaceutical related provisions
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2019 · third_quarter · Q3
S. 73, End Taxpayer Subsidies for Drug Ads Act, regarding all bio-pharmaceutical related provisions. S. 378/H.R. 1093, Stop Price Gouging Act, regarding all bio-pharmaceutical related provisions. S. 425, LifeBOAT Act, regarding all bio-pharmaceutical related provisions.
H.R. 2209, To establish the position of Chief Pharmaceutical Negotiator in the Office of the United States Trade Representative responsible for conducting trade negotiations and enforcing trade agreements related to acts, policies, and practices of foreign governments that fail to appropriately reward United States innovation with respect to pharmaceuticals, and for other purposes, regarding all bio-pharmaceutical related provisions. Unite States, Mexico, Canada Trade Agreement, regarding all bio-pharmaceutical related provisions.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2019 · second_quarter · Q2
S. 73, End Taxpayer Subsidies for Drug Ads Act, regarding all bio-pharmaceutical related provisions. S. 378/H.R. 1093, Stop Price Gouging Act, regarding all bio-pharmaceutical related provisions. S. 425, LifeBOAT Act, regarding all bio-pharmaceutical related provisions.
H.R. 2209, To establish the position of Chief Pharmaceutical Negotiator in the Office of the United States Trade Representative responsible for conducting trade negotiations and enforcing trade agreements related to acts, policies, and practices of foreign governments that fail to appropriately reward United States innovation with respect to pharmaceuticals, and for other purposes, regarding all bio-pharmaceutical related provisions. Unite States, Mexico, Canada Trade Agreement, regarding all bio-pharmaceutical related provisions.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2019 · first_quarter · Q1
H.R. 1499, Protecting Consumer Access to Generic Drugs Act, regarding all bio-pharmaceutical related provisions H.R. 965, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 1344, Competitive DRUGS Act, regarding all bio-pharmaceutical related provisions. S. 64, Preserve Access to Affordable Generics and Biosimilars Act,regarding all bio-pharmaceutical related provisions. S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, regarding all bio-pharmaceutical related provisions.
H.R. 2209, To establish the position of Chief Pharmaceutical Negotiator in the Office of the United States Trade Representative responsible for conducting trade negotiations and enforcing trade agreements related to acts, policies, and practices of foreign governments that fail to appropriately reward United States innovation with respect to pharmaceuticals, and for other purposes, regarding all bio-pharmaceutical related provisions. Unite States, Mexico, Canada Trade Agreement, regarding all bio-pharmaceutical related provisions.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2018 · fourth_quarter · Q4
H.R. 1, Tax Cuts and Jobs Act, regarding all pharmaceutical related provisions.
No bill, lobbied to raise awareness about Atrial Fibrillation and stroke prevention. No bill, lobbied regarding biosimilars issues including naming, labeling and interchangeability. H.R. 1245 and S. 469, Affordable and Safe Prescription Drug Importation Act, lobbied regarding all biopharmaceutical provisions. H.R. 1703, Medical Product Communications Act of 2017, regarding all biopharmaceutical related provisions H.R. 2851, Stop the Importation and Trafficking of Synthetic Analogues Act of 2017, regarding all biopharmaceutical related provisions No bill, lobbied for changes to the 340B Drug Discount Program. H.R. 4710, 340B PAUSE Act, lobbied regarding all biopharmaceutical provisions. H.R. 4392, a bill to repeal the HOPPS final regulation related to changes in the payment amount for certain drugs under the 340B program, lobbied regarding all biopharmaceutical provisions. H.R. 2026, the Pharmaceutical Information Exchange (PIE) Act of 2017, lobbied regarding all biopharmaceutical provisions. S. 2312, Helping Ensure Low-Income Patients have Access to Care and Treatment (HELP) Act, regarding all biopharmaceutical related provisions. S.2453, Ensuring the Value of the 340B Program Act of 2018, regarding all biopharmaceutical related provisions. H.R. 5598 340B Optimization Act, regarding all biopharmaceutical related provisions. H.R. 6071 SERV Communities Act, regarding all biopharmaceutical related provisions. H.R. 6240, Drug Discount Accountability Act, regarding all biopharmaceutical related provisions. H.R. 6143, S. 2554, Patient Right to Know Drug Prices Act, regarding all biopharmaceutical related provisions. H.R. 6, SUPPORT for Patients and Communities Act, regarding all biopharmaceutical related provisions.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2018 · third_quarter · Q3
American Health Care Act, regarding all biopharmaceutical related provisions. Continuing Budget Resolution, lobbied regarding all biopharmaceutical provisions. Better Care Reconciliation Act, regarding all biopharmaceutical related provisions. S. 1771, Department of Labor, HHS and Education Appropriations Act, regarding all pharmaceutical related provisions. H.R. 1625, Consolidates Appropriations Act, regarding all pharmaceutical related provisions.
H.R. 849, S. 260, S. 251 Protecting Seniors Access to Medicare Act, lobbied regarding all biopharmaceutical related provisions. S.771, Improving Access To Affordable Prescription Drugs Act, lobbied regarding all biopharmaceutical related provisions. S.348, Prescription Drug and Health Improvement Act of 2017, lobbied regarding all biopharmaceutical related provisions. S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017, lobbied regarding all biopharmaceutical related provisions. No bill, American Patients First Prescription Drug Blueprint, regarding all biopharmaceutical related provisions. H.R. 6505, Medicare Negotiation and Competitive Licensing Act of 2018, regarding all biopharmaceutical related provisions. H.R. 6642, to amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs, regarding all biopharmaceutical related provisions. S. 2553, H.R. 6144, Know the Lowest Price Act of 2018, regarding all biopharmaceutical related provisions.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2018 · second_quarter · Q2
American Health Care Act, regarding all biopharmaceutical related provisions. Continuing Budget Resolution, lobbied regarding all biopharmaceutical provisions. Better Care Reconciliation Act, regarding all biopharmaceutical related provisions. S. 1771, Department of Labor, HHS and Education Appropriations Act, regarding all pharmaceutical related provisions. H.R. 1625, Consolidates Appropriations Act, regarding all pharmaceutical related provisions.
Lobbied regarding intellectual property rights in trade agreements and international negotiations. Saudi Arabia, Saudi Food and Drug Authority, lobbied Congress regarding pharmaceutical patent infringement issues.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2018 · first_quarter · Q1
H.R. 849, S. 260, S. 251 Protecting Seniors Access to Medicare Act, lobbied regarding all biopharmaceutical related provisions. S.771, Improving Access To Affordable Prescription Drugs Act, lobbied regarding all biopharmaceutical related provisions. S.348, Prescription Drug and Health Improvement Act of 2017, lobbied regarding all biopharmaceutical related provisions. S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017, lobbied regarding all biopharmaceutical related provisions.
American Health Care Act, regarding all biopharmaceutical related provisions. Continuing Budget Resolution, lobbied regarding all biopharmaceutical provisions. Better Care Reconciliation Act, regarding all biopharmaceutical related provisions. S. 1771, Department of Labor, HHS and Education Appropriations Act, regarding all pharmaceutical related provisions. H.R. 1625, Consolidates Appropriations Act, regarding all pharmaceutical related provisions.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2017 · fourth_quarter · Q4
H.R. 849, S. 260, S. 251 Protecting Seniors Access to Medicare Act, lobbied regarding all biopharmaceutical related provisions. No bill, Children's Health Insurance Program, lobbied regarding all biopharmaceutical related provisions. S.771, Improving Access To Affordable Prescription Drugs Act, lobbied regarding all biopharmaceutical related provisions. S.348, Prescription Drug and Health Improvement Act of 2017, lobbied regarding all biopharmaceutical related provisions. S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017, lobbied regarding all biopharmaceutical related provisions.
No bill, lobbied on patent troll issues regarding biopharmaceutical patents.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2017 · third_quarter · Q3
American Health Care Act, regarding all biopharmaceutical related provisions. Continuing Budget Resolution, lobbied regarding all biopharmaceutical provisions. Better Care Reconciliation Act, regarding all biopharmaceutical related provisions. S. 1771, Department of Labor, HHS and Education Appropriations Act, regarding all pharmaceutical related provisions.
No bill, lobbied to raise awareness about Atrial Fibrillation and stroke prevention. H.R. 878, Right to Try Act of 2017 and S. 204, Trickett Wendler Right to Try Act of 2017,lobbied regarding all biopharmaceutical provisions. Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act, lobbied regarding all biopharmaceutical provisions. No bill, lobbied regarding biosimilars issues including naming, labeling and interchangeability. HR 2430,FDA Reauthorization Act, lobbied regarding all biopharmaceutical provisions. H.R. 1245 and S. 469, Affordable and Safe Prescription Drug Importation Act, lobbied regarding all biopharmaceutical provisions. H.R.1231 and S. 456, RACE for Children Act, lobbied regarding all biopharmaceutical provisions. H.R. 1703, Medical Product Communications Act of 2017, regarding all biopharmaceutical related provisions H.R. 2851, Stop the Importation and Trafficking of Synthetic Analogues Act of 2017, regarding all biopharmaceutical related provisions No bill, lobbied for changes to the 340B Drug Discount Program.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2017 · second_quarter · Q2
No bill, lobbied to raise awareness about Atrial Fibrillation and stroke prevention. H.R. 878, Right to Try Act of 2017 and S. 204, Trickett Wendler Right to Try Act of 2017,lobbied regarding all biopharmaceutical provisions. Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act, lobbied regarding all biopharmaceutical provisions. No bill, lobbied regarding biosimilars issues including naming, labeling and interchangeability. HR 2430,FDA Reauthorization Act, lobbied regarding all biopharmaceutical provisions. H.R. 1245 and S. 469, Affordable and Safe Prescription Drug Importation Act, lobbied regarding all biopharmaceutical provisions. H.R.1231 and S. 456, RACE for Children Act, lobbied regarding all biopharmaceutical provisions. H.R. 1703, Medical Product Communications Act of 2017, regarding all biopharmaceutical related provisions H.R. 2851, Stop the Importation and Trafficking of Synthetic Analogues Act of 2017, regarding all biopharmaceutical related provisions
American Health Care Act, regarding all biopharmaceutical related provisions. Continuing Budget Resolution, lobbied regarding all biopharmaceutical provisions. Better Care Reconciliation Act, regarding all biopharmaceutical related provisions.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2017 · first_quarter · Q1
Lobbied regarding intellectual property rights in trade agreements and international negotiations.
No bill, lobbied on patent troll issues regarding biopharmaceutical patents.
H.R. 849, S. 260, S. 251 Protecting Seniors Access to Medicare Act, lobbied regarding all biopharmaceutical related provisions. No bill, Children's Health Insurance Program, lobbied regarding all biopharmaceutical related provisions. S.771, Improving Access To Affordable Prescription Drugs Act, lobbied regarding all biopharmaceutical related provisions. S.348, Prescription Drug and Health Improvement Act of 2017, lobbied regarding all biopharmaceutical related provisions. S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017, lobbied regarding all biopharmaceutical related provisions.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2016 · fourth_quarter · Q4
S. 995, H.R. 2146 Bipartisan Congressional Trade Priorities and Accountability Act, regarding intellectual property rights in trade agreements and international negotiations. Trans-Pacific Partnership Trade Agreement, regardng all biopharmaceutical related provisions.
H.R. 1416, Cancer Patient Protection Act, regarding all biopharmaceutical related provisions. H.R. 1190 and S. 41, Protecting Seniors' Access to Medicare Act, regarding all biopharmaceutical related provisions. H.R. 2, Medicare Access and CHIP Authorization Act, regarding all biopharmaceutical related provisions H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors Act, regarding all biopharmaceutical related provisions. No Bill, lobbied on price controls for biopharmaceuticals in government health care programs. No Bill, lobbied on the proposed rule on the CMMI Medicare Part B demonstration project. H.R. 5122, legislation to prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models,regarding all biopharmaceutical related provisions.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2016 · third_quarter · Q3
Labor, Health and Human Services, Education, and Related Agencies Appropriations Bill, regarding all biopharmaceutical related provisions. Agriculture Appropriations, regarding all biopharmaceutical related provisions. H.R. 1078, FDA Safety Over Sequestration Act, regarding all biopharmaceutical related provisions. No bill, raised awareness about atrial fibrillation and stroke prevention. H/R. 1101, Viral Hepatitis Testing Act, regarding all biopharmaceutical related provisions. H.R.6, 21st Century Cures Initiative and Senate Innovation for a Healthier America proposal, regarding all biopharmaceutical related provisions. No Bill, lobbied Congress on biosimilar issues including naming, labeling and interchangeability. No Bill, lobbied Congress on importation of prescription drugs. S. 2912, Trickett Wendler Right to Try Act of 2016, S. 2912, regarding all biopharmaceutical related provisions. S. 3056, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2016, regarding all biopharmaceutical related provisions. No Bill, Prescription Drug User Fee Act, regarding all biopharmaceutical related provisions. No Bill, Biosimilar User Fee Act, regarding all biopharmaceutical related provisions. S. 3335/H.R. 6043 the Fair Accountability and Innovative Research Drug Pricing Act, regarding all biopharmaceutical related provisions.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2016 · second_quarter · Q2
S. Con. Res. 11, budget resolution, regarding all biopharmaceutical related provisions. H.R. 719, Continuing Appropriations Act,regarding all biopharmaceutical related provisions. H.R. 2029, Consolidates Appropriations Act, regarding all biopharmaceutical related provsions. H.R. 3762, Restoring America's Healthcare Freedom Reconciliation Act, regarding all biopharmaceutical related provisions.
HR 9, the Innovation Act, regarding all biopharmaceutical related provisions. S. 1137, Protecting American Talent and Entrepreneurship Act, regarding all biopharmaceutical related provisions. S. 1890 Defend Trade Secrets Act of 2016, regardng all biopharmaceutical related provisions.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2016 · first_quarter · Q1
S. 995, H.R. 2146 Bipartisan Congressional Trade Priorities and Accountability Act, regarding intellectual property rights in trade agreements and international negotiations.
H.R. 1416, Cancer Patient Protection Act, regarding all biopharmaceutical related provisions. H.R. 1190 and S. 41, Protecting Seniors' Access to Medicare Act, regarding all biopharmaceutical related provisions. H.R. 2, Medicare Access and CHIP Authorization Act, regarding all biopharmaceutical related provisions H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors Act, regarding all biopharmaceutical related provisions. No Bill, lobbied on price controls for biopharmaceuticals in government health care programs. No Bill, lobbied on the proposed rule on the CMMI Medicare Part B demonstration project.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2015 · second_quarter · 2A
No bill, lobbied to strengthen intellectual property rights in trade agreements and international negotiations.
S. Con. Res. 11, budget resolution, regarding all biopharmaceutical related provisions.
H.R. 1416, Cancer Patient Protection Act, regarding all biopharmaceutical related provisions. H.R. 1190 and S. 41, Protecting Seniors' Access to Medicare Act, regarding all biopharmaceutical related provisions. H.R. 2, Medicare Access and CHIP Authorization Act, regarding all biopharmaceutical related provisions H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors Act, regarding all biopharmaceutical related provisions.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2015 · fourth_quarter · Q4
S. 995, H.R. 2146 Bipartisan Congressional Trade Priorities and Accountability Act, regarding intellectual property rights in trade agreements and international negotiations.
Labor, HHS Appropriations,regarding all biopharmaceutical related provisions. Agriculture Appropriations, regarding all biopharmaceutical related provisions. H.R. 1078, FDA Safety Over Sequestration Act, regarding all biopharmaceutical related provisions. No bill, raised awareness about atrial fibrillation and stroke prevention. H/R. 1101, Viral Hepatitis Testing Act, regarding all biopharmaceutical related provisions. H.R.6, 21st Century Cures Initiative and Senate Innovation for a Healthier America proposal, regarding all biopharmaceutical related provisions. No Bill, lobbied Congress on biosimilar issues including naming, labeling and interchangability.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2015 · third_quarter · Q3
HR 9, the Innovation Act, regarding all biopharmaceutical related provisions. S. 1137, Protecting American Talent and Entrepreneurship Act, regarding all biopharmaceutical related provisions.
S. 995, H.R. 2146 Bipartisan Congressional Trade Priorities and Accountability Act, regarding intellectual property rights in trade agreements and international negotiations.
S. Con. Res. 11, budget resolution, regarding all biopharmaceutical related provisions. H.R. 719, Continuing Appropriations Act,regarding all biopharmaceutical related provisions.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2015 · second_quarter · Q2
Labor, HHS Appropriations,regarding all biopharmaceutical related provisions. Agriculture Appropriations, regarding all biopharmaceutical related provisions. H.R. 1078, FDA Safety Over Sequestration Act, regarding all biopharmaceutical related provisions. No bill, raised awareness about atrial fibrillation and stroke prevention. H/R. 1101, Viral Hepatitis Testing Act, regarding all biopharmaceutical related provisions. H.R.6, 21st Century Cures Initiative, regarding all biopharmaceutical related provisions.
HR 9, the Innovation Act, regarding all biopharmaceutical related provisions. S. 1137, Protecting American Talent and Entrepreneurship Act, regarding all biopharmaceutical related provisions.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2015 · first_quarter · Q1
No bill, lobbied to strengthen intellectual property rights in trade agreements and international negotiations.
H.R. 1416, Cancer Patient Protection Act, regarding all biopharmaceutical related provisions. H.R. 1190 and S. 41, Protecting Seniors' Access to Medicare Act, regarding all biopharmaceutical related provisions. H.R. 2, Medicare Access and CHIP Authorization Act, regarding all biopharmaceutical related provisions
Labor, HHS Appropriations,regarding all biopharmaceutical related provisions. Agriculture Appropriations, regarding all biopharmaceutical related provisions. H.R. 1078, FDA Safety Over Sequestration Act, regarding all biopharmaceutical related provisions. No bill, raised awareness about atrial fibrillation and stroke prevention. H/R. 1101, Viral Hepatitis Testing Act, regarding all biopharmaceutical related provisions. No bill, 21st Century Cures Initiative, regarding all biopharmaceutical related provisions.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2014 · fourth_quarter · 4A
No bill, trade agreements and international intellectual property issues in India and Canada related to biopharmaceuticals. H.R. 3830 amend S. 1900, Bipartisan Congressional Trade Priorities Act, regarding all biopharmaceutical related provisions.
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions. H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2014 · fourth_quarter · Q4
No bill, trade agreements and international intellectual property issues in India and Canada related to biopharmaceuticals. H.R. 3830 amend S. 1900, Bipartisan Congressional Trade Priorities Act, regarding all biopharmaceutical related provisions.
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions. H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2014 · third_quarter · Q3
No bill, trade agreements and international intellectual property issues in India and Canada related to biopharmaceuticals. H.R. 3830 amend S. 1900, Bipartisan Congressional Trade Priorities Act, regarding all biopharmaceutical related provisions.
H.R. 3474, Tax Extenders legislation, regarding all biopharmaceutical related provisions. H.R. 4438, American Research and Investment Act, regarding all biopharmaceutical related provisions.
H.R. 3309, S. 1720, and S. 1612, S. 1013, S. 866, legislation to amend certain patent laws. Regarding all provisions.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2014 · second_quarter · Q2
No bill, trade agreements and international intelectual property issues in India and Canada related to biopharmaceuticals. H.R. 3830 amnd S. 1900, Biaprtisan Congressional Trade Priorities Act, regarding all biopharmaceutical related provisions.
H.R. 3309, S. 1720, and S. 1612, S. 1013, S. 866, legislation to amend certain patent laws. Regarding all provisions.
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provsions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 an dS. 1821, SGR Reform, regarding all provisions.H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2014 · first_quarter · Q1
H.R. 3309, S. 1720, and S. 1612, S. 1013, S. 866, legislation to amend certain patent laws. Regarding all provisions.
No Bill, Trade and International Negotiation, regarding intellectual property rights in trade agreements and international negotiations. H.R. 3830 and S. 1900, Bipartisan Congressional Trade Priorities Act, regarding international intellectual property provisions.
No bill - "Health Care Reform Implementation" - regarding Essential health benefits coverage. No bill - Raise awareness about Atrial Fibrillation and stroke prevention.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2013 · fourth_quarter · Q4
S.Con.Res.8 and H.Con. Res 25 concurrent resolutions setting forth the congressional budget for the United States Government for fiscal year 2014, revising the appropriate budgetary levels for fiscal year 2013, and setting forth the appropriate budgetary levels for fiscal years 2015 through 2023. Regarding Medicare and biopharmaceutical provisions.
H.R. 3309, S. 1720, and S. 1612, S. 1013, S. 866, legislation to amend certain patent laws. Regarding all provisions.
No Bill, Trade and International Negotiation, regarding intellectual property rights in trade agreements and international negotiations.
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2013 · third_quarter · Q3
No Bill, Trade and International Negotiation, regarding intellectual property rights in trade agreements and international negotiations.
H. J. Res 59, "Making continuing appropriations for fiscal year 2014, and for other purpose," regarding AIDS Drug Assistance Program, Medicare, and importation of prescription drugs.No bill - "Labor, HHS Appropriations," regarding the AIDS Drug Assistance Program. No bill - "Health Care Reform Implementation" - regarding Essential health benefits coverage. S.959/ H.R. 1919/ H.R. 3204 Drug Quality and Security Act, regarding all provisions. H.R. 2725/ S. 1413- "FDA Safety Over Sequestration Act," regarding all provisions. S. 539/H.R. 1074, "National Diabetes Clinical Care Commission Act," regarding all provisions. No bill - Raise awareness about Atrial Fibrillation and stroke prevention.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2013 · second_quarter · Q2
No Bill, Trade and international IP issues.Lobbied to strengthen intellectual property rights in trade agreements and international negotiations.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
BRISTOL-MYERS SQUIBB COMPANY via BRISTOL-MYERS SQUIBB COMPANY
2013 · second_quarter · RA
Implementation of health care reform H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013 and the Senate bill, Drug Supply Chain and Security Act. H.R. 1588, the Medicare Drug Savings Act of 2013. Drug Coumpounding draft legislation.
Implementation of health care reform H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013 and the Senate bill, Drug Supply Chain and Security Act. H.R. 1588, the Medicare Drug Savings Act of 2013. Drug Coumpounding draft legislation.
Implementation of health care reform H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013 and the Senate bill, Drug Supply Chain and Security Act. H.R. 1588, the Medicare Drug Savings Act of 2013. Drug Coumpounding draft legislation.
Discussions regarding health equity H.R.830, HELP Copays Act of 2023 H.R.3561, The PATIENT Act H.R.4895, Lowering Drug Costs for American Families Act Biosimilars reimbursement issues International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathways to Innovation Cures (EPIC) Act ORPHAN Act Implementation of Inflation Reduction Act of 2022 MINI Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
HR 1319, American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464/HR 2163, Safe Step Act - regarding all bio-pharmaceutical related provisions Proposed reconciliation bill encompassing all pharmaceutical provisions Discussions regarding health equity Issues regarding HR 6833, Continuing Resolution HR 5376, the Build Back Better Act regarding all bio-pharmaceutical provisions Discussions regarding HR 3173, Improving Seniors' Timely Access to Care Act PBM reform including S.4293, Pharmacy Benefit Manager Transparency Act of 2022
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number S 1854, the National Critical Capabilities Act of 2021 - regarding all bio-pharmaceutical related provisions HR 4521, United States Innovation and Competition Act of 2021 S 1260, USICA conference bill
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number S 1854, the National Critical Capabilities Act of 2021 - regarding all bio-pharmaceutical related provisions HR 4521, United States Innovation and Competition Act of 2021 S 1260, USICA conference bill
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
International Reference Pricing/Most Favored Nation regarding all bio-pharmaceutical related issues. No bill number. Essential Medicines/Buy American - regarding all bio-pharmaceutical related provisions. No bill number. Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number. S.1854, the National Critical Capabilities Act of 2021 - regarding all bio-pharmaceutical related provisions
H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes - regarding all bio-pharmaceutical related provisions. H.R 5376, the Build Back Better Act - regarding all bio-pharmaceutical related provisions and corporate tax provisions.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
H.R. 2163 To amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for an medication step therapy protocol, and for other purposes regarding all bio-pharmaceutical related provisions. H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes regarding all bio-pharmaceutical related provisions. International Reference Pricing/Most Favored Nation regarding all bio-pharmaceutical related issues. No bill number. Issues related to the six protected classes of medicines under Medicare Part D regarding all bio-pharmaceutical related issues. No bill number. H.R 1319 - The American Rescue Plan regarding all bio-pharmaceutical related provisions. Cancer Drug Parity Act/Oral Parity regarding all bio-pharmaceutical related provisions. No bill number. Issues related to the 340B Drug Pricing Program regarding all bio-pharmaceutical related provisions. No bill number. Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number.
International Reference Pricing/Most Favored Nation regarding all bio-pharmaceutical related issues. No bill number. Essential Medicines/Buy American regarding all bio-pharmaceutical related provisions. No bill number. Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number.
Intellectual Property Reform concerning bio-pharmaceutical industry. No related bill number Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
International Reference Pricing/Most Favored Nation regarding all bio-pharmaceutical related issues. No bill number. Essential Medicines/Buy American - regarding all bio-pharmaceutical related provisions. No bill number. Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number. S.1854, the National Critical Capabilities Act of 2021 - regarding all bio-pharmaceutical related provisions
Intellectual Property Reform concerning bio-pharmaceutical industry. No related bill number Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number. S.1435/H.R. 2873 - Affordable Prescriptions for Patients Act of 2021 - prohibition on product hopping
HR 1319 - American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S.464 - Safe Step Act - regarding all bio-pharmaceutical related provisions H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes - regarding all bio-pharmaceutical related provisions. International Reference Pricing/Most Favored Nation - regarding all bio-pharmaceutical related issues. No bill number. Issues related to the six protected classes of medicines under Medicare Part D - regarding all bio-pharmaceutical related issues. No bill number. H.R 1319 - The American Rescue Plan - regarding all bio-pharmaceutical related provisions. Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions. No bill number. Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions. No bill number. Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number. Essential Medicines/Buy American - regarding all bio-pharmaceutical related provisions. No bill number. H.R 5237 - To amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes - regarding all bio-pharmaceutical related provisions. H.R 5376, the Build Back Better Act - regarding all bio-pharmaceutical related provisions.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
Intellectual Property Reform concerning bio-pharmaceutical industry. No related bill number Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number. S.1435/H.R. 2873 - Affordable Prescriptions for Patients Act of 2021 - prohibition on product hopping
HR 1319 - American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S.464 - Safe Step Act - regarding all bio-pharmaceutical related provisions H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes - regarding all bio-pharmaceutical related provisions. International Reference Pricing/Most Favored Nation - regarding all bio-pharmaceutical related issues. No bill number. Issues related to the six protected classes of medicines under Medicare Part D - regarding all bio-pharmaceutical related issues. No bill number. H.R 1319 - The American Rescue Plan - regarding all bio-pharmaceutical related provisions. Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions. No bill number. Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions. No bill number. Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number. Essential Medicines/Buy American - regarding all bio-pharmaceutical related provisions. No bill number. H.R 5237 - To amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes - regarding all bio-pharmaceutical related provisions.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
HR 1319 - American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S.464 - Safe Step Act - regarding all bio-pharmaceutical related provisions H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes - regarding all bio-pharmaceutical related provisions. International Reference Pricing/Most Favored Nation - regarding all bio-pharmaceutical related issues. No bill number. Issues related to the six protected classes of medicines under Medicare Part D - regarding all bio-pharmaceutical related issues. No bill number. H.R 1319 - The American Rescue Plan - regarding all bio-pharmaceutical related provisions. Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions. No bill number. Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions. No bill number. Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number. Essential Medicines/Buy American - regarding all bio-pharmaceutical related provisions. No bill number.
Proposed policies regarding corporate tax reform regarding all bio-pharmaceutical related provisions. No bill number Import Taxes regarding all bio-pharmaceutical related provisions. No bill number.
H.R. 2163 To amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for an medication step therapy protocol, and for other purposes regarding all bio-pharmaceutical related provisions. H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes regarding all bio-pharmaceutical related provisions. International Reference Pricing/Most Favored Nation regarding all bio-pharmaceutical related issues. No bill number. Issues related to the six protected classes of medicines under Medicare Part D regarding all bio-pharmaceutical related issues. No bill number. H.R 1319 - The American Rescue Plan regarding all bio-pharmaceutical related provisions. H.R 4385 - Cancer Drug Parity Act/Oral Parity regarding all bio-pharmaceutical related provisions. No bill number. Issues related to the 340B Drug Pricing Program regarding all bio-pharmaceutical related provisions. No bill number. Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number. H.R. 3 Elijah E. Cummings Lower Drug Costs Now Act - Establishes several programs and requirements relating to the prices of prescription drugs, health care coverage and costs, and public health regarding all bio-pharmaceutical related provisions H.R. 19 Lower Cost, More Cures Act of 2021 - To provide for certain reforms with respect to the Medicare program under title XVIII of the Social Security Act, the Medicaid program under title XIX of such Act, the Food and Drug Administration, and for other purposes regarding all bio-pharmaceutical related provisions
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
HR 1319 - American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S.464 - Safe Step Act - regarding all bio-pharmaceutical related provisions H.R. 2163 To amend the Employee Retirement Income Security Act to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for an medication step therapy protocol, and for other purposes -regarding all bio-pharmaceutical related provisions. H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes - regarding all bio-pharmaceutical related provisions. International Reference Pricing/Most Favored Nation - regarding all bio-pharmaceutical related issues. No bill number. Issues related to the six protected classes of medicines under Medicare Part D - regarding all bio-pharmaceutical related issues. No bill number. H.R 1319 - The American Rescue Plan - regarding all bio-pharmaceutical related provisions. Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions. No bill number. Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions. No bill number. Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number. Essential Medicines/Buy American - regarding all bio-pharmaceutical related provisions. No bill number.
International Reference Pricing/Most Favored Nation regarding all bio-pharmaceutical related issues. No bill number. Essential Medicines/Buy American regarding all bio-pharmaceutical related provisions. No bill number. Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number.
Intellectual Property Reform concerning bio-pharmaceutical industry. No related bill number Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
H.R. 2209, To establish the position of Chief Pharmaceutical Negotiator in the Office of the United States Trade Representative responsible for conducting trade negotiations and enforcing trade agreements related to acts, policies, and practices of foreign governments that fail to appropriately reward United States innovation with respect to pharmaceuticals, and for other purposes, regarding all bio-pharmaceutical related provisions. Unite States, Mexico, Canada Trade Agreement, regarding all bio-pharmaceutical related provisions. S. 3537, Protecting our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions S. 3538, Strengthening Americas Supply Chain and National Security Act, regarding all bio-pharmaceutical related provisions No Bill, potential Buy American executive order for health-related goods, regarding all bio-pharmaceutical related provisions H.R. 4710, Pharmaceutical Independence Long-Term Readiness Reform Act, regarding all bio-pharmaceutical related provisions H.R. 4866, National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 5381, International Pharmaceutical Transparency Act of 2019 , regarding all bio-pharmaceutical related provisions H.R. 5982, Safe Medicine Act, regarding all bio-pharmaceutical related provisions H.R. 6049/S3343, Medical Supply Chain Security Act, regarding all bio-pharmaceutical related provisions H.R. 6080, Preventing Drug Shortages Act, regarding all bio-pharmaceutical , regarding all bio-pharmaceutical related provisions related provisions H.R. 6393, Strengthening America's Supply Chain and National Security Act, regarding all bio-pharmaceutical related provisions H.R.6399/S.3715 , SAVE Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6431, Made in America Emergency Preparedness Act, regarding all bio-pharmaceutical related provisions H.R. 6482, Protecting Our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6670, Prescription for American Drug Independence Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6690, Bring Entrepreneurial Advancements To Consumers Here In North America Act ,regarding all bio-pharmaceutical related provisions H.R. 6708/S. 3432, Securing America's Medicine Cabinet Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6930, MADE in America Act of 2020, regarding all bio-pharmaceutical related provisions S. 3635, Protecting Our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions S. 2723, Mitigating Emergency Drug Shortages Act, regarding all bio-pharmaceutical related provisions S.3945, Bring Entrepreneurial Advancements To Consumers Here In North America Act, regarding all bio-pharmaceutical related provisions
H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 985, Fair Access for Safe and Timely (FAST) Generics Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 986, Protecting American with Preexisting Conditions Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1010, Short-Term, Limited Duration Insurance (STLDI), regarding all bio-pharmaceutical related provisions. H.R. 1323, Rural Hospital Frontier Fairness Act, regarding all bio-pharmaceutical related provisions. H.R. 1385, State Allowance for a Variety of Exchanges (SAVE) Act, regarding all bio-pharmaceutical related provisions. H.R. 1386, Expanded Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act, regarding all bio-pharmaceutical related provisions. H.R. 1409, Transparency in All Health Care Pricing Act, regarding all bio-pharmaceutical related provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions. H.R. 1478, Insulin importation, regarding all bio-pharmaceutical related provisions. H.R. 1503, Orange Book Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1506, Fair and Immediate Release (FAIR) of Generics Act, regarding all bio-pharmaceutical related provisions. H.R. 1520, Purple Book Continuity Act, regarding all bio-pharmaceutical related provisions. H.R. 2011, Protecting Access to Biosimilars Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2038, State-based , Market-Oriented, Prescription Drug Negotiations Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2064, Product Sample reporting, regarding all bio-pharmaceutical related provisions. S. 61, Safe and Affordable Drugs from Canada Act, regarding all bio-pharmaceutical related provisions. S. 97, Affordable and Safe Drug Importation Act, regarding all bio-pharmaceutical related provisions. S. 102, Prescription Drug Price Relief Act, regarding all bio-pharmaceutical related provisions. S. 344/H.R. 990, Hatch-Waxman Integrity Act, regarding all bio-pharmaceutical related provisions. S. 366/H.R. 1188, FLAT Prices Act- Reduced exclusivity period for certain price hikes, regarding all bio-pharmaceutical related provisions. S. 418, FDA Accountability for Public Safety Act, regarding all bio-pharmaceutical related provisions. S. 419, Protecting Americans from Dangerous Opioids Act, regarding all bio-pharmaceutical related provisions. S. 637, CURE High Drug Prices Act, regarding all bio-pharmaceutical related provisions. S. 657, Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. S. 658, Accelerated Drug Approval for Prescription Therapies Act, regarding all bio-pharmaceutical related provisions. S. 659, Biologic Patent Transparency Act, regarding all bio-pharmaceutical related provisions. S. 660, Transparency in Petitions Act, regarding all bio-pharmaceutical related provisions. S. 709, Establishes public dashboard for price and utilization of drugs purchased by federal programs, regarding all bio-pharmaceutical related provisions. S. 741 /H.R. 1730, Cancer Drug Parity Act, regarding all bio-pharmaceutical related provisions. S. 844, Short Competition Act, regarding all bio-pharmaceutical related provisions. S. 977, Transparent Drug Pricing Act of 2019, regarding all bio-pharmaceutical related provisions. S. 989, STEER Act, regarding all bio-pharmaceutical related provisions. S. 1140, A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009, regarding all bio-pharmaceutical related provisions. S.1169, FDA citizen petition, regarding all bio-pharmaceutical related provisions. S. 1209, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications, regarding all bio-pharmaceutical related provisions. H.R. 2115, Public Disclosure of Drug Discounts Act, regarding all bio-pharmaceutical related provisions H.R.2296/S.1391, FAIR Drug Pricing Act, regarding all bio-pharmaceutical related provisions H.R.2700, Lowering Prescription Drug Costs and Extending Community Health Centers and other Health Priorities Act, regarding all bio-pharmaceutical related provisions H.R. 3223, Pharmacy Benefit Manager Accountability Study Act, regarding all bio-pharmaceutical related provisions S. 1361/H.R.2584, Preventive Health Savings Act, regarding all bio-pharmaceutical related provisions S. 1437, DTC Act, regarding all bio-pharmaceutical related provisions S.1532, Pharmacy Benefit Managers Accountability Study Act, regarding all bio-pharmaceutical related provisions S.1636, Ensuring Innovation Act, regarding all bio-pharmaceutical related provisions S. 1664, Prescription Drug Price Reporting Act, regarding all bio-pharmaceutical related provisions S. 1801, Affordable Medications Act, regarding all bio-pharmaceutical related provisions S. 1895, Lowering Health Costs Act, regarding all bio-pharmaceutical related provisions S. 1897, a bill to establish a process for updating the labeling of certain drugs with outdated labeling, regarding all bio-pharmaceutical related provisions S. 1897/H.R. 3523, End Price Gouging for Medications Act, regarding all bio-pharmaceutical related provisions S. 2004, Emergency Access to Insulin Act, regarding all bio-pharmaceutical related provisions H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions H.R 748/S. 3548, Coronavirus Aid, Relief and Economic Security Act (CARES Act), regarding all bio-pharmaceutical provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, regarding all bio-pharmaceutical related provisions
H.R. 1499, Protecting Consumer Access to Generic Drugs Act, regarding all bio-pharmaceutical related provisions H.R. 965, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 1344, Competitive DRUGS Act, regarding all bio-pharmaceutical related provisions. H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions S. 64, Preserve Access to Affordable Generics and Biosimilars Act,regarding all bio-pharmaceutical related provisions. H.R.2375, Preserve Access to Affordable Generics and Biosimilars Act, regarding all bio-pharmaceutical related provisions H.R. 2387, STOP GAMES Act, regarding all bio-pharmaceutical related provisions H.R. 3199, TERM Act, regarding all bio-pharmaceutical related provisions S. 440, PACED Act, regarding all bio-pharmaceutical related provisions S. 1224/H.R.2374, Stop STALLING Act, regarding all bio-pharmaceutical related provisions S.1416, Affordable Prescriptions for Patients Act, regarding all bio-pharmaceutical related provisions S. 1617, Second Look at Drug Patents Act, regarding all bio-pharmaceutical related provisions
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
H.R. 1158, Further Consolidated Appropriations Act of 2020, regarding all bio-pharmaceutical related provisions H.R.1865, Further Consolidated Appropriations Act of 2020, regarding all bio-pharmaceutical related provisions
H.R. 1499, Protecting Consumer Access to Generic Drugs Act, regarding all bio-pharmaceutical related provisions H.R. 965, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 1344, Competitive DRUGS Act, regarding all bio-pharmaceutical related provisions. H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions S. 64, Preserve Access to Affordable Generics and Biosimilars Act,regarding all bio-pharmaceutical related provisions. H.R.2375, Preserve Access to Affordable Generics and Biosimilars Act, regarding all bio-pharmaceutical related provisions H.R. 2387, STOP GAMES Act, regarding all bio-pharmaceutical related provisions H.R. 3199, TERM Act, regarding all bio-pharmaceutical related provisions S. 440, PACED Act, regarding all bio-pharmaceutical related provisions S. 1224/H.R.2374, Stop STALLING Act, regarding all bio-pharmaceutical related provisions S.1416, Affordable Prescriptions for Patients Act, regarding all bio-pharmaceutical related provisions S. 1617, Second Look at Drug Patents Act, regarding all bio-pharmaceutical related provisions
S. 73, End Taxpayer Subsidies for Drug Ads Act, regarding all bio-pharmaceutical related provisions. S. 378/H.R. 1093, Stop Price Gouging Act, regarding all bio-pharmaceutical related provisions. S. 425, LifeBOAT Act, regarding all bio-pharmaceutical related provisions.
H.R. 107, Burgess: Rebate cap, regarding all bio-pharmaceutical related provisions. H.R. 275, Medicare Prescription Drug Negotiation Act, regarding all bio-pharmaceutical related provisions. H.R. 366, Insulin Access for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1034, D. Collins/S. 640, Kennedy: Phair Pricing Act - Share the savings, regarding all bio-pharmaceutical related provisions. H.R. 1035, Prescription Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1332, Fair Care Act, regarding all bio-pharmaceutical related provisions. H.R. 1346, Medicare Buy-In and Health Care Stabilization Act, regarding all bio-pharmaceutical related provisions. H.R. 1384, Medicare for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1781, Payment Commission Data Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1788, Limits the penalty for Part B late enrollment to 15 percent and twice the period of no enrollment, regarding all bio-pharmaceutical related provisions. H.R. 2087, Reporting drug pricing information to Medicare, regarding all bio-pharmaceutical related provisions. H.R. 2113, Prescription STAR Act, regarding all bio-pharmaceutical related provisions. H.R.3, Lower Drug Costs Now Act of 2019, regarding all bio-pharmaceutical related provisions S. 62, Empowering Medicare Seniors to Negotiate Drug Prices, regarding all bio-pharmaceutical related provisions. S. 99, Medicare Drug Price Negotiation Act, regarding all bio-pharmaceutical related provisions. S. 205, Right Rebate Act, regarding all bio-pharmaceutical related provisions. S. 377/H.R. 1046, Medicare Negotiation and Competitive Licensing Act, regarding all bio-pharmaceutical related provisions. S. 470, Medicare at 50 Act, regarding all bio-pharmaceutical related provisions. S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 , regarding all bio-pharmaceutical related provisions. S. 475, RxCAP Act, regarding all bio-pharmaceutical related provisions. S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU Act) of 2019, regarding all bio-pharmaceutical related provisions. S. 551, REFUND Act of 2019, regarding all bio-pharmaceutical related provisions. S. 691, Expands Part D OOP assistance for low-income seniors and individuals with disabilities, regarding all bio-pharmaceutical related provisions. S. 801/H.R. 1781, Allows MedPAC and MACPAC to have access to information on drug rebates, regarding all bio-pharmaceutical related provisions. S. 981, Medicare-X Choice Act of 2019, regarding all bio-pharmaceutical related provisions. Pending rule to change the Rebate Safe Harbor, regarding all bio-pharmaceutical related provisions. H.R. 1839, Medicaid Services Investment and Accountability Act, regarding all bio-pharmaceutical related provisions H.R. 2452, Medicare for America Act, regarding all bio-pharmaceutical related provisions H.R. 3107, Improving Seniors Timely Access to Care Act, regarding all bio-pharmaceutical related provisions H.R. 3327, Drug Price Transparency for Medicare Patients Act, regarding all bio-pharmaceutical related provisions S. 1261/H.R. 2463, Choose Medicare Act, regarding all bio-pharmaceutical related provisions S. 1497, Health Care Price Check Act, regarding all bio-pharmaceutical related provisions S. 2081, a bill to require drug manufacturers to provide rebates for drugs furnished under Medicare Part B for which the growth in average sales price has exceeded inflation, regarding all bio-pharmaceutical related provisions. S. 2543, Prescription Drug Pricing Reduction Act of 2019, regarding all bio-pharmaceutical provisions. H.R. 19/S.3129 , Lower Costs, More Cures Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 6218/S. 3457, Preserving Patient Access to Home Infusion Act, regarding all bio-pharmaceutical related provisions No Bill, Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies.
H.R. 2209, To establish the position of Chief Pharmaceutical Negotiator in the Office of the United States Trade Representative responsible for conducting trade negotiations and enforcing trade agreements related to acts, policies, and practices of foreign governments that fail to appropriately reward United States innovation with respect to pharmaceuticals, and for other purposes, regarding all bio-pharmaceutical related provisions. Unite States, Mexico, Canada Trade Agreement, regarding all bio-pharmaceutical related provisions. S. 3537, Protecting our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions S. 3538, Strengthening Americas Supply Chain and National Security Act, regarding all bio-pharmaceutical related provisions No Bill, potential Buy American executive order for health-related goods, regarding all bio-pharmaceutical related provisions H.R. 4710, Pharmaceutical Independence Long-Term Readiness Reform Act, regarding all bio-pharmaceutical related provisions H.R. 4866, National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 5381, International Pharmaceutical Transparency Act of 2019 , regarding all bio-pharmaceutical related provisions H.R. 5982, Safe Medicine Act, regarding all bio-pharmaceutical related provisions H.R. 6049/S3343, Medical Supply Chain Security Act, regarding all bio-pharmaceutical related provisions H.R. 6080, Preventing Drug Shortages Act, regarding all bio-pharmaceutical , regarding all bio-pharmaceutical related provisions related provisions H.R. 6393, Strengthening America's Supply Chain and National Security Act, regarding all bio-pharmaceutical related provisions H.R.6399/S.3715 , SAVE Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6431, Made in America Emergency Preparedness Act, regarding all bio-pharmaceutical related provisions H.R. 6482, Protecting Our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6670, Prescription for American Drug Independence Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6690, Bring Entrepreneurial Advancements To Consumers Here In North America Act ,regarding all bio-pharmaceutical related provisions H.R. 6708/S. 3432, Securing America's Medicine Cabinet Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6930, MADE in America Act of 2020, regarding all bio-pharmaceutical related provisions S. 3635, Protecting Our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions S. 2723, Mitigating Emergency Drug Shortages Act, regarding all bio-pharmaceutical related provisions S.3945, Bring Entrepreneurial Advancements To Consumers Here In North America Act, regarding all bio-pharmaceutical related provisions
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
S. 73, End Taxpayer Subsidies for Drug Ads Act, regarding all bio-pharmaceutical related provisions. S. 378/H.R. 1093, Stop Price Gouging Act, regarding all bio-pharmaceutical related provisions. S. 425, LifeBOAT Act, regarding all bio-pharmaceutical related provisions.
H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 985, Fair Access for Safe and Timely (FAST) Generics Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 986, Protecting American with Preexisting Conditions Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1010, Short-Term, Limited Duration Insurance (STLDI), regarding all bio-pharmaceutical related provisions. H.R. 1323, Rural Hospital Frontier Fairness Act, regarding all bio-pharmaceutical related provisions. H.R. 1385, State Allowance for a Variety of Exchanges (SAVE) Act, regarding all bio-pharmaceutical related provisions. H.R. 1386, Expanded Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act, regarding all bio-pharmaceutical related provisions. H.R. 1409, Transparency in All Health Care Pricing Act, regarding all bio-pharmaceutical related provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions. H.R. 1478, Insulin importation, regarding all bio-pharmaceutical related provisions. H.R. 1503, Orange Book Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1506, Fair and Immediate Release (FAIR) of Generics Act, regarding all bio-pharmaceutical related provisions. H.R. 1520, Purple Book Continuity Act, regarding all bio-pharmaceutical related provisions. H.R. 2011, Protecting Access to Biosimilars Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2038, State-based , Market-Oriented, Prescription Drug Negotiations Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2064, Product Sample reporting, regarding all bio-pharmaceutical related provisions. S. 61, Safe and Affordable Drugs from Canada Act, regarding all bio-pharmaceutical related provisions. S. 97, Affordable and Safe Drug Importation Act, regarding all bio-pharmaceutical related provisions. S. 102, Prescription Drug Price Relief Act, regarding all bio-pharmaceutical related provisions. S. 344/H.R. 990, Hatch-Waxman Integrity Act, regarding all bio-pharmaceutical related provisions. S. 366/H.R. 1188, FLAT Prices Act- Reduced exclusivity period for certain price hikes, regarding all bio-pharmaceutical related provisions. S. 418, FDA Accountability for Public Safety Act, regarding all bio-pharmaceutical related provisions. S. 419, Protecting Americans from Dangerous Opioids Act, regarding all bio-pharmaceutical related provisions. S. 637, CURE High Drug Prices Act, regarding all bio-pharmaceutical related provisions. S. 657, Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. S. 658, Accelerated Drug Approval for Prescription Therapies Act, regarding all bio-pharmaceutical related provisions. S. 659, Biologic Patent Transparency Act, regarding all bio-pharmaceutical related provisions. S. 660, Transparency in Petitions Act, regarding all bio-pharmaceutical related provisions. S. 709, Establishes public dashboard for price and utilization of drugs purchased by federal programs, regarding all bio-pharmaceutical related provisions. S. 741 /H.R. 1730, Cancer Drug Parity Act, regarding all bio-pharmaceutical related provisions. S. 844, Short Competition Act, regarding all bio-pharmaceutical related provisions. S. 977, Transparent Drug Pricing Act of 2019, regarding all bio-pharmaceutical related provisions. S. 989, STEER Act, regarding all bio-pharmaceutical related provisions. S. 1140, A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009, regarding all bio-pharmaceutical related provisions. S.1169, FDA citizen petition, regarding all bio-pharmaceutical related provisions. S. 1209, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications, regarding all bio-pharmaceutical related provisions. H.R. 2115, Public Disclosure of Drug Discounts Act, regarding all bio-pharmaceutical related provisions H.R.2296/S.1391, FAIR Drug Pricing Act, regarding all bio-pharmaceutical related provisions H.R.2700, Lowering Prescription Drug Costs and Extending Community Health Centers and other Health Priorities Act, regarding all bio-pharmaceutical related provisions H.R. 3223, Pharmacy Benefit Manager Accountability Study Act, regarding all bio-pharmaceutical related provisions S. 1361/H.R.2584, Preventive Health Savings Act, regarding all bio-pharmaceutical related provisions S. 1437, DTC Act, regarding all bio-pharmaceutical related provisions S.1532, Pharmacy Benefit Managers Accountability Study Act, regarding all bio-pharmaceutical related provisions S.1636, Ensuring Innovation Act, regarding all bio-pharmaceutical related provisions S. 1664, Prescription Drug Price Reporting Act, regarding all bio-pharmaceutical related provisions S. 1801, Affordable Medications Act, regarding all bio-pharmaceutical related provisions S. 1895, Lowering Health Costs Act, regarding all bio-pharmaceutical related provisions S. 1897, a bill to establish a process for updating the labeling of certain drugs with outdated labeling, regarding all bio-pharmaceutical related provisions S. 1897/H.R. 3523, End Price Gouging for Medications Act, regarding all bio-pharmaceutical related provisions S. 2004, Emergency Access to Insulin Act, regarding all bio-pharmaceutical related provisions H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions H.R 748/S. 3548, Coronavirus Aid, Relief and Economic Security Act (CARES Act), regarding all bio-pharmaceutical provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, regarding all bio-pharmaceutical related provisions
H.R. 1499, Protecting Consumer Access to Generic Drugs Act, regarding all bio-pharmaceutical related provisions H.R. 965, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 1344, Competitive DRUGS Act, regarding all bio-pharmaceutical related provisions. H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions S. 64, Preserve Access to Affordable Generics and Biosimilars Act,regarding all bio-pharmaceutical related provisions. H.R.2375, Preserve Access to Affordable Generics and Biosimilars Act, regarding all bio-pharmaceutical related provisions H.R. 2387, STOP GAMES Act, regarding all bio-pharmaceutical related provisions H.R. 3199, TERM Act, regarding all bio-pharmaceutical related provisions S. 440, PACED Act, regarding all bio-pharmaceutical related provisions S. 1224/H.R.2374, Stop STALLING Act, regarding all bio-pharmaceutical related provisions S.1416, Affordable Prescriptions for Patients Act, regarding all bio-pharmaceutical related provisions S. 1617, Second Look at Drug Patents Act, regarding all bio-pharmaceutical related provisions H.R. 133, the Consolidated Appropriations Act of 2021, regarding all bio-pharmaceutical related provisions
H.R. 1158, Further Consolidated Appropriations Act of 2020, regarding all bio-pharmaceutical related provisions H.R.1865, Further Consolidated Appropriations Act of 2020, regarding all bio-pharmaceutical related provisions
H.R. 2209, To establish the position of Chief Pharmaceutical Negotiator in the Office of the United States Trade Representative responsible for conducting trade negotiations and enforcing trade agreements related to acts, policies, and practices of foreign governments that fail to appropriately reward United States innovation with respect to pharmaceuticals, and for other purposes, regarding all bio-pharmaceutical related provisions. Unite States, Mexico, Canada Trade Agreement, regarding all bio-pharmaceutical related provisions. S. 3537, Protecting our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions S. 3538, Strengthening Americas Supply Chain and National Security Act, regarding all bio-pharmaceutical related provisions No Bill, potential Buy American executive order for health-related goods, regarding all bio-pharmaceutical related provisions H.R. 4710, Pharmaceutical Independence Long-Term Readiness Reform Act, regarding all bio-pharmaceutical related provisions H.R. 4866, National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 5381, International Pharmaceutical Transparency Act of 2019 , regarding all bio-pharmaceutical related provisions H.R. 5982, Safe Medicine Act, regarding all bio-pharmaceutical related provisions H.R. 6049/S3343, Medical Supply Chain Security Act, regarding all bio-pharmaceutical related provisions H.R. 6080, Preventing Drug Shortages Act, regarding all bio-pharmaceutical , regarding all bio-pharmaceutical related provisions related provisions H.R. 6393, Strengthening America's Supply Chain and National Security Act, regarding all bio-pharmaceutical related provisions H.R.6399/S.3715 , SAVE Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6431, Made in America Emergency Preparedness Act, regarding all bio-pharmaceutical related provisions H.R. 6482, Protecting Our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6670, Prescription for American Drug Independence Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6690, Bring Entrepreneurial Advancements To Consumers Here In North America Act ,regarding all bio-pharmaceutical related provisions H.R. 6708/S. 3432, Securing America's Medicine Cabinet Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6930, MADE in America Act of 2020, regarding all bio-pharmaceutical related provisions S. 3635, Protecting Our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions S. 2723, Mitigating Emergency Drug Shortages Act, regarding all bio-pharmaceutical related provisions S.3945, Bring Entrepreneurial Advancements To Consumers Here In North America Act, regarding all bio-pharmaceutical related provisions
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
H.R. 107, Burgess: Rebate cap, regarding all bio-pharmaceutical related provisions. H.R. 275, Medicare Prescription Drug Negotiation Act, regarding all bio-pharmaceutical related provisions. H.R. 366, Insulin Access for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1034, D. Collins/S. 640, Kennedy: Phair Pricing Act - Share the savings, regarding all bio-pharmaceutical related provisions. H.R. 1035, Prescription Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1332, Fair Care Act, regarding all bio-pharmaceutical related provisions. H.R. 1346, Medicare Buy-In and Health Care Stabilization Act, regarding all bio-pharmaceutical related provisions. H.R. 1384, Medicare for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1781, Payment Commission Data Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1788, Limits the penalty for Part B late enrollment to 15 percent and twice the period of no enrollment, regarding all bio-pharmaceutical related provisions. H.R. 2087, Reporting drug pricing information to Medicare, regarding all bio-pharmaceutical related provisions. H.R. 2113, Prescription STAR Act, regarding all bio-pharmaceutical related provisions. H.R.3, Lower Drug Costs Now Act of 2019, regarding all bio-pharmaceutical related provisions S. 62, Empowering Medicare Seniors to Negotiate Drug Prices, regarding all bio-pharmaceutical related provisions. S. 99, Medicare Drug Price Negotiation Act, regarding all bio-pharmaceutical related provisions. S. 205, Right Rebate Act, regarding all bio-pharmaceutical related provisions. S. 377/H.R. 1046, Medicare Negotiation and Competitive Licensing Act, regarding all bio-pharmaceutical related provisions. S. 470, Medicare at 50 Act, regarding all bio-pharmaceutical related provisions. S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 , regarding all bio-pharmaceutical related provisions. S. 475, RxCAP Act, regarding all bio-pharmaceutical related provisions. S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU Act) of 2019, regarding all bio-pharmaceutical related provisions. S. 551, REFUND Act of 2019, regarding all bio-pharmaceutical related provisions. S. 691, Expands Part D OOP assistance for low-income seniors and individuals with disabilities, regarding all bio-pharmaceutical related provisions. S. 801/H.R. 1781, Allows MedPAC and MACPAC to have access to information on drug rebates, regarding all bio-pharmaceutical related provisions. S. 981, Medicare-X Choice Act of 2019, regarding all bio-pharmaceutical related provisions. Pending rule to change the Rebate Safe Harbor, regarding all bio-pharmaceutical related provisions. H.R. 1839, Medicaid Services Investment and Accountability Act, regarding all bio-pharmaceutical related provisions H.R. 2452, Medicare for America Act, regarding all bio-pharmaceutical related provisions H.R. 3107, Improving Seniors Timely Access to Care Act, regarding all bio-pharmaceutical related provisions H.R. 3327, Drug Price Transparency for Medicare Patients Act, regarding all bio-pharmaceutical related provisions S. 1261/H.R. 2463, Choose Medicare Act, regarding all bio-pharmaceutical related provisions S. 1497, Health Care Price Check Act, regarding all bio-pharmaceutical related provisions S. 2081, a bill to require drug manufacturers to provide rebates for drugs furnished under Medicare Part B for which the growth in average sales price has exceeded inflation, regarding all bio-pharmaceutical related provisions. S. 2543, Prescription Drug Pricing Reduction Act of 2019, regarding all bio-pharmaceutical provisions. H.R. 19/S.3129 , Lower Costs, More Cures Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 6218/S. 3457, Preserving Patient Access to Home Infusion Act, regarding all bio-pharmaceutical related provisions No Bill, Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies. Most Favored Nation (MFN) Model - (CMS-5528-IFC)
S. 73, End Taxpayer Subsidies for Drug Ads Act, regarding all bio-pharmaceutical related provisions. S. 378/H.R. 1093, Stop Price Gouging Act, regarding all bio-pharmaceutical related provisions. S. 425, LifeBOAT Act, regarding all bio-pharmaceutical related provisions.
H.R. 1499, Protecting Consumer Access to Generic Drugs Act, regarding all bio-pharmaceutical related provisions H.R. 965, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 1344, Competitive DRUGS Act, regarding all bio-pharmaceutical related provisions. H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions S. 64, Preserve Access to Affordable Generics and Biosimilars Act,regarding all bio-pharmaceutical related provisions. H.R.2375, Preserve Access to Affordable Generics and Biosimilars Act, regarding all bio-pharmaceutical related provisions H.R. 2387, STOP GAMES Act, regarding all bio-pharmaceutical related provisions H.R. 3199, TERM Act, regarding all bio-pharmaceutical related provisions S. 440, PACED Act, regarding all bio-pharmaceutical related provisions S. 1224/H.R.2374, Stop STALLING Act, regarding all bio-pharmaceutical related provisions S.1416, Affordable Prescriptions for Patients Act, regarding all bio-pharmaceutical related provisions S. 1617, Second Look at Drug Patents Act, regarding all bio-pharmaceutical related provisions H.R. 133, the Consolidated Appropriations Act of 2021, regarding all bio-pharmaceutical related provisions
H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 985, Fair Access for Safe and Timely (FAST) Generics Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 986, Protecting American with Preexisting Conditions Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1010, Short-Term, Limited Duration Insurance (STLDI), regarding all bio-pharmaceutical related provisions. H.R. 1323, Rural Hospital Frontier Fairness Act, regarding all bio-pharmaceutical related provisions. H.R. 1385, State Allowance for a Variety of Exchanges (SAVE) Act, regarding all bio-pharmaceutical related provisions. H.R. 1386, Expanded Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act, regarding all bio-pharmaceutical related provisions. H.R. 1409, Transparency in All Health Care Pricing Act, regarding all bio-pharmaceutical related provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions. H.R. 1478, Insulin importation, regarding all bio-pharmaceutical related provisions. H.R. 1503, Orange Book Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1506, Fair and Immediate Release (FAIR) of Generics Act, regarding all bio-pharmaceutical related provisions. H.R. 1520, Purple Book Continuity Act, regarding all bio-pharmaceutical related provisions. H.R. 2011, Protecting Access to Biosimilars Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2038, State-based , Market-Oriented, Prescription Drug Negotiations Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2064, Product Sample reporting, regarding all bio-pharmaceutical related provisions. S. 61, Safe and Affordable Drugs from Canada Act, regarding all bio-pharmaceutical related provisions. S. 97, Affordable and Safe Drug Importation Act, regarding all bio-pharmaceutical related provisions. S. 102, Prescription Drug Price Relief Act, regarding all bio-pharmaceutical related provisions. S. 344/H.R. 990, Hatch-Waxman Integrity Act, regarding all bio-pharmaceutical related provisions. S. 366/H.R. 1188, FLAT Prices Act- Reduced exclusivity period for certain price hikes, regarding all bio-pharmaceutical related provisions. S. 418, FDA Accountability for Public Safety Act, regarding all bio-pharmaceutical related provisions. S. 419, Protecting Americans from Dangerous Opioids Act, regarding all bio-pharmaceutical related provisions. S. 637, CURE High Drug Prices Act, regarding all bio-pharmaceutical related provisions. S. 657, Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. S. 658, Accelerated Drug Approval for Prescription Therapies Act, regarding all bio-pharmaceutical related provisions. S. 659, Biologic Patent Transparency Act, regarding all bio-pharmaceutical related provisions. S. 660, Transparency in Petitions Act, regarding all bio-pharmaceutical related provisions. S. 709, Establishes public dashboard for price and utilization of drugs purchased by federal programs, regarding all bio-pharmaceutical related provisions. S. 741 /H.R. 1730, Cancer Drug Parity Act, regarding all bio-pharmaceutical related provisions. S. 844, Short Competition Act, regarding all bio-pharmaceutical related provisions. S. 977, Transparent Drug Pricing Act of 2019, regarding all bio-pharmaceutical related provisions. S. 989, STEER Act, regarding all bio-pharmaceutical related provisions. S. 1140, A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009, regarding all bio-pharmaceutical related provisions. S.1169, FDA citizen petition, regarding all bio-pharmaceutical related provisions. S. 1209, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications, regarding all bio-pharmaceutical related provisions. H.R. 2115, Public Disclosure of Drug Discounts Act, regarding all bio-pharmaceutical related provisions H.R.2296/S.1391, FAIR Drug Pricing Act, regarding all bio-pharmaceutical related provisions H.R.2700, Lowering Prescription Drug Costs and Extending Community Health Centers and other Health Priorities Act, regarding all bio-pharmaceutical related provisions H.R. 3223, Pharmacy Benefit Manager Accountability Study Act, regarding all bio-pharmaceutical related provisions S. 1361/H.R.2584, Preventive Health Savings Act, regarding all bio-pharmaceutical related provisions S. 1437, DTC Act, regarding all bio-pharmaceutical related provisions S.1532, Pharmacy Benefit Managers Accountability Study Act, regarding all bio-pharmaceutical related provisions S.1636, Ensuring Innovation Act, regarding all bio-pharmaceutical related provisions S. 1664, Prescription Drug Price Reporting Act, regarding all bio-pharmaceutical related provisions S. 1801, Affordable Medications Act, regarding all bio-pharmaceutical related provisions S. 1895, Lowering Health Costs Act, regarding all bio-pharmaceutical related provisions S. 1897, a bill to establish a process for updating the labeling of certain drugs with outdated labeling, regarding all bio-pharmaceutical related provisions S. 1897/H.R. 3523, End Price Gouging for Medications Act, regarding all bio-pharmaceutical related provisions S. 2004, Emergency Access to Insulin Act, regarding all bio-pharmaceutical related provisions H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions H.R 748/S. 3548, Coronavirus Aid, Relief and Economic Security Act (CARES Act), regarding all bio-pharmaceutical provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions H.R. 6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act, regarding all bio-pharmaceutical related provisions
H.R. 1158, Further Consolidated Appropriations Act of 2020, regarding all bio-pharmaceutical related provisions H.R.1865, Further Consolidated Appropriations Act of 2020, regarding all bio-pharmaceutical related provisions
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
H.R. 2209, To establish the position of Chief Pharmaceutical Negotiator in the Office of the United States Trade Representative responsible for conducting trade negotiations and enforcing trade agreements related to acts, policies, and practices of foreign governments that fail to appropriately reward United States innovation with respect to pharmaceuticals, and for other purposes, regarding all bio-pharmaceutical related provisions. Unite States, Mexico, Canada Trade Agreement, regarding all bio-pharmaceutical related provisions. S. 3537, Protecting our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions S. 3538, Strengthening Americas Supply Chain and National Security Act, regarding all bio-pharmaceutical related provisions No Bill, potential Buy American executive order for health-related goods, regarding all bio-pharmaceutical related provisions H.R. 4710, Pharmaceutical Independence Long-Term Readiness Reform Act, regarding all bio-pharmaceutical related provisions H.R. 4866, National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 5381, International Pharmaceutical Transparency Act of 2019 , regarding all bio-pharmaceutical related provisions H.R. 5982, Safe Medicine Act, regarding all bio-pharmaceutical related provisions H.R. 6049/S3343, Medical Supply Chain Security Act, regarding all bio-pharmaceutical related provisions H.R. 6080, Preventing Drug Shortages Act, regarding all bio-pharmaceutical , regarding all bio-pharmaceutical related provisions related provisions H.R. 6393, Strengthening America's Supply Chain and National Security Act, regarding all bio-pharmaceutical related provisions H.R.6399/S.3715 , SAVE Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6431, Made in America Emergency Preparedness Act, regarding all bio-pharmaceutical related provisions H.R. 6482, Protecting Our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6670, Prescription for American Drug Independence Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6690, Bring Entrepreneurial Advancements To Consumers Here In North America Act ,regarding all bio-pharmaceutical related provisions H.R. 6708/S. 3432, Securing America's Medicine Cabinet Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6930, MADE in America Act of 2020, regarding all bio-pharmaceutical related provisions S. 3635, Protecting Our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions S. 2723, Mitigating Emergency Drug Shortages Act, regarding all bio-pharmaceutical related provisions S.3945, Bring Entrepreneurial Advancements To Consumers Here In North America Act, regarding all bio-pharmaceutical related provisions
S. 73, End Taxpayer Subsidies for Drug Ads Act, regarding all bio-pharmaceutical related provisions. S. 378/H.R. 1093, Stop Price Gouging Act, regarding all bio-pharmaceutical related provisions. S. 425, LifeBOAT Act, regarding all bio-pharmaceutical related provisions.
H.R. 107, Burgess: Rebate cap, regarding all bio-pharmaceutical related provisions. H.R. 275, Medicare Prescription Drug Negotiation Act, regarding all bio-pharmaceutical related provisions. H.R. 366, Insulin Access for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1034, D. Collins/S. 640, Kennedy: Phair Pricing Act - Share the savings, regarding all bio-pharmaceutical related provisions. H.R. 1035, Prescription Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1332, Fair Care Act, regarding all bio-pharmaceutical related provisions. H.R. 1346, Medicare Buy-In and Health Care Stabilization Act, regarding all bio-pharmaceutical related provisions. H.R. 1384, Medicare for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1781, Payment Commission Data Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1788, Limits the penalty for Part B late enrollment to 15 percent and twice the period of no enrollment, regarding all bio-pharmaceutical related provisions. H.R. 2087, Reporting drug pricing information to Medicare, regarding all bio-pharmaceutical related provisions. H.R. 2113, Prescription STAR Act, regarding all bio-pharmaceutical related provisions. H.R.3, Lower Drug Costs Now Act of 2019, regarding all bio-pharmaceutical related provisions S. 62, Empowering Medicare Seniors to Negotiate Drug Prices, regarding all bio-pharmaceutical related provisions. S. 99, Medicare Drug Price Negotiation Act, regarding all bio-pharmaceutical related provisions. S. 205, Right Rebate Act, regarding all bio-pharmaceutical related provisions. S. 377/H.R. 1046, Medicare Negotiation and Competitive Licensing Act, regarding all bio-pharmaceutical related provisions. S. 470, Medicare at 50 Act, regarding all bio-pharmaceutical related provisions. S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 , regarding all bio-pharmaceutical related provisions. S. 475, RxCAP Act, regarding all bio-pharmaceutical related provisions. S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU Act) of 2019, regarding all bio-pharmaceutical related provisions. S. 551, REFUND Act of 2019, regarding all bio-pharmaceutical related provisions. S. 691, Expands Part D OOP assistance for low-income seniors and individuals with disabilities, regarding all bio-pharmaceutical related provisions. S. 801/H.R. 1781, Allows MedPAC and MACPAC to have access to information on drug rebates, regarding all bio-pharmaceutical related provisions. S. 981, Medicare-X Choice Act of 2019, regarding all bio-pharmaceutical related provisions. Pending rule to change the Rebate Safe Harbor, regarding all bio-pharmaceutical related provisions. H.R. 1839, Medicaid Services Investment and Accountability Act, regarding all bio-pharmaceutical related provisions H.R. 2452, Medicare for America Act, regarding all bio-pharmaceutical related provisions H.R. 3107, Improving Seniors Timely Access to Care Act, regarding all bio-pharmaceutical related provisions H.R. 3327, Drug Price Transparency for Medicare Patients Act, regarding all bio-pharmaceutical related provisions S. 1261/H.R. 2463, Choose Medicare Act, regarding all bio-pharmaceutical related provisions S. 1497, Health Care Price Check Act, regarding all bio-pharmaceutical related provisions S. 2081, a bill to require drug manufacturers to provide rebates for drugs furnished under Medicare Part B for which the growth in average sales price has exceeded inflation, regarding all bio-pharmaceutical related provisions. S. 2543, Prescription Drug Pricing Reduction Act of 2019, regarding all bio-pharmaceutical provisions. H.R. 19/S.3129 , Lower Costs, More Cures Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 6218/S. 3457, Preserving Patient Access to Home Infusion Act, regarding all bio-pharmaceutical related provisions No Bill, Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies.
H.R. 1158, Further Consolidated Appropriations Act of 2020, regarding all bio-pharmaceutical related provisions H.R.1865, Further Consolidated Appropriations Act of 2020, regarding all bio-pharmaceutical related provisions
H.R. 1499, Protecting Consumer Access to Generic Drugs Act, regarding all bio-pharmaceutical related provisions H.R. 965, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 1344, Competitive DRUGS Act, regarding all bio-pharmaceutical related provisions. H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions S. 64, Preserve Access to Affordable Generics and Biosimilars Act,regarding all bio-pharmaceutical related provisions. H.R.2375, Preserve Access to Affordable Generics and Biosimilars Act, regarding all bio-pharmaceutical related provisions H.R. 2387, STOP GAMES Act, regarding all bio-pharmaceutical related provisions H.R. 3199, TERM Act, regarding all bio-pharmaceutical related provisions S. 440, PACED Act, regarding all bio-pharmaceutical related provisions S. 1224/H.R.2374, Stop STALLING Act, regarding all bio-pharmaceutical related provisions S.1416, Affordable Prescriptions for Patients Act, regarding all bio-pharmaceutical related provisions S. 1617, Second Look at Drug Patents Act, regarding all bio-pharmaceutical related provisions
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
H.R. 1158, Further Consolidated Appropriations Act of 2020, regarding all bio-pharmaceutical related provisions H.R.1865, Further Consolidated Appropriations Act of 2020, regarding all bio-pharmaceutical related provisions
H.R. 107, Burgess: Rebate cap, regarding all bio-pharmaceutical related provisions. H.R. 275, Medicare Prescription Drug Negotiation Act, regarding all bio-pharmaceutical related provisions. H.R. 366, Insulin Access for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1034, D. Collins/S. 640, Kennedy: Phair Pricing Act - Share the savings, regarding all bio-pharmaceutical related provisions. H.R. 1035, Prescription Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1332, Fair Care Act, regarding all bio-pharmaceutical related provisions. H.R. 1346, Medicare Buy-In and Health Care Stabilization Act, regarding all bio-pharmaceutical related provisions. H.R. 1384, Medicare for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1781, Payment Commission Data Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1788, Limits the penalty for Part B late enrollment to 15 percent and twice the period of no enrollment, regarding all bio-pharmaceutical related provisions. H.R. 2087, Reporting drug pricing information to Medicare, regarding all bio-pharmaceutical related provisions. H.R. 2113, Prescription STAR Act, regarding all bio-pharmaceutical related provisions. H.R.3, Lower Drug Costs Now Act of 2019, regarding all bio-pharmaceutical related provisions S. 62, Empowering Medicare Seniors to Negotiate Drug Prices, regarding all bio-pharmaceutical related provisions. S. 99, Medicare Drug Price Negotiation Act, regarding all bio-pharmaceutical related provisions. S. 205, Right Rebate Act, regarding all bio-pharmaceutical related provisions. S. 377/H.R. 1046, Medicare Negotiation and Competitive Licensing Act, regarding all bio-pharmaceutical related provisions. S. 470, Medicare at 50 Act, regarding all bio-pharmaceutical related provisions. S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 , regarding all bio-pharmaceutical related provisions. S. 475, RxCAP Act, regarding all bio-pharmaceutical related provisions. S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU Act) of 2019, regarding all bio-pharmaceutical related provisions. S. 551, REFUND Act of 2019, regarding all bio-pharmaceutical related provisions. S. 691, Expands Part D OOP assistance for low-income seniors and individuals with disabilities, regarding all bio-pharmaceutical related provisions. S. 801/H.R. 1781, Allows MedPAC and MACPAC to have access to information on drug rebates, regarding all bio-pharmaceutical related provisions. S. 981, Medicare-X Choice Act of 2019, regarding all bio-pharmaceutical related provisions. Pending rule to change the Rebate Safe Harbor, regarding all bio-pharmaceutical related provisions. H.R. 1839, Medicaid Services Investment and Accountability Act, regarding all bio-pharmaceutical related provisions H.R. 2452, Medicare for America Act, regarding all bio-pharmaceutical related provisions H.R. 3107, Improving Seniors Timely Access to Care Act, regarding all bio-pharmaceutical related provisions H.R. 3327, Drug Price Transparency for Medicare Patients Act, regarding all bio-pharmaceutical related provisions S. 1261/H.R. 2463, Choose Medicare Act, regarding all bio-pharmaceutical related provisions S. 1497, Health Care Price Check Act, regarding all bio-pharmaceutical related provisions S. 2081, a bill to require drug manufacturers to provide rebates for drugs furnished under Medicare Part B for which the growth in average sales price has exceeded inflation, regarding all bio-pharmaceutical related provisions. S. 2543, Prescription Drug Pricing Reduction Act of 2019, regarding all bio-pharmaceutical provisions. H.R. 19/S.3129 , Lower Costs, More Cures Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 6218/S. 3457, Preserving Patient Access to Home Infusion Act, regarding all bio-pharmaceutical related provisions No Bill, Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies.
H.R. 2209, To establish the position of Chief Pharmaceutical Negotiator in the Office of the United States Trade Representative responsible for conducting trade negotiations and enforcing trade agreements related to acts, policies, and practices of foreign governments that fail to appropriately reward United States innovation with respect to pharmaceuticals, and for other purposes, regarding all bio-pharmaceutical related provisions. Unite States, Mexico, Canada Trade Agreement, regarding all bio-pharmaceutical related provisions. S. 3537, Protecting our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions S. 3538, Strengthening Americas Supply Chain and National Security Act, regarding all bio-pharmaceutical related provisions No Bill, potential Buy American executive order for health-related goods, regarding all bio-pharmaceutical related provisions H.R. 4710, Pharmaceutical Independence Long-Term Readiness Reform Act, regarding all bio-pharmaceutical related provisions H.R. 4866, National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 5381, International Pharmaceutical Transparency Act of 2019 , regarding all bio-pharmaceutical related provisions H.R. 5982, Safe Medicine Act, regarding all bio-pharmaceutical related provisions H.R. 6049/S3343, Medical Supply Chain Security Act, regarding all bio-pharmaceutical related provisions H.R. 6080, Preventing Drug Shortages Act, regarding all bio-pharmaceutical , regarding all bio-pharmaceutical related provisions related provisions H.R. 6393, Strengthening America's Supply Chain and National Security Act, regarding all bio-pharmaceutical related provisions H.R.6399/S.3715 , SAVE Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6431, Made in America Emergency Preparedness Act, regarding all bio-pharmaceutical related provisions H.R. 6482, Protecting Our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6670, Prescription for American Drug Independence Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6690, Bring Entrepreneurial Advancements To Consumers Here In North America Act ,regarding all bio-pharmaceutical related provisions H.R. 6708/S. 3432, Securing America's Medicine Cabinet Act of 2020, regarding all bio-pharmaceutical related provisions H.R. 6930, MADE in America Act of 2020, regarding all bio-pharmaceutical related provisions S. 3635, Protecting Our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions S. 2723, Mitigating Emergency Drug Shortages Act, regarding all bio-pharmaceutical related provisions S.3945, Bring Entrepreneurial Advancements To Consumers Here In North America Act, regarding all bio-pharmaceutical related provisions
H.R. 1499, Protecting Consumer Access to Generic Drugs Act, regarding all bio-pharmaceutical related provisions H.R. 965, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 1344, Competitive DRUGS Act, regarding all bio-pharmaceutical related provisions. H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions S. 64, Preserve Access to Affordable Generics and Biosimilars Act,regarding all bio-pharmaceutical related provisions. H.R.2375, Preserve Access to Affordable Generics and Biosimilars Act, regarding all bio-pharmaceutical related provisions H.R. 2387, STOP GAMES Act, regarding all bio-pharmaceutical related provisions H.R. 3199, TERM Act, regarding all bio-pharmaceutical related provisions S. 440, PACED Act, regarding all bio-pharmaceutical related provisions S. 1224/H.R.2374, Stop STALLING Act, regarding all bio-pharmaceutical related provisions S.1416, Affordable Prescriptions for Patients Act, regarding all bio-pharmaceutical related provisions S. 1617, Second Look at Drug Patents Act, regarding all bio-pharmaceutical related provisions
S. 73, End Taxpayer Subsidies for Drug Ads Act, regarding all bio-pharmaceutical related provisions. S. 378/H.R. 1093, Stop Price Gouging Act, regarding all bio-pharmaceutical related provisions. S. 425, LifeBOAT Act, regarding all bio-pharmaceutical related provisions.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
S. 73, End Taxpayer Subsidies for Drug Ads Act, regarding all bio-pharmaceutical related provisions. S. 378/H.R. 1093, Stop Price Gouging Act, regarding all bio-pharmaceutical related provisions. S. 425, LifeBOAT Act, regarding all bio-pharmaceutical related provisions.
H.R. 107, Burgess: Rebate cap, regarding all bio-pharmaceutical related provisions. H.R. 275, Medicare Prescription Drug Negotiation Act, regarding all bio-pharmaceutical related provisions. H.R. 366, Insulin Access for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1034, D. Collins/S. 640, Kennedy: Phair Pricing Act - Share the savings, regarding all bio-pharmaceutical related provisions. H.R. 1035, Prescription Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1332, Fair Care Act, regarding all bio-pharmaceutical related provisions. H.R. 1346, Medicare Buy-In and Health Care Stabilization Act, regarding all bio-pharmaceutical related provisions. H.R. 1384, Medicare for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1781, Payment Commission Data Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1788, Limits the penalty for Part B late enrollment to 15 percent and twice the period of no enrollment, regarding all bio-pharmaceutical related provisions. H.R. 2087, Reporting drug pricing information to Medicare, regarding all bio-pharmaceutical related provisions. H.R. 2113, Prescription STAR Act, regarding all bio-pharmaceutical related provisions. H.R.3, Lower Drug Costs Now Act of 2019, regarding all bio-pharmaceutical related provisions S. 62, Empowering Medicare Seniors to Negotiate Drug Prices, regarding all bio-pharmaceutical related provisions. S. 99, Medicare Drug Price Negotiation Act, regarding all bio-pharmaceutical related provisions. S. 205, Right Rebate Act, regarding all bio-pharmaceutical related provisions. S. 377/H.R. 1046, Medicare Negotiation and Competitive Licensing Act, regarding all bio-pharmaceutical related provisions. S. 470, Medicare at 50 Act, regarding all bio-pharmaceutical related provisions. S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 , regarding all bio-pharmaceutical related provisions. S. 475, RxCAP Act, regarding all bio-pharmaceutical related provisions. S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU Act) of 2019, regarding all bio-pharmaceutical related provisions. S. 551, REFUND Act of 2019, regarding all bio-pharmaceutical related provisions. S. 691, Expands Part D OOP assistance for low-income seniors and individuals with disabilities, regarding all bio-pharmaceutical related provisions. S. 801/H.R. 1781, Allows MedPAC and MACPAC to have access to information on drug rebates, regarding all bio-pharmaceutical related provisions. S. 981, Medicare-X Choice Act of 2019, regarding all bio-pharmaceutical related provisions. Pending rule to change the Rebate Safe Harbor, regarding all bio-pharmaceutical related provisions. H.R. 1839, Medicaid Services Investment and Accountability Act, regarding all bio-pharmaceutical related provisions H.R. 2452, Medicare for America Act, regarding all bio-pharmaceutical related provisions H.R. 3107, Improving Seniors Timely Access to Care Act, regarding all bio-pharmaceutical related provisions H.R. 3327, Drug Price Transparency for Medicare Patients Act, regarding all bio-pharmaceutical related provisions S. 1261/H.R. 2463, Choose Medicare Act, regarding all bio-pharmaceutical related provisions S. 1497, Health Care Price Check Act, regarding all bio-pharmaceutical related provisions S. 2081, a bill to require drug manufacturers to provide rebates for drugs furnished under Medicare Part B for which the growth in average sales price has exceeded inflation, regarding all bio-pharmaceutical related provisions. S. 2543, Prescription Drug Pricing Reduction Act of 2019, regarding all bio-pharmaceutical provisions. H.R. 19/S.3129 , Lower Costs, More Cures Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 6218/S. 3457, Preserving Patient Access to Home Infusion Act, regarding all bio-pharmaceutical related provisions No Bill, Reimbursement for and patient access to Chimeric Antigen Receptor (CAR) T-cell therapies.
H.R. 1499, Protecting Consumer Access to Generic Drugs Act, regarding all bio-pharmaceutical related provisions H.R. 965, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 1344, Competitive DRUGS Act, regarding all bio-pharmaceutical related provisions. H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions S. 64, Preserve Access to Affordable Generics and Biosimilars Act,regarding all bio-pharmaceutical related provisions. H.R.2375, Preserve Access to Affordable Generics and Biosimilars Act, regarding all bio-pharmaceutical related provisions H.R. 2387, STOP GAMES Act, regarding all bio-pharmaceutical related provisions H.R. 3199, TERM Act, regarding all bio-pharmaceutical related provisions S. 440, PACED Act, regarding all bio-pharmaceutical related provisions S. 1224/H.R.2374, Stop STALLING Act, regarding all bio-pharmaceutical related provisions S.1416, Affordable Prescriptions for Patients Act, regarding all bio-pharmaceutical related provisions S. 1617, Second Look at Drug Patents Act, regarding all bio-pharmaceutical related provisions
H.R. 1158, Further Consolidated Appropriations Act of 2020, regarding all bio-pharmaceutical related provisions H.R.1865, Further Consolidated Appropriations Act of 2020, regarding all bio-pharmaceutical related provisions
H.R. 2209, To establish the position of Chief Pharmaceutical Negotiator in the Office of the United States Trade Representative responsible for conducting trade negotiations and enforcing trade agreements related to acts, policies, and practices of foreign governments that fail to appropriately reward United States innovation with respect to pharmaceuticals, and for other purposes, regarding all bio-pharmaceutical related provisions. Unite States, Mexico, Canada Trade Agreement, regarding all bio-pharmaceutical related provisions. S. 3537, Protecting our Pharmaceutical Supply Chain from China Act of 2020, regarding all bio-pharmaceutical related provisions S. 3538, Strengthening Americas Supply Chain and National Security Act, regarding all bio-pharmaceutical related provisions No Bill, potential Buy American executive order for health-related goods, regarding all bio-pharmaceutical related provisions
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
H.R. 1158, Further Consolidated Appropriations Act of 2020, regarding all bio-pharmaceutical related provisions H.R.1865, Further Consolidated Appropriations Act of 2020, regarding all bio-pharmaceutical related provisions
H.R. 107, Burgess: Rebate cap, regarding all bio-pharmaceutical related provisions. H.R. 275, Medicare Prescription Drug Negotiation Act, regarding all bio-pharmaceutical related provisions. H.R. 366, Insulin Access for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1034, D. Collins/S. 640, Kennedy: Phair Pricing Act - Share the savings, regarding all bio-pharmaceutical related provisions. H.R. 1035, Prescription Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1332, Fair Care Act, regarding all bio-pharmaceutical related provisions. H.R. 1346, Medicare Buy-In and Health Care Stabilization Act, regarding all bio-pharmaceutical related provisions. H.R. 1384, Medicare for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1781, Payment Commission Data Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1788, Limits the penalty for Part B late enrollment to 15 percent and twice the period of no enrollment, regarding all bio-pharmaceutical related provisions. H.R. 2087, Reporting drug pricing information to Medicare, regarding all bio-pharmaceutical related provisions. H.R. 2113, Prescription STAR Act, regarding all bio-pharmaceutical related provisions. H.R.3, Lower Drug Costs Now Act of 2019, regarding all bio-pharmaceutical related provisions S. 62, Empowering Medicare Seniors to Negotiate Drug Prices, regarding all bio-pharmaceutical related provisions. S. 99, Medicare Drug Price Negotiation Act, regarding all bio-pharmaceutical related provisions. S. 205, Right Rebate Act, regarding all bio-pharmaceutical related provisions. S. 377/H.R. 1046, Medicare Negotiation and Competitive Licensing Act, regarding all bio-pharmaceutical related provisions. S. 470, Medicare at 50 Act, regarding all bio-pharmaceutical related provisions. S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 , regarding all bio-pharmaceutical related provisions. S. 475, RxCAP Act, regarding all bio-pharmaceutical related provisions. S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU Act) of 2019, regarding all bio-pharmaceutical related provisions. S. 551, REFUND Act of 2019, regarding all bio-pharmaceutical related provisions. S. 691, Expands Part D OOP assistance for low-income seniors and individuals with disabilities, regarding all bio-pharmaceutical related provisions. S. 801/H.R. 1781, Allows MedPAC and MACPAC to have access to information on drug rebates, regarding all bio-pharmaceutical related provisions. S. 981, Medicare-X Choice Act of 2019, regarding all bio-pharmaceutical related provisions. Pending rule to change the Rebate Safe Harbor, regarding all bio-pharmaceutical related provisions. H.R. 1839, Medicaid Services Investment and Accountability Act, regarding all bio-pharmaceutical related provisions H.R. 2452, Medicare for America Act, regarding all bio-pharmaceutical related provisions H.R. 3107, Improving Seniors Timely Access to Care Act, regarding all bio-pharmaceutical related provisions H.R. 3327, Drug Price Transparency for Medicare Patients Act, regarding all bio-pharmaceutical related provisions S. 1261/H.R. 2463, Choose Medicare Act, regarding all bio-pharmaceutical related provisions S. 1497, Health Care Price Check Act, regarding all bio-pharmaceutical related provisions S. 2081, a bill to require drug manufacturers to provide rebates for drugs furnished under Medicare Part B for which the growth in average sales price has exceeded inflation, regarding all bio-pharmaceutical related provisions. S. 2543, Prescription Drug Pricing Reduction Act of 2019, regarding all bio-pharmaceutical provisions. H.R. 19/S.3129 , Lower Costs, More Cures Act of 2019, regarding all bio-pharmaceutical related provisions
H.R. 2209, To establish the position of Chief Pharmaceutical Negotiator in the Office of the United States Trade Representative responsible for conducting trade negotiations and enforcing trade agreements related to acts, policies, and practices of foreign governments that fail to appropriately reward United States innovation with respect to pharmaceuticals, and for other purposes, regarding all bio-pharmaceutical related provisions. Unite States, Mexico, Canada Trade Agreement, regarding all bio-pharmaceutical related provisions.
H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 985, Fair Access for Safe and Timely (FAST) Generics Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 986, Protecting American with Preexisting Conditions Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1010, Short-Term, Limited Duration Insurance (STLDI), regarding all bio-pharmaceutical related provisions. H.R. 1323, Rural Hospital Frontier Fairness Act, regarding all bio-pharmaceutical related provisions. H.R. 1385, State Allowance for a Variety of Exchanges (SAVE) Act, regarding all bio-pharmaceutical related provisions. H.R. 1386, Expanded Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act, regarding all bio-pharmaceutical related provisions. H.R. 1409, Transparency in All Health Care Pricing Act, regarding all bio-pharmaceutical related provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions. H.R. 1478, Insulin importation, regarding all bio-pharmaceutical related provisions. H.R. 1503, Orange Book Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1506, Fair and Immediate Release (FAIR) of Generics Act, regarding all bio-pharmaceutical related provisions. H.R. 1520, Purple Book Continuity Act, regarding all bio-pharmaceutical related provisions. H.R. 2011, Protecting Access to Biosimilars Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2038, State-based , Market-Oriented, Prescription Drug Negotiations Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2064, Product Sample reporting, regarding all bio-pharmaceutical related provisions. S. 61, Safe and Affordable Drugs from Canada Act, regarding all bio-pharmaceutical related provisions. S. 97, Affordable and Safe Drug Importation Act, regarding all bio-pharmaceutical related provisions. S. 102, Prescription Drug Price Relief Act, regarding all bio-pharmaceutical related provisions. S. 344/H.R. 990, Hatch-Waxman Integrity Act, regarding all bio-pharmaceutical related provisions. S. 366/H.R. 1188, FLAT Prices Act- Reduced exclusivity period for certain price hikes, regarding all bio-pharmaceutical related provisions. S. 418, FDA Accountability for Public Safety Act, regarding all bio-pharmaceutical related provisions. S. 419, Protecting Americans from Dangerous Opioids Act, regarding all bio-pharmaceutical related provisions. S. 637, CURE High Drug Prices Act, regarding all bio-pharmaceutical related provisions. S. 657, Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. S. 658, Accelerated Drug Approval for Prescription Therapies Act, regarding all bio-pharmaceutical related provisions. S. 659, Biologic Patent Transparency Act, regarding all bio-pharmaceutical related provisions. S. 660, Transparency in Petitions Act, regarding all bio-pharmaceutical related provisions. S. 709, Establishes public dashboard for price and utilization of drugs purchased by federal programs, regarding all bio-pharmaceutical related provisions. S. 741 /H.R. 1730, Cancer Drug Parity Act, regarding all bio-pharmaceutical related provisions. S. 844, Short Competition Act, regarding all bio-pharmaceutical related provisions. S. 977, Transparent Drug Pricing Act of 2019, regarding all bio-pharmaceutical related provisions. S. 989, STEER Act, regarding all bio-pharmaceutical related provisions. S. 1140, A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009, regarding all bio-pharmaceutical related provisions. S.1169, FDA citizen petition, regarding all bio-pharmaceutical related provisions. S. 1209, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications, regarding all bio-pharmaceutical related provisions. H.R. 2115, Public Disclosure of Drug Discounts Act, regarding all bio-pharmaceutical related provisions H.R.2296/S.1391, FAIR Drug Pricing Act, regarding all bio-pharmaceutical related provisions H.R.2700, Lowering Prescription Drug Costs and Extending Community Health Centers and other Health Priorities Act, regarding all bio-pharmaceutical related provisions H.R. 3223, Pharmacy Benefit Manager Accountability Study Act, regarding all bio-pharmaceutical related provisions S. 1361/H.R.2584, Preventive Health Savings Act, regarding all bio-pharmaceutical related provisions S. 1437, DTC Act, regarding all bio-pharmaceutical related provisions S.1532, Pharmacy Benefit Managers Accountability Study Act, regarding all bio-pharmaceutical related provisions S.1636, Ensuring Innovation Act, regarding all bio-pharmaceutical related provisions S. 1664, Prescription Drug Price Reporting Act, regarding all bio-pharmaceutical related provisions S. 1801, Affordable Medications Act, regarding all bio-pharmaceutical related provisions S. 1895, Lowering Health Costs Act, regarding all bio-pharmaceutical related provisions S. 1897, a bill to establish a process for updating the labeling of certain drugs with outdated labeling, regarding all bio-pharmaceutical related provisions S. 1897/H.R. 3523, End Price Gouging for Medications Act, regarding all bio-pharmaceutical related provisions S. 2004, Emergency Access to Insulin Act, regarding all bio-pharmaceutical related provisions H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
H.R. 1499, Protecting Consumer Access to Generic Drugs Act, regarding all bio-pharmaceutical related provisions H.R. 965, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 1344, Competitive DRUGS Act, regarding all bio-pharmaceutical related provisions. H.R. 2279/S. 2546, Safe Step Act of 2019, regarding all bio-pharmaceutical related provisions S. 64, Preserve Access to Affordable Generics and Biosimilars Act,regarding all bio-pharmaceutical related provisions. S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R.2375, Preserve Access to Affordable Generics and Biosimilars Act, regarding all bio-pharmaceutical related provisions H.R. 2387, STOP GAMES Act, regarding all bio-pharmaceutical related provisions H.R. 3199, TERM Act, regarding all bio-pharmaceutical related provisions S. 440, PACED Act, regarding all bio-pharmaceutical related provisions S. 1224/H.R.2374, Stop STALLING Act, regarding all bio-pharmaceutical related provisions S.1416, Affordable Prescriptions for Patients Act, regarding all bio-pharmaceutical related provisions S. 1617, Second Look at Drug Patents Act, regarding all bio-pharmaceutical related provisions
H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 985, Fair Access for Safe and Timely (FAST) Generics Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 986, Protecting American with Preexisting Conditions Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1010, Short-Term, Limited Duration Insurance (STLDI), regarding all bio-pharmaceutical related provisions. H.R. 1323, Rural Hospital Frontier Fairness Act, regarding all bio-pharmaceutical related provisions. H.R. 1385, State Allowance for a Variety of Exchanges (SAVE) Act, regarding all bio-pharmaceutical related provisions. H.R. 1386, Expanded Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act, regarding all bio-pharmaceutical related provisions. H.R. 1409, Transparency in All Health Care Pricing Act, regarding all bio-pharmaceutical related provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions. H.R. 1478, Insulin importation, regarding all bio-pharmaceutical related provisions. H.R. 1503, Orange Book Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1506, Fair and Immediate Release (FAIR) of Generics Act, regarding all bio-pharmaceutical related provisions. H.R. 1520, Purple Book Continuity Act, regarding all bio-pharmaceutical related provisions. H.R. 2011, Protecting Access to Biosimilars Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2038, State-based , Market-Oriented, Prescription Drug Negotiations Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2064, Product Sample reporting, regarding all bio-pharmaceutical related provisions. S. 61, Safe and Affordable Drugs from Canada Act, regarding all bio-pharmaceutical related provisions. S. 97, Affordable and Safe Drug Importation Act, regarding all bio-pharmaceutical related provisions. S. 102, Prescription Drug Price Relief Act, regarding all bio-pharmaceutical related provisions. S. 344/H.R. 990, Hatch-Waxman Integrity Act, regarding all bio-pharmaceutical related provisions. S. 366/H.R. 1188, FLAT Prices Act- Reduced exclusivity period for certain price hikes, regarding all bio-pharmaceutical related provisions. S. 418, FDA Accountability for Public Safety Act, regarding all bio-pharmaceutical related provisions. S. 419, Protecting Americans from Dangerous Opioids Act, regarding all bio-pharmaceutical related provisions. S. 637, CURE High Drug Prices Act, regarding all bio-pharmaceutical related provisions. S. 657, Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. S. 658, Accelerated Drug Approval for Prescription Therapies Act, regarding all bio-pharmaceutical related provisions. S. 659, Biologic Patent Transparency Act, regarding all bio-pharmaceutical related provisions. S. 660, Transparency in Petitions Act, regarding all bio-pharmaceutical related provisions. S. 709, Establishes public dashboard for price and utilization of drugs purchased by federal programs, regarding all bio-pharmaceutical related provisions. S. 741 /H.R. 1730, Cancer Drug Parity Act, regarding all bio-pharmaceutical related provisions. S. 844, Short Competition Act, regarding all bio-pharmaceutical related provisions. S. 977, Transparent Drug Pricing Act of 2019, regarding all bio-pharmaceutical related provisions. S. 989, STEER Act, regarding all bio-pharmaceutical related provisions. S. 1140, A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009, regarding all bio-pharmaceutical related provisions. S.1169, FDA citizen petition, regarding all bio-pharmaceutical related provisions. S. 1209, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications, regarding all bio-pharmaceutical related provisions. H.R. 2115, Public Disclosure of Drug Discounts Act, regarding all bio-pharmaceutical related provisions H.R.2296/S.1391, FAIR Drug Pricing Act, regarding all bio-pharmaceutical related provisions H.R.2700, Lowering Prescription Drug Costs and Extending Community Health Centers and other Health Priorities Act, regarding all bio-pharmaceutical related provisions H.R. 3223, Pharmacy Benefit Manager Accountability Study Act, regarding all bio-pharmaceutical related provisions S. 1361/H.R.2584, Preventive Health Savings Act, regarding all bio-pharmaceutical related provisions S. 1437, DTC Act, regarding all bio-pharmaceutical related provisions S.1532, Pharmacy Benefit Managers Accountability Study Act, regarding all bio-pharmaceutical related provisions S.1636, Ensuring Innovation Act, regarding all bio-pharmaceutical related provisions S. 1664, Prescription Drug Price Reporting Act, regarding all bio-pharmaceutical related provisions S. 1801, Affordable Medications Act, regarding all bio-pharmaceutical related provisions S. 1895, Lowering Health Costs Act, regarding all bio-pharmaceutical related provisions S. 1897, a bill to establish a process for updating the labeling of certain drugs with outdated labeling, regarding all bio-pharmaceutical related provisions S. 1897/H.R. 3523, End Price Gouging for Medications Act, regarding all bio-pharmaceutical related provisions S. 2004, Emergency Access to Insulin Act, regarding all bio-pharmaceutical related provisions
H.R. 107, Burgess: Rebate cap, regarding all bio-pharmaceutical related provisions. H.R. 275, Medicare Prescription Drug Negotiation Act, regarding all bio-pharmaceutical related provisions. H.R. 366, Insulin Access for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1034, D. Collins/S. 640, Kennedy: Phair Pricing Act - Share the savings, regarding all bio-pharmaceutical related provisions. H.R. 1035, Prescription Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1332, Fair Care Act, regarding all bio-pharmaceutical related provisions. H.R. 1346, Medicare Buy-In and Health Care Stabilization Act, regarding all bio-pharmaceutical related provisions. H.R. 1384, Medicare for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1781, Payment Commission Data Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1788, Limits the penalty for Part B late enrollment to 15 percent and twice the period of no enrollment, regarding all bio-pharmaceutical related provisions. H.R. 2087, Reporting drug pricing information to Medicare, regarding all bio-pharmaceutical related provisions. H.R. 2113, Prescription STAR Act, regarding all bio-pharmaceutical related provisions. H.R.3, Lower Drug Costs Now Act of 2019, regarding all bio-pharmaceutical related provisions S. 62, Empowering Medicare Seniors to Negotiate Drug Prices, regarding all bio-pharmaceutical related provisions. S. 99, Medicare Drug Price Negotiation Act, regarding all bio-pharmaceutical related provisions. S. 205, Right Rebate Act, regarding all bio-pharmaceutical related provisions. S. 377/H.R. 1046, Medicare Negotiation and Competitive Licensing Act, regarding all bio-pharmaceutical related provisions. S. 470, Medicare at 50 Act, regarding all bio-pharmaceutical related provisions. S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 , regarding all bio-pharmaceutical related provisions. S. 475, RxCAP Act, regarding all bio-pharmaceutical related provisions. S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU Act) of 2019, regarding all bio-pharmaceutical related provisions. S. 551, REFUND Act of 2019, regarding all bio-pharmaceutical related provisions. S. 691, Expands Part D OOP assistance for low-income seniors and individuals with disabilities, regarding all bio-pharmaceutical related provisions. S. 801/H.R. 1781, Allows MedPAC and MACPAC to have access to information on drug rebates, regarding all bio-pharmaceutical related provisions. S. 981, Medicare-X Choice Act of 2019, regarding all bio-pharmaceutical related provisions. Pending rule to change the Rebate Safe Harbor, regarding all bio-pharmaceutical related provisions. H.R. 1839, Medicaid Services Investment and Accountability Act, regarding all bio-pharmaceutical related provisions H.R. 2452, Medicare for America Act, regarding all bio-pharmaceutical related provisions H.R. 3107, Improving Seniors Timely Access to Care Act, regarding all bio-pharmaceutical related provisions H.R. 3327, Drug Price Transparency for Medicare Patients Act, regarding all bio-pharmaceutical related provisions S. 1261/H.R. 2463, Choose Medicare Act, regarding all bio-pharmaceutical related provisions S. 1497, Health Care Price Check Act, regarding all bio-pharmaceutical related provisions S. 2081, a bill to require drug manufacturers to provide rebates for drugs furnished under Medicare Part B for which the growth in average sales price has exceeded inflation, regarding all bio-pharmaceutical related provisions. S. 2543, Prescription Drug Pricing Reduction Act of 2019, regarding all bio-pharmaceutical provisions.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 985, Fair Access for Safe and Timely (FAST) Generics Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 986, Protecting American with Preexisting Conditions Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1010, Short-Term, Limited Duration Insurance (STLDI), regarding all bio-pharmaceutical related provisions. H.R. 1323, Rural Hospital Frontier Fairness Act, regarding all bio-pharmaceutical related provisions. H.R. 1385, State Allowance for a Variety of Exchanges (SAVE) Act, regarding all bio-pharmaceutical related provisions. H.R. 1386, Expanded Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act, regarding all bio-pharmaceutical related provisions. H.R. 1409, Transparency in All Health Care Pricing Act, regarding all bio-pharmaceutical related provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions. H.R. 1478, Insulin importation, regarding all bio-pharmaceutical related provisions. H.R. 1503, Orange Book Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1506, Fair and Immediate Release (FAIR) of Generics Act, regarding all bio-pharmaceutical related provisions. H.R. 1520, Purple Book Continuity Act, regarding all bio-pharmaceutical related provisions. H.R. 2011, Protecting Access to Biosimilars Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2038, State-based , Market-Oriented, Prescription Drug Negotiations Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2064, Product Sample reporting, regarding all bio-pharmaceutical related provisions. S. 61, Safe and Affordable Drugs from Canada Act, regarding all bio-pharmaceutical related provisions. S. 97, Affordable and Safe Drug Importation Act, regarding all bio-pharmaceutical related provisions. S. 102, Prescription Drug Price Relief Act, regarding all bio-pharmaceutical related provisions. S. 344/H.R. 990, Hatch-Waxman Integrity Act, regarding all bio-pharmaceutical related provisions. S. 366/H.R. 1188, FLAT Prices Act- Reduced exclusivity period for certain price hikes, regarding all bio-pharmaceutical related provisions. S. 418, FDA Accountability for Public Safety Act, regarding all bio-pharmaceutical related provisions. S. 419, Protecting Americans from Dangerous Opioids Act, regarding all bio-pharmaceutical related provisions. S. 637, CURE High Drug Prices Act, regarding all bio-pharmaceutical related provisions. S. 657, Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. S. 658, Accelerated Drug Approval for Prescription Therapies Act, regarding all bio-pharmaceutical related provisions. S. 659, Biologic Patent Transparency Act, regarding all bio-pharmaceutical related provisions. S. 660, Transparency in Petitions Act, regarding all bio-pharmaceutical related provisions. S. 709, Establishes public dashboard for price and utilization of drugs purchased by federal programs, regarding all bio-pharmaceutical related provisions. S. 741 /H.R. 1730, Cancer Drug Parity Act, regarding all bio-pharmaceutical related provisions. S. 844, Short Competition Act, regarding all bio-pharmaceutical related provisions. S. 977, Transparent Drug Pricing Act of 2019, regarding all bio-pharmaceutical related provisions. S. 989, STEER Act, regarding all bio-pharmaceutical related provisions. S. 1140, A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009, regarding all bio-pharmaceutical related provisions. S.1169, FDA citizen petition, regarding all bio-pharmaceutical related provisions. S. 1209, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications, regarding all bio-pharmaceutical related provisions. H.R. 2115, Public Disclosure of Drug Discounts Act, regarding all bio-pharmaceutical related provisions H.R.2296/S.1391, FAIR Drug Pricing Act, regarding all bio-pharmaceutical related provisions H.R.2700, Lowering Prescription Drug Costs and Extending Community Health Centers and other Health Priorities Act, regarding all bio-pharmaceutical related provisions H.R. 3223, Pharmacy Benefit Manager Accountability Study Act, regarding all bio-pharmaceutical related provisions S. 1361/H.R.2584, Preventive Health Savings Act, regarding all bio-pharmaceutical related provisions S. 1437, DTC Act, regarding all bio-pharmaceutical related provisions S.1532, Pharmacy Benefit Managers Accountability Study Act, regarding all bio-pharmaceutical related provisions S.1636, Ensuring Innovation Act, regarding all bio-pharmaceutical related provisions S. 1664, Prescription Drug Price Reporting Act, regarding all bio-pharmaceutical related provisions S. 1801, Affordable Medications Act, regarding all bio-pharmaceutical related provisions S. 1895, Lowering Health Costs Act, regarding all bio-pharmaceutical related provisions S. 1897, a bill to establish a process for updating the labeling of certain drugs with outdated labeling, regarding all bio-pharmaceutical related provisions S. 1897/H.R. 3523, End Price Gouging for Medications Act, regarding all bio-pharmaceutical related provisions S. 2004, Emergency Access to Insulin Act, regarding all bio-pharmaceutical related provisions
H.R. 107, Burgess: Rebate cap, regarding all bio-pharmaceutical related provisions. H.R. 275, Medicare Prescription Drug Negotiation Act, regarding all bio-pharmaceutical related provisions. H.R. 366, Insulin Access for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1034, D. Collins/S. 640, Kennedy: Phair Pricing Act - Share the savings, regarding all bio-pharmaceutical related provisions. H.R. 1035, Prescription Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1332, Fair Care Act, regarding all bio-pharmaceutical related provisions. H.R. 1346, Medicare Buy-In and Health Care Stabilization Act, regarding all bio-pharmaceutical related provisions. H.R. 1384, Medicare for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1781, Payment Commission Data Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1788, Limits the penalty for Part B late enrollment to 15 percent and twice the period of no enrollment, regarding all bio-pharmaceutical related provisions. H.R. 2087, Reporting drug pricing information to Medicare, regarding all bio-pharmaceutical related provisions. H.R. 2113, Prescription STAR Act, regarding all bio-pharmaceutical related provisions. S. 62, Empowering Medicare Seniors to Negotiate Drug Prices, regarding all bio-pharmaceutical related provisions. S. 99, Medicare Drug Price Negotiation Act, regarding all bio-pharmaceutical related provisions. S. 205, Right Rebate Act, regarding all bio-pharmaceutical related provisions. S. 377/H.R. 1046, Medicare Negotiation and Competitive Licensing Act, regarding all bio-pharmaceutical related provisions. S. 470, Medicare at 50 Act, regarding all bio-pharmaceutical related provisions. S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 , regarding all bio-pharmaceutical related provisions. S. 475, RxCAP Act, regarding all bio-pharmaceutical related provisions. S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU Act) of 2019, regarding all bio-pharmaceutical related provisions. S. 551, REFUND Act of 2019, regarding all bio-pharmaceutical related provisions. S. 691, Expands Part D OOP assistance for low-income seniors and individuals with disabilities, regarding all bio-pharmaceutical related provisions. S. 801/H.R. 1781, Allows MedPAC and MACPAC to have access to information on drug rebates, regarding all bio-pharmaceutical related provisions. S. 981, Medicare-X Choice Act of 2019, regarding all bio-pharmaceutical related provisions. Pending rule to change the Rebate Safe Harbor, regarding all bio-pharmaceutical related provisions. H.R. 1839, Medicaid Services Investment and Accountability Act, regarding all bio-pharmaceutical related provisions H.R. 2452, Medicare for America Act, regarding all bio-pharmaceutical related provisions H.R. 3107, Improving Seniors Timely Access to Care Act, regarding all bio-pharmaceutical related provisions H.R. 3327, Drug Price Transparency for Medicare Patients Act, regarding all bio-pharmaceutical related provisions S. 1261/H.R. 2463, Choose Medicare Act, regarding all bio-pharmaceutical related provisions S. 1497, Health Care Price Check Act, regarding all bio-pharmaceutical related provisions S. 2081, a bill to require drug manufacturers to provide rebates for drugs furnished under Medicare Part B for which the growth in average sales price has exceeded inflation, regarding all bio-pharmaceutical related provisions
H.R. 1499, Protecting Consumer Access to Generic Drugs Act, regarding all bio-pharmaceutical related provisions H.R. 965, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, regarding all bio-pharmaceutical related provisions H.R. 1344, Competitive DRUGS Act, regarding all bio-pharmaceutical related provisions. S. 64, Preserve Access to Affordable Generics and Biosimilars Act,regarding all bio-pharmaceutical related provisions. S. 340, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R.2375, Preserve Access to Affordable Generics and Biosimilars Act, regarding all bio-pharmaceutical related provisions H.R. 2387, STOP GAMES Act, regarding all bio-pharmaceutical related provisions H.R. 3199, TERM Act, regarding all bio-pharmaceutical related provisions S. 440, PACED Act, regarding all bio-pharmaceutical related provisions S. 1224/H.R.2374, Stop STALLING Act, regarding all bio-pharmaceutical related provisions S.1416, Affordable Prescriptions for Patients Act, regarding all bio-pharmaceutical related provisions S. 1617, Second Look at Drug Patents Act, regarding all bio-pharmaceutical related provisions
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
S. 73, End Taxpayer Subsidies for Drug Ads Act, regarding all bio-pharmaceutical related provisions. S. 378/H.R. 1093, Stop Price Gouging Act, regarding all bio-pharmaceutical related provisions. S. 425, LifeBOAT Act, regarding all bio-pharmaceutical related provisions.
H.R. 107, Burgess: Rebate cap, regarding all bio-pharmaceutical related provisions. H.R. 275, Medicare Prescription Drug Negotiation Act, regarding all bio-pharmaceutical related provisions. H.R. 366, Insulin Access for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1034, D. Collins/S. 640, Kennedy: Phair Pricing Act - Share the savings, regarding all bio-pharmaceutical related provisions. H.R. 1035, Prescription Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1332, Fair Care Act, regarding all bio-pharmaceutical related provisions. H.R. 1346, Medicare Buy-In and Health Care Stabilization Act, regarding all bio-pharmaceutical related provisions. H.R. 1384, Medicare for All Act, regarding all bio-pharmaceutical related provisions. H.R. 1781, Payment Commission Data Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1788, Limits the penalty for Part B late enrollment to 15 percent and twice the period of no enrollment, regarding all bio-pharmaceutical related provisions. H.R. 2087, Reporting drug pricing information to Medicare, regarding all bio-pharmaceutical related provisions. H.R. 2113, Prescription STAR Act, regarding all bio-pharmaceutical related provisions. S. 62, Empowering Medicare Seniors to Negotiate Drug Prices, regarding all bio-pharmaceutical related provisions. S. 99, Medicare Drug Price Negotiation Act, regarding all bio-pharmaceutical related provisions. S. 205, Right Rebate Act, regarding all bio-pharmaceutical related provisions. S. 377/H.R. 1046, Medicare Negotiation and Competitive Licensing Act, regarding all bio-pharmaceutical related provisions. S. 470, Medicare at 50 Act, regarding all bio-pharmaceutical related provisions. S. 474, Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019 , regarding all bio-pharmaceutical related provisions. S. 475, RxCAP Act, regarding all bio-pharmaceutical related provisions. S. 476, Creating Transparency to Have Drug Rebates Unlocked (C-THRU Act) of 2019, regarding all bio-pharmaceutical related provisions. S. 551, REFUND Act of 2019, regarding all bio-pharmaceutical related provisions. S. 691, Expands Part D OOP assistance for low-income seniors and individuals with disabilities, regarding all bio-pharmaceutical related provisions. S. 801/H.R. 1781, Allows MedPAC and MACPAC to have access to information on drug rebates, regarding all bio-pharmaceutical related provisions. S. 981, Medicare-X Choice Act of 2019, regarding all bio-pharmaceutical related provisions. Pending rule to change the Rebate Safe Harbor, regarding all bio-pharmaceutical related provisions.
H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 985, Fair Access for Safe and Timely (FAST) Generics Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 986, Protecting American with Preexisting Conditions Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 987, Marketing and Outreach Restoration to Empower Health Education Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 1010, Short-Term, Limited Duration Insurance (STLDI), regarding all bio-pharmaceutical related provisions. H.R. 1323, Rural Hospital Frontier Fairness Act, regarding all bio-pharmaceutical related provisions. H.R. 1385, State Allowance for a Variety of Exchanges (SAVE) Act, regarding all bio-pharmaceutical related provisions. H.R. 1386, Expanded Navigators Resources for Outreach, Learning, and Longevity (ENROLL) Act, regarding all bio-pharmaceutical related provisions. H.R. 1409, Transparency in All Health Care Pricing Act, regarding all bio-pharmaceutical related provisions. H.R. 1425, State Health Care Premium Reduction Act, regarding all bio-pharmaceutical related provisions. H.R. 1478, Insulin importation, regarding all bio-pharmaceutical related provisions. H.R. 1503, Orange Book Transparency Act, regarding all bio-pharmaceutical related provisions. H.R. 1506, Fair and Immediate Release (FAIR) of Generics Act, regarding all bio-pharmaceutical related provisions. H.R. 1520, Purple Book Continuity Act, regarding all bio-pharmaceutical related provisions. H.R. 2011, Protecting Access to Biosimilars Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2038, State-based , Market-Oriented, Prescription Drug Negotiations Act of 2019, regarding all bio-pharmaceutical related provisions. H.R. 2064, Product Sample reporting, regarding all bio-pharmaceutical related provisions. S. 61, Safe and Affordable Drugs from Canada Act, regarding all bio-pharmaceutical related provisions. S. 97, Affordable and Safe Drug Importation Act, regarding all bio-pharmaceutical related provisions. S. 102, Prescription Drug Price Relief Act, regarding all bio-pharmaceutical related provisions. S. 344/H.R. 990, Hatch-Waxman Integrity Act, regarding all bio-pharmaceutical related provisions. S. 366/H.R. 1188, FLAT Prices Act- Reduced exclusivity period for certain price hikes, regarding all bio-pharmaceutical related provisions. S. 418, FDA Accountability for Public Safety Act, regarding all bio-pharmaceutical related provisions. S. 419, Protecting Americans from Dangerous Opioids Act, regarding all bio-pharmaceutical related provisions. S. 637, CURE High Drug Prices Act, regarding all bio-pharmaceutical related provisions. S. 657, Drug Price Transparency Act, regarding all bio-pharmaceutical related provisions. S. 658, Accelerated Drug Approval for Prescription Therapies Act, regarding all bio-pharmaceutical related provisions. S. 659, Biologic Patent Transparency Act, regarding all bio-pharmaceutical related provisions. S. 660, Transparency in Petitions Act, regarding all bio-pharmaceutical related provisions. S. 709, Establishes public dashboard for price and utilization of drugs purchased by federal programs, regarding all bio-pharmaceutical related provisions. S. 741 /H.R. 1730, Cancer Drug Parity Act, regarding all bio-pharmaceutical related provisions. S. 844, Short Competition Act, regarding all bio-pharmaceutical related provisions. S. 977, Transparent Drug Pricing Act of 2019, regarding all bio-pharmaceutical related provisions. S. 989, STEER Act, regarding all bio-pharmaceutical related provisions. S. 1140, A bill to amend the Public Health Service Act with respect to the treatment under section 351(k)(7) of such Act (relating to exclusivity for reference products) of certain products deemed to have a biological product license pursuant to section 7002 of the Biologics Price Competition and Innovation Act of 2009, regarding all bio-pharmaceutical related provisions. S.1169, FDA citizen petition, regarding all bio-pharmaceutical related provisions. S. 1209, A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications, regarding all bio-pharmaceutical related provisions.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
American Health Care Act, regarding all biopharmaceutical related provisions. Continuing Budget Resolution, lobbied regarding all biopharmaceutical provisions. Better Care Reconciliation Act, regarding all biopharmaceutical related provisions. S. 1771, Department of Labor, HHS and Education Appropriations Act, regarding all pharmaceutical related provisions. H.R. 1625, Consolidates Appropriations Act, regarding all pharmaceutical related provisions.
No bill, lobbied on patent troll issues regarding biopharmaceutical patents. H.R. 1892, Bipartisan Budget Act, regarding all biopharmaceutical provisions. H.R. 6157, the Department of Defense and Labor, Health and Human Services and Education Appropriations Act for Fiscal Year 2019 and Continuing Resolution, regarding all biopharmaceutical provisions.
Lobbied regarding intellectual property rights in trade agreements and international negotiations. Saudi Arabia, Saudi Food and Drug Authority, lobbied Congress regarding pharmaceutical patent infringement issues.
H.R. 849, S. 260, S. 251 Protecting Seniors Access to Medicare Act, lobbied regarding all biopharmaceutical related provisions. S.771, Improving Access To Affordable Prescription Drugs Act, lobbied regarding all biopharmaceutical related provisions. S.348, Prescription Drug and Health Improvement Act of 2017, lobbied regarding all biopharmaceutical related provisions. S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017, lobbied regarding all biopharmaceutical related provisions. No bill, American Patients First Prescription Drug Blueprint, regarding all biopharmaceutical related provisions. H.R. 6505, Medicare Negotiation and Competitive Licensing Act of 2018, regarding all biopharmaceutical related provisions. H.R. 6642, to amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs, regarding all biopharmaceutical related provisions. S. 2553, H.R. 6144, Know the Lowest Price Act of 2018, regarding all biopharmaceutical related provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
Lobbied regarding intellectual property rights in trade agreements and international negotiations. Saudi Arabia, Saudi Food and Drug Authority, lobbied Congress regarding pharmaceutical patent infringement issues.
H.R. 1, Tax Cuts and Jobs Act, regarding all pharmaceutical related provisions.
No bill, lobbied on patent troll issues regarding biopharmaceutical patents. H.R. 1892, Bipartisan Budget Act, regarding all biopharmaceutical provisions. H.R. 6157, the Department of Defense and Labor, Health and Human Services and Education Appropriations Act for Fiscal Year 2019 and Continuing Resolution, regarding all biopharmaceutical provisions.
No bill, lobbied to raise awareness about Atrial Fibrillation and stroke prevention. No bill, lobbied regarding biosimilars issues including naming, labeling and interchangeability. H.R. 1245 and S. 469, Affordable and Safe Prescription Drug Importation Act, lobbied regarding all biopharmaceutical provisions. H.R. 1703, Medical Product Communications Act of 2017, regarding all biopharmaceutical related provisions H.R. 2851, Stop the Importation and Trafficking of Synthetic Analogues Act of 2017, regarding all biopharmaceutical related provisions No bill, lobbied for changes to the 340B Drug Discount Program. H.R. 4710, 340B PAUSE Act, lobbied regarding all biopharmaceutical provisions. H.R. 4392, a bill to repeal the HOPPS final regulation related to changes in the payment amount for certain drugs under the 340B program, lobbied regarding all biopharmaceutical provisions. H.R. 2026, the Pharmaceutical Information Exchange (PIE) Act of 2017, lobbied regarding all biopharmaceutical provisions. S. 2312, Helping Ensure Low-Income Patients have Access to Care and Treatment (HELP) Act, regarding all biopharmaceutical related provisions. S.2453, Ensuring the Value of the 340B Program Act of 2018, regarding all biopharmaceutical related provisions. H.R. 5598 340B Optimization Act, regarding all biopharmaceutical related provisions. H.R. 6071 SERV Communities Act, regarding all biopharmaceutical related provisions. H.R. 6240, Drug Discount Accountability Act, regarding all biopharmaceutical related provisions. H.R. 6143, S. 2554, Patient Right to Know Drug Prices Act, regarding all biopharmaceutical related provisions. H.R. 6, SUPPORT for Patients and Communities Act, regarding all biopharmaceutical related provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
H.R. 849, S. 260, S. 251 Protecting Seniors Access to Medicare Act, lobbied regarding all biopharmaceutical related provisions. S.771, Improving Access To Affordable Prescription Drugs Act, lobbied regarding all biopharmaceutical related provisions. S.348, Prescription Drug and Health Improvement Act of 2017, lobbied regarding all biopharmaceutical related provisions. S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017, lobbied regarding all biopharmaceutical related provisions. No bill, American Patients First Prescription Drug Blueprint,regarding all biopharmaceutical related provisions.
No bill, lobbied to raise awareness about Atrial Fibrillation and stroke prevention. No bill, lobbied regarding biosimilars issues including naming, labeling and interchangeability. H.R. 1245 and S. 469, Affordable and Safe Prescription Drug Importation Act, lobbied regarding all biopharmaceutical provisions. H.R. 1703, Medical Product Communications Act of 2017, regarding all biopharmaceutical related provisions H.R. 2851, Stop the Importation and Trafficking of Synthetic Analogues Act of 2017, regarding all biopharmaceutical related provisions No bill, lobbied for changes to the 340B Drug Discount Program. H.R. 4710, 340B PAUSE Act, lobbied regarding all biopharmaceutical provisions. H.R. 4392, a bill to repeal the HOPPS final regulation related to changes in the payment amount for certain drugs under the 340B program, lobbied regarding all biopharmaceutical provisions. H.R. 2026, the Pharmaceutical Information Exchange (PIE) Act of 2017, lobbied regarding all biopharmaceutical provisions. S. 2312, Helping Ensure Low-Income Patients have Access to Care and Treatment (HELP) Act, regarding all pharmaceutical related provisions. S.2453, Ensuring the Value of the 340B Program Act of 2018, regarding all pharmaceutical related provisions. H.R. 5598 340B Optimization Act, regarding all pharmaceutical related provisions. H.R. 6071 SERV Communities Act, regarding all pharmaceutical related provisions. H.R. 6240, Drug Discount Accountability Act, regarding all pharmaceutical related provisions.
H.R. 1, Tax Cuts and Jobs Act, regarding all pharmaceutical related provisions.
No bill, lobbied on patent troll issues regarding biopharmaceutical patents. H.R. 1892, Bipartisan Budget Act, regarding all biopharmaceutical provisions
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
H.R. 1, Tax Cuts and Jobs Act, regarding all pharmaceutical related provisions.
No bill, lobbied on patent troll issues regarding biopharmaceutical patents.
Lobbied regarding intellectual property rights in trade agreements and international negotiations. Saudi Arabia, Saudi Food and Drug Authority, lobbied Congress regarding pharmaceutical patent infringement issues.
No bill, lobbied to raise awareness about Atrial Fibrillation and stroke prevention. No bill, lobbied regarding biosimilars issues including naming, labeling and interchangeability. H.R. 1245 and S. 469, Affordable and Safe Prescription Drug Importation Act, lobbied regarding all biopharmaceutical provisions. H.R. 1703, Medical Product Communications Act of 2017, regarding all biopharmaceutical related provisions H.R. 2851, Stop the Importation and Trafficking of Synthetic Analogues Act of 2017, regarding all biopharmaceutical related provisions No bill, lobbied for changes to the 340B Drug Discount Program. H.R. 4710, 340B PAUSE Act, lobbied regarding all biopharmaceutical provisions. H.R. 4392, a bill to repeal the HOPPS final regulation related to changes in the payment amount for certain drugs under the 340B program, lobbied regarding all biopharmaceutical provisions. H.R. 2026, the Pharmaceutical Information Exchange (PIE) Act of 2017, lobbied regarding all biopharmaceutical provisions. S. 2312, Helping Ensure Low-Income Patients have Access to Care and Treatment (HELP) Act, regarding all pharmaceutical related provisions. S.2453, Ensuring the Value of the 340B Program Act of 2018, regarding all pharmaceutical related provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
Lobbied regarding intellectual property rights in trade agreements and international negotiations. Saudi Arabia, Saudi Food and Drug Authority, lobbied Congress regarding pharmaceutical patent infringement issues.
American Health Care Act, regarding all biopharmaceutical related provisions. Continuing Budget Resolution, lobbied regarding all biopharmaceutical provisions. Better Care Reconciliation Act, regarding all biopharmaceutical related provisions. S. 1771, Department of Labor, HHS and Education Appropriations Act, regarding all pharmaceutical related provisions.
No bill, lobbied to raise awareness about Atrial Fibrillation and stroke prevention. H.R. 878, Right to Try Act of 2017 and S. 204, Trickett Wendler Right to Try Act of 2017,lobbied regarding all biopharmaceutical provisions. Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act, lobbied regarding all biopharmaceutical provisions. No bill, lobbied regarding biosimilars issues including naming, labeling and interchangeability. HR 2430,FDA Reauthorization Act, lobbied regarding all biopharmaceutical provisions. H.R. 1245 and S. 469, Affordable and Safe Prescription Drug Importation Act, lobbied regarding all biopharmaceutical provisions. H.R.1231 and S. 456, RACE for Children Act, lobbied regarding all biopharmaceutical provisions. H.R. 1703, Medical Product Communications Act of 2017, regarding all biopharmaceutical related provisions H.R. 2851, Stop the Importation and Trafficking of Synthetic Analogues Act of 2017, regarding all biopharmaceutical related provisions No bill, lobbied for changes to the 340B Drug Discount Program. H.R. 4710, 340B PAUSE Act, lobbied regarding all biopharmaceutical provisions. H.R. 4392, a bill to repeal the HOPPS final regulation related to changes in the payment amount for certain drugs under the 340B program, lobbied regarding all biopharmaceutical provisions. H.R. 2026, the Pharmaceutical Information Exchange (PIE) Act of 2017, lobbied regarding all biopharmaceutical provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
Lobbied regarding intellectual property rights in trade agreements and international negotiations. Saudi Arabia, Saudi Food and Drug Authority, lobbied Congress regarding pharmaceutical patent infringement issues.
H.R. 849, S. 260, S. 251 Protecting Seniors Access to Medicare Act, lobbied regarding all biopharmaceutical related provisions. No bill, Children's Health Insurance Program, lobbied regarding all biopharmaceutical related provisions. S.771, Improving Access To Affordable Prescription Drugs Act, lobbied regarding all biopharmaceutical related provisions. S.348, Prescription Drug and Health Improvement Act of 2017, lobbied regarding all biopharmaceutical related provisions. S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017, lobbied regarding all biopharmaceutical related provisions.
No bill, lobbied on patent troll issues regarding biopharmaceutical patents.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
H.R. 849, S. 260, S. 251 Protecting Seniors Access to Medicare Act, lobbied regarding all biopharmaceutical related provisions. No bill, Children's Health Insurance Program, lobbied regarding all biopharmaceutical related provisions. S.771, Improving Access To Affordable Prescription Drugs Act, lobbied regarding all biopharmaceutical related provisions. S.348, Prescription Drug and Health Improvement Act of 2017, lobbied regarding all biopharmaceutical related provisions. S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017, lobbied regarding all biopharmaceutical related provisions.
No bill, lobbied on patent troll issues regarding biopharmaceutical patents.
Lobbied regarding intellectual property rights in trade agreements and international negotiations.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
American Health Care Act, regarding all biopharmaceutical related provisions. Continuing Budget Resolution, lobbied regarding all biopharmaceutical provisions.
No bill, lobbied to raise awareness about Atrial Fibrillation and stroke prevention. H.R. 878, Right to Try Act of 2017 and S. 204, Trickett Wendler Right to Try Act of 2017,lobbied regarding all biopharmaceutical provisions. Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act, lobbied regarding all biopharmaceutical provisions. No bill, lobbied regarding biosimilars issues including naming, labeling and interchangeability. FDA Reauthorization Act, lobbied regarding all biopharmaceutical provisions. H.R. 1245 and S. 469, Affordable and Safe Prescription Drug Importation Act, lobbied regarding all biopharmaceutical provisions. H.R.1231 and S. 456, RACE for Children Act, lobbied regarding all biopharmaceutical provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
S. Con. Res. 11, budget resolution, regarding all biopharmaceutical related provisions. H.R. 719, Continuing Appropriations Act,regarding all biopharmaceutical related provisions. H.R. 2029, Consolidates Appropriations Act, regarding all biopharmaceutical related provsions. H.R. 3762, Restoring America's Healthcare Freedom Reconciliation Act, regarding all biopharmaceutical related provisions.
HR 9, the Innovation Act, regarding all biopharmaceutical related provisions. S. 1137, Protecting American Talent and Entrepreneurship Act, regarding all biopharmaceutical related provisions. S. 1890 Defend Trade Secrets Act of 2016, regardng all biopharmaceutical related provisions.
Labor, Health and Human Services, Education, and Related Agencies Appropriations Bill, regarding all biopharmaceutical related provisions. Agriculture Appropriations, regarding all biopharmaceutical related provisions. H.R. 1078, FDA Safety Over Sequestration Act, regarding all biopharmaceutical related provisions. No bill, raised awareness about atrial fibrillation and stroke prevention. H/R. 1101, Viral Hepatitis Testing Act, regarding all biopharmaceutical related provisions. H.R.6 and H.R. 34, 21st Century Cures Initiative and Senate Innovation for a Healthier America proposal, regarding all biopharmaceutical related provisions. No Bill, lobbied Congress on biosimilar issues including naming, labeling and interchangeability. No Bill, lobbied Congress on importation of prescription drugs. S. 2912, Trickett Wendler Right to Try Act of 2016, S. 2912, regarding all biopharmaceutical related provisions. S. 3056, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2016, regarding all biopharmaceutical related provisions. No Bill, Prescription Drug User Fee Act, regarding all biopharmaceutical related provisions. No Bill, Biosimilar User Fee Act, regarding all biopharmaceutical related provisions. S. 3335/H.R. 6043 the Fair Accountability and Innovative Research Drug Pricing Act, regarding all biopharmaceutical related provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
HR 9, the Innovation Act, regarding all biopharmaceutical related provisions. S. 1137, Protecting American Talent and Entrepreneurship Act, regarding all biopharmaceutical related provisions. S. 1890 Defend Trade Secrets Act of 2016, regardng all biopharmaceutical related provisions.
S. Con. Res. 11, budget resolution, regarding all biopharmaceutical related provisions. H.R. 719, Continuing Appropriations Act,regarding all biopharmaceutical related provisions. H.R. 2029, Consolidates Appropriations Act, regarding all biopharmaceutical related provsions. H.R. 3762, Restoring America's Healthcare Freedom Reconciliation Act, regarding all biopharmaceutical related provisions.
S. 995, H.R. 2146 Bipartisan Congressional Trade Priorities and Accountability Act, regarding intellectual property rights in trade agreements and international negotiations. Trans-Pacific Partnership Trade Agreement, regardng all biopharmaceutical related provisions.
H.R. 1416, Cancer Patient Protection Act, regarding all biopharmaceutical related provisions. H.R. 1190 and S. 41, Protecting Seniors' Access to Medicare Act, regarding all biopharmaceutical related provisions. H.R. 2, Medicare Access and CHIP Authorization Act, regarding all biopharmaceutical related provisions H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors Act, regarding all biopharmaceutical related provisions. No Bill, lobbied on price controls for biopharmaceuticals in government health care programs. No Bill, lobbied on the proposed rule on the CMMI Medicare Part B demonstration project. H.R. 5122, legislation to prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models,regarding all biopharmaceutical related provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
H.R. 1416, Cancer Patient Protection Act, regarding all biopharmaceutical related provisions. H.R. 1190 and S. 41, Protecting Seniors' Access to Medicare Act, regarding all biopharmaceutical related provisions. H.R. 2, Medicare Access and CHIP Authorization Act, regarding all biopharmaceutical related provisions H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors Act, regarding all biopharmaceutical related provisions. No Bill, lobbied on price controls for biopharmaceuticals in government health care programs. No Bill, lobbied on the proposed rule on the CMMI Medicare Part B demonstration project. H.R. 5122, legislation to prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models,regarding all biopharmaceutical related provisions.
Labor, Health and Human Services, Education, and Related Agencies Appropriations Bill, regardng all biopharmaceutical related provisions. Agriculture Appropriations, regarding all biopharmaceutical related provisions. H.R. 1078, FDA Safety Over Sequestration Act, regarding all biopharmaceutical related provisions. No bill, raised awareness about atrial fibrillation and stroke prevention. H/R. 1101, Viral Hepatitis Testing Act, regarding all biopharmaceutical related provisions. H.R.6, 21st Century Cures Initiative and Senate Innovation for a Healthier America proposal, regarding all biopharmaceutical related provisions. No Bill, lobbied Congress on biosimilar issues including naming, labeling and interchangability. No Bill, lobbied Congress on importation of prescription drugs. S. 2912, Trickett Wendler Right to Try Act of 2016, S. 2912, regardng all biopharmaceutical related provisions. S. 3056, Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2016, regardng all biopharmaceutical related provisions. No Bill, Prescription Drug User Fee Act, regardng all biopharmaceutical related provisions. No Bill, Biosimilar User Fee Act, regardng all biopharmaceutical related provisions.
S. 995, H.R. 2146 Bipartisan Congressional Trade Priorities and Accountability Act, regarding intellectual property rights in trade agreements and international negotiations. Trans-Pacific Partnership Trade Agreement, regardng all biopharmaceutical related provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
Labor, HHS Appropriations,regarding all biopharmaceutical related provisions. Agriculture Appropriations, regarding all biopharmaceutical related provisions. H.R. 1078, FDA Safety Over Sequestration Act, regarding all biopharmaceutical related provisions. No bill, raised awareness about atrial fibrillation and stroke prevention. H/R. 1101, Viral Hepatitis Testing Act, regarding all biopharmaceutical related provisions. H.R.6, 21st Century Cures Initiative and Senate Innovation for a Healthier America proposal, regarding all biopharmaceutical related provisions. No Bill, lobbied Congress on biosimilar issues including naming, labeling and interchangability. No Bill, lobbied Congress on importation of prescription drugs.
S. Con. Res. 11, budget resolution, regarding all biopharmaceutical related provisions. H.R. 719, Continuing Appropriations Act,regarding all biopharmaceutical related provisions. H.R. 2029, Consolidates Appropriations Act, regarding all biopharmaceutical related provsions. H.R. 3762, Restoring America's Healthcare Freedom Reconciliation Act, regarding all biopharmaceutical related provisions.
HR 9, the Innovation Act, regarding all biopharmaceutical related provisions. S. 1137, Protecting American Talent and Entrepreneurship Act, regarding all biopharmaceutical related provisions. S. 1890 Defend Trade Secrets Act of 2016, regardng all biopharmaceutical related provision.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
Labor, HHS Appropriations,regarding all biopharmaceutical related provisions. Agriculture Appropriations, regarding all biopharmaceutical related provisions. H.R. 1078, FDA Safety Over Sequestration Act, regarding all biopharmaceutical related provisions. No bill, raised awareness about atrial fibrillation and stroke prevention. H/R. 1101, Viral Hepatitis Testing Act, regarding all biopharmaceutical related provisions. H.R.6, 21st Century Cures Initiative, regarding all biopharmaceutical related provisions.
HR 9, the Innovation Act, regarding all biopharmaceutical related provisions. S. 1137, Protecting American Talent and Entrepreneurship Act, regarding all biopharmaceutical related provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
H.R. 1416, Cancer Patient Protection Act, regarding all biopharmaceutical related provisions. H.R. 1190 and S. 41, Protecting Seniors' Access to Medicare Act, regarding all biopharmaceutical related provisions. H.R. 2, Medicare Access and CHIP Authorization Act, regarding all biopharmaceutical related provisions H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors Act, regarding all biopharmaceutical related provisions.
HR 9, the Innovation Act, regarding all biopharmaceutical related provisions. S. 1137, Protecting American Talent and Entrepreneurship Act, regarding all biopharmaceutical related provisions.
S. Con. Res. 11, budget resolution, regarding all biopharmaceutical related provisions. H.R. 719, Continuing Appropriations Act,regarding all biopharmaceutical related provisions. H.R. 2029, Consolidates Appropriations Act, regarding all biopharmaceutical related provsions. H.R. 3762, Restoring America's Healthcare Freedom Reconciliation Act, regarding all biopharmaceutical related provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
Labor, HHS Appropriations,regarding all biopharmaceutical related provisions. Agriculture Appropriations, regarding all biopharmaceutical related provisions. H.R. 1078, FDA Safety Over Sequestration Act, regarding all biopharmaceutical related provisions. No bill, raised awareness about atrial fibrillation and stroke prevention. H/R. 1101, Viral Hepatitis Testing Act, regarding all biopharmaceutical related provisions. H.R.6, 21st Century Cures Initiative and Senate Innovation for a Healthier America proposal, regarding all biopharmaceutical related provisions. No Bill, lobbied Congress on biosimilar issues including naming, labeling and interchangability.
H.R. 1416, Cancer Patient Protection Act, regarding all biopharmaceutical related provisions. H.R. 1190 and S. 41, Protecting Seniors' Access to Medicare Act, regarding all biopharmaceutical related provisions. H.R. 2, Medicare Access and CHIP Authorization Act, regarding all biopharmaceutical related provisions H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors Act, regarding all biopharmaceutical related provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
H.R. 1416, Cancer Patient Protection Act, regarding all biopharmaceutical related provisions. H.R. 1190 and S. 41, Protecting Seniors' Access to Medicare Act, regarding all biopharmaceutical related provisions. H.R. 2, Medicare Access and CHIP Authorization Act, regarding all biopharmaceutical related provisions H.R. 2570, Strengthening Medicare Advantage through Innovation and Transparency for Seniors Act, regarding all biopharmaceutical related provisions.
S. Con. Res. 11, budget resolution, regarding all biopharmaceutical related provisions.
No bill, lobbied to strengthen intellectual property rights in trade agreements and international negotiations.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
HR 9, the Innovation Act, regarding all biopharmaceutical related provisions.
S. Con. Res. 11, budget resolution, regarding all biopharmaceutical related provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
H.R. 3474, Tax Extenders legislation, regarding all biopharmaceutical related provisions. H.R. 4438, American Research and Investment Act, regarding all biopharmaceutical related provisions. H.R. 5771, to amend the Internal Revenue Code of 1986 to extend certain expiring provisions, including the research and development tax credit, regarding all biopharmaceutical related provisions.
H.J. Res 59, Continuing Appropriations Resolution, regarding all biopharmaceutical related provisions. Labor, HHS Appropriations, regarding all biopharmaceutical related provisions. Agriculture appropriations, regarding all biopharmceutical related provisions. H.R. 2725/S. 1413, FDA Safety over Sequestration Act, regarding all biopharmaceutical user-fees. No-bill, educational meetings regarding atrial fibrillation. No bill - regarding FDA regulatory issues and patent incentives related to the 21st Century Cures Initiative. Health Care Reform implementation - regarding essential health benefits coverage and all biopharmaceutical related provisions. H.R. 3723, Viral Hepatitis Testing Act, regarding all provisions.
H.R. 3309, S. 1720, and S. 1612, S. 1013, S. 866, legislation to amend certain patent laws. Regarding all provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
H.J. Res 59, Continuing Appropriations Resolution, regarding all biopharmaceutical related provisions. Labor, HHS Appropriations, regarding all biopharmaceutical related provisions. Agriculture appropriations, regarding all biopharmceutical related provisions. H.R. 2725/S. 1413, FDA Safety over Sequestration Act, regarding all biopharmaceutical user-fees. No-bill, educational meetings regarding atrial fibrillation. No bill - regarding FDA regulatory issues and patent incentives related to the 21st Century Cures Initiative. Health Care Reform implementation - regarding essential health benefits coverage and all biopharmaceutical related provisions. H.R. 3723, Viral Hepatitis Testing Act, regarding all provisions.
H.R. 3309, S. 1720, and S. 1612, S. 1013, S. 866, legislation to amend certain patent laws. Regarding all provisions.
H.R. 3474, Tax Extenders legislation, regarding all biopharmaceutical related provisions. H.R. 4438, American Research and Investment Act, regarding all biopharmaceutical related provisions. H.R. 5771, to amend the Internal Revenue Code of 1986 to extend certain expiring provisions, including the research and development tax credit, regarding all biopharmaceutical related provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
H.R. 1325 S. 323, "Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act" regarding all provisions. H.R. 1416, "Cancer Patient Protection Act of 2013," regarding all provisions. H.R. 351 and S. 351, "Protecting Seniors' Access to Medicare Act of 2013," regarding all provisions. H.R. 2010 and S. 1821, SGR Reform, regarding all provisions.H.R. 4301, Protecting Access to Medicare act, regarding all provisions.
H.J. Res 59, Continuing Appropriations Resolution, regarding all biopharmaceutical related provisions. Labor, HHS Appropriations, regarding all biopharmaceutical related provisons. Agriculture approrpiations, regarding all biopharmceutical related provisions.H.R. 2725/S. 1413, FDA Safety over Sequestration Act, regarding all biopharmaceutical user-fees. No-bill, educational meetings regarding atrial fibrillation. No bill - regarding FDA regulatory issues and patent incentives related to the 21st Century Cures Initiative. Health Care Reform implementation - regarding essential health benefits coverage and all biopharmaceutical related provisions. H.R. 3723, Viral Hepatitis Testing Act, regarding all provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
H.J. Res 59, Continuing Appropriations Resolution, regarding all biopharmaceutical related provisions. Labor, HHS Appropriations, regarding all biopharmaceutical related provisons. Agriculture approrpiations, regarding all biopharmceutical related provisions.H.R. 2725/S. 1413, FDA Safety over Sequestration Act, regarding all biopharmaceutical user-fees. No-bill, edcuational meetings regarding atrial fibrilation. No bill - regarding FDA regulatory issues and patent incentives related to the 21st Century Cures Initiative. Health Care Reform implementation - regarding essential health benefits coverage and all biopharmaceutical related provisions. H.R. 3723, Viral Hepatitis Testing Act, regarding all provisions.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Implementation of health care reform H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013 and the Senate bill, Drug Supply Chain and Security Act. H.R. 1588, the Medicare Drug Savings Act of 2013. Drug Coumpounding draft legislation.